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Abstract
The pro-inflamm atory cytokine, T N F a  has been linked with several patologies like 
malaria, toxic shock and rheum atoid artheritis. M oreover the circulating levels of 
T N F a  have been shown to correlate positively with disease severity in both murine 
and hum an malaria. Among clinical features thought to be produced by T N F a  are 
fever and cachexia. TN Fa, however, has also been shown to play a protective role in 
malaria. Indeed protection against the asexual stages of the murine malaria 
Plasmodium chabaudi chabaudi AS has been shown to depend on the sequential 
appearance o f T h l and Th2 cell functions with the T h l stim ulation leading to the 
early production of T N F a  through activation of m acrophages by IFNy released from 
the T h l cells. This indicates, therefore, that certain levels o f this cytokine are essential 
for protection but excessive levels are detrimental to the host. Various m ethods have 
been used to suppress excessive levels of circulating T N F a  levels in various 
pathologies. These include, the use o f anti T N F a  monoclonal antibodies and the use 
of soluble T N F a  receptors.
In the studies presented here, a new method for suppressing circulating T N F a  was 
investigated. It involves the use of empty non-ionic surfactant vesicles (NISV) which 
had been shown previously to cause a less degree of weight loss in Toxoplasma 
gondii-infe-cità mice than infected but untreated mice. Since high circulating T N F a 
levels have been shown to be linked with cachexia, the m echanism  suggested for the 
reduced weight loss in the T. gcM^ri'-infected mice was the possibility that empty 
NISV were suppressing the release o f T N F a from the activated m acrophages. In the 
present studies, empty NISV were used in P. chabaudi chabaudi AS-infected mice to 
investigate their potential in reducing the amount of weight loss caused by this 
particular infection. It was also investigated in these studies the hypothesis that the 
reduced weight loss was due to suppression of the T N F a  production by NISV from 
the macrophages and the mechanisms involved in this suppression.
Experim ents were repeated a num ber of times in 2 different animal houses (Glasgow 
University and Strathclyde University). Pre-infection treatment with NISV produced a
significantly less degree of weight loss (p<0.05) in the treated animals than their 
counterparts in the experiments conducted at Strathclyde University, while at 
Glasgow University, less weight loss was observed in the untreated group. Variability 
in a num ber of parameters (including diet, PABA content in water, coinfection of the 
animals with other pathogens) was considered in order to explain the discrepancy in 
the results but all parameters were identical in both venues. Furthermore, combining 
the results of the experiments conducted at each venue showed no significant 
difference between the 2 groups. M oreover, the time points where a significant 
difference in weight loss between the 2 groups was seen, were different in different 
experiments. The conclusion was that pre-infection treatment with em pty NISV had 
no significant effect on the weights o f P. c. c AS- infected BALB/c mice.
Levels o f parasitaemia were also measured in both groups of all experiments. 
Discrepancy was also observed here between the experiments conducted at the 2 
venues. Lower levels of parasitaem ia were detected in the NISV-treated animals than 
the untreated ones at certain time points in individual experiments conducted at 
Strathclyde University. W ith the 2 experiments combined no difference was seen 
between the 2 groups. In the experiments conducted at Glasgow University, lower 
levels of parasitaemia were seen in the NISV-untreated group in one experim ent and 
in the NISV-treated group in the second experim ent on day 9 during the incline of 
parasitaemia. A higher parasitaem ia was seen on day 11 in the NISV -treated group 
during the declining phase of parasitaemia. Again the time points where a difference 
was observed were different in different experiments indicating that the difference 
was not due to treatment with NISV. Also, taking the results together showed no 
significant difference between the 2 groups. The conclusion was that pre-infection 
treatm ent with NISV had no effects on the levels of parasitaemia in P. c. c. AS- 
infected mice.
A health status score was developed to m onitor the animals closely. It consisted of 
degree of pilo erection, degree of activity of the animals, and level of self-hygiene. A 
significantly higher score was observed in the NISV-treated group in the experiments 
conducted at Strathclyde University on days 11 and 12 post infection. A significantly 
higher score on the other hand was seen in the untreated group in the experiments 
conducted at Glasgow University on days 12, 13 and 14. The conclusion was that
pre-infection treatment with NISV had no effect on the general health status of the P. 
c. c AS infected animals.
The effects of pre-infection treatment with NISV on plasma T N F a levels were studied 
in 3 of the above experiments. Results showed an apparent suppression in plasm a 
T N F a  levels in the NISV-treated group in all the 3 experiments. The significance of 
the suppression could not be confirmed due to absence of standard errors since 
samples o f each group had to be pooled to allow multi-cytokine analysis. The 
observation that plasm a T N F a  levels were suppressed in the experim ents yielding 
contradictory results with regards to weight loss, parasitaem ia levels and health status 
,indicated that either the NISV had no genuine suppressive effect on circulating 
T N F a  levels or that NISV suppressed T N F a  in an uncontrollable manner.
To investigate whether the above suppression was due to chance or a due to 
uncontrollable effect o f NISV, NISV effects were further investigated in in vitro 
settings. NISV were found to induce production of T N F a from liver and bone 
m arrow adherent cells. NISV were also found to induce the production o f NO from 
splenocytes, and liver and bone marrow adherent cells in a dose dependent manner. 
NISV also caused suppression of splenocyte proliferation which partly was reversed 
by LNM M M A. Since the in vitro settings were different from the ex-vivo settings 
with regards to the time interval between NISV treatment and T N F a  m easurem ent, it 
was suggested to modify the experiments. NISV treatment should be adm inistered at 
tim e of infection and plasma T N F a  levels should be measured in the first 4 hours post 
infection to resemble the in vitro experiments. This suggested m odification, however, 
was not done in these experiments due to shortage of time.
To investigate any possible imm unoregulatory effects of NISV in the P. c. c AS- 
infected mice, plasma levels of cytokines representing activation of T h l and Th2 arms 
o f the immune response were measured. Plasm a levels of IFNy, EL-4 and IL-10 were 
measured in all experiments. No consistent difference was seen between the NISV- 
treated and untreated groups with regards to IFNy or EL-4 levels. IL-10 levels were 
not reported due to problems with IL-10 standards. No consistent difference was
observed in the nitrate levels between the 2 groups. The conclusion was that pre­
infection treatment with NISV had no effects on plasm a IFNy, IL-4 or nitrate levels.
The possibility of running ELIS As on whole lysed blood was also tested. It was found 
that it was indeed possible to detect T N Fa, I F N /  and IL-4 in whole lysed blood 
samples by ELISA with a slight m odification in the steps. After adding the samples to 
the wells, the plate was left at 4°C overnight instead o f the usual 2 hrs.
To investigate the effect of haemolysis on the levels of cytokines detected by ELISA 
method, levels of T N F a  and IFNy were m easured in samples of lysed whole blood, 
serum, plasma, lysed packed cells rem aining after removal o f plasm a and lysed 
packed cells remaining after the removal of serum. Highest T N F a  and IFNy levels 
were detected in lysed packed cells remaining after removal of plasma.
Also investigated in these studies was the effect of repeated freezing and thawing on 
plasm a samples. Different levels of the above cytokines were detected after repeated 
freezing and thawing. Higher IFNy levels were detected after 6^*’ time of thawing than 
after second thawing. The results indicate the importance of standardizing the m ethod 
of m easuring cytokines by ELISA and stating if repeated freezing and thawing had 
been involved.
The final collective conclusions of the studies presented here are that pre-infection 
treatm ent o f P chabaudi chabaudi AS-infected BALB/c mice with empty NISV had 
no effect on the clinical features (weight, parasitaem ia levels, general health status) of 
the treated animals. The treatment had no effects on the plasma levels o f IFNy, IL-4 
and NO. In vitro settings, NISV induced the production of T N F a  and NO and 
suppressed splenocyte proliferation to various stimulants. A m odification of the ex- 
vivo  experiments is required along with the use of standard errors to investigate 
whether the ex-vivo suppression of plasma T N F a  was a chance finding or a genuine 
result of NISV. Finally, further studies are required to explore the use of whole lysed 
blood samples in cytokine measurements by ELISA.
Chapter 1
General Introduction
Background
Malaria remains one of the major threats to mankind today. It affects 300-500 million 
people and causes 1.5-2.7 million deaths every year half of which occur in children under 
five years of age in the sub-Saharan Africa (Trigg, 1998). Malaria also imposes a huge 
economic burden on the endemic areas, and seems to be linked with poverty in a vicious 
circle. Ill health caused by malaria impedes economic growth, which in turn prevents the 
implementation of measures required to combat the disease such as bednets, use of 
chemotherapy and insecticides (Sachs and Malaney, 2002).
The disease is not new. It was known to the ancients. Hippocrates, who lived in the fifth 
century b c , was the first to describe the clinical appearance of malaria and some of its 
complications. The disease was named malaria, which means bad air, by the Italians who 
believed it to be associated with the foul air near marshy areas (Gilles and W arrell, 1993). 
Malaria used to be widely distributed and malaria fever was reported in central Europe, 
much of Asia and North America. Its decline and eventual disappearance from the USA 
was due to improved health style with the use of screened homes, and programmes 
aiming at modifying the mosquito habitat. It also declined in central Europe but without 
any special efforts. In Southern Europe, Turkey and some parts of Asia it declined 
because of the use of (dichlorodiphenyltrichloroethane) DDT. In the 1950s and 1960s 
DDT was used in an attempt to eradicate the disease globally and indeed good results 
were obtained in several countries such as India, Sri Lanka and former USSR, while in 
sub-Saharan Africa no sustained effort was made to control the disease. In the early 
1960s, however, and due to excessive use of DDT in agriculture, DDT-resistant 
mosquitoes appeared. At the same time, there was lack of funding in the eradication 
programme with the consequences of the disease re-emerging (Shiff, 2002). For the next 
25 years, interest in malaria had fallen with only 3 of 1,223 new drugs between 1975- 
1996 were antimalarials, and support for malaria research declined. Furthermore, in many 
malaria-endemic areas, national malaria control programmes established during the 
colonial period collapsed (Greenwood and Mutabingwa, 2002). In recent years, the
malaria situation has deteriorated due to parasite resistance to anti-malarial drugs, vector 
resistance to insecticides and civil strife. Furthermore, modern easy travel, global 
warming and movement of refugees are causing a threat to areas considered previously as 
malaria-free (Greenwood and Mutingawa, 2002).
The Parasite
Malaria is caused by a protozoan which is classified as follows: phylum: Apicomplexa, 
class; Sporozoasida, subclass: Coccidiasina, order: Cossidiasina, suborder:
Haemospororina, genus: Plasmodium  (Mlurray et a i , 1990). It was first identified and 
described by Laveran who in 1880 described malaria parasites in human red blood cells 
(Gilles and Warrell, 1993). There are about 120 species of Plasmodium  (Gilles and 
Warrell, 1993) but only four of them routinely infect humans. This is because the parasite 
is generally host specific, i.e. certain plasmodial species cause disease in certain host 
species. It must be mentioned, however, that P. falciparum  which is a human infecting 
plasmodial species, can infect some South American monkeys such as Aotiis and Saimiri 
spp and some monkey malaria parasites such as P. cynomolgi, and P. knowlesi can 
infect humans (Garnham, 1967).
The four species that infect humans are P. falciparum, P. vivax, P. rnalariae and P. ovale. 
P. falciparum  and P. vivax contribute most heavily to the malaria morbidity, while most 
of the deaths are attributed to P. falciparum  which is, therefore, considered clinically as 
the most important species. A diagrammatic summary of the parasite life cycle is 
illustrated in figure 1.1.
Malaria is transmitted by female anopheline mosquitoes. There are about 400 species of 
Anopheles, 60 of which have been proven as vectors for human malaria (Gilles and 
Warrell, 1993). The involvement of mosquitoes in malaria transmission was identified by 
Ronald Ross in 1897. Ross found a developing form of malaria parasites in the body of a 
mosquito that had fed on the blood of a malaria patient (Gilles and W arrell, 1993). It is
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said that mosquito involvement was suggested to Ross by Manson who had described the 
mosquito as the arthropod host for human filarial in 1878 (Sherman 1998). It must be 
mentioned however, that ARMutanabbi (915-965 AD) an Arab poet, while in Egypt 
described himself suffering from a well known common disease characterized by rigors 
and caused by mosquitoes biting at night. This disease, was said to be malaria (school 
teacher, personal communication) (see Appendix 3 for part of the poem).
M osquito’s role in the spread of the disease depends on several factors including the 
temperature and humidity of the environment, which determine the longetivity of the 
mosquitoes, and also the rate of parasite development inside the vector and hence the 
completion of the parasite life cycle. The period required for completion of parasite life 
cycle increases as the ambient temperature declines, with development ceasing 
completely below 16“C (Gilles and Warrell, 1993).
The cycle starts when the female Anopheles mosquito introduces its proboscis into a 
blood vessel to feed on the host's blood. This is important for the development of her eggs 
while the male feeds on nectar and other plant juices (Gilles and Warrell, 1993). During 
this process she injects her saliva containing an anticoagulant into the host to facilitate 
blood uptake. Unfortunately for the host, if any sporozoites exist in the saliva, they are 
also injected into the circulation. Recently it was shown that P, berghei in mice infeetion 
occurred when sporozoites were injected into skin, muscle, peritoneal cavity and tail end 
of mice. Animals also developed the infection when A. stephensi was forced not to take 
blood but only to probe into the skin. Sporozoites that were injected into skin were found 
to remain at the site of injection for at least 5 minutes and later appear in the circulation 
(Matsuoka et a l, 2002). The released sporozoites are cleared from the circulation within 
an hour as Fairlay’s work showed in 1946 (reviewed by Meis and Verhave, 1988) and 
gain access into the hepatocytes where they develop (Shortt and Garnham, 1948). 
Subsequent work done to examine the interaction of sporozoites and Kupffer cells by 
transmission electron microscopy showed that in fact 10-15 minutes following 
inoculation sporozoites are seen both free in sinusoids and inside Kupffer cells (Meis et
a l,  1983). Recent work has shown that sporozoites pass through several hepatocytes 
before intrahepatic parasite development is established (Mota e{ a i, 2001). Carrolo el al 
have reported on the significance of the sporozoite journey throught several hepatocytes. 
They have shown that while the sporozoites travel through the heaptocytes they wound 
these hepatocytes causing the release of hepatocyte growth factor (HGF). HGF then binds 
to its receptor and the complex mediates rearrangement of the hepatocyte actin 
cytoskeleton rendering the cells susceptible to infection (Carrolo el al., 2003). The 
authors suggested important clinical implications for their findings in developing new 
strategies against the disease by inhibiting HGF synthesis or its activation. Their findings, 
however, may be difficult to reconcile with findings reported previously in the same year 
by Kaiser et al. This group has found that P. berghei sporozoites that reside in the 
salivary glands of mosquitoes can transform into the exoerythrocytic forms without 
residence in the host hepatocytes. Their transformation was dependent on serum and 
temperature of 37°C and did not require hepatocytes or specific host cell-derived growth 
factors (Kaiser el ah, 2003). Most of the bites by infected mosquitoes results in 
inoculation with only a few sporozoites although the salivary glands frequently contain 
several thousand sporozoites (Beier et ah, 1991).
Sporozoites are found to exhibit gliding motility associated with the secretion of the 
circumsporozoite protein (CSP) from their apical end and the translocation of CSP 
posteriorly (Stewart and Vanderberg, 1991). The mechanisms through which the parasites 
manage to gain access into hepatocytes are unknown. Since the hepatic sinusoidal 
endothelium has small fenestra of 0. Ijim in diameter (Wisse, 1985) and since the 
sporozoites are lxl5|um  in size, it was thought that access of sporozoites through 
sinusoidal fenestra was not possible. Studies on P. bergheihnîœl&d rats showed a role for 
Kupffer cells in delivering the sporozoites from the sinusoids to the space of Disse and 
the bordering hepatocytes. Impairment of Kupffer cells function by silica treatment led to 
significant prolongation of circulating time of sporozoites and a significant reduction in 
the number of developing schizonts (Verhave et a i,  1980). In 1983 Meis and colleagues 
examined the interaction between P. berghei sporozoites and rat Kupffer cells using
transmission electron microscope. They found that sporozoites were found inside 
endocytotic vacuoles of Kupffer cells and that their morphology was intact even one hour 
later with no signs of lysosomal digestion. They, therefore, suggested that Kupffer cells 
played an important role in delivering the sporozoites to the space of Disse and that 
endothelial cells had no role. How exactly do sporozoites enter the hepatocytes is still not 
known but it has been shown that the sporozoites bind through the region II of their CSP 
to heparan sulphate proteoglycans (HSPGs) on the hepatocyte’s surface (Nussenzweig et 
a i,  1985). This binding on its own, however, is not enough and a mechanism for 
internalization is needed. The natural ligands of the HSPGs are chylomicrons and very 
low density lipoproteins (VLDL) which, following binding to HSPGs, are internalized by 
the low density lipoprotein (DDL) receptor and the LDL receptor related protein (LRP). 
It was shown that CSP also binds to LRP, therefore raising the possibility that sporozoites 
may depend on coordinated activity of HSGP and LRP (Shakibaei el al., 1996). 
Subsequent studies, however, have shown that sporozoites of P. yoelii yoelii infect LRP- 
deficient hepatocytes in vivo and LRP-null cells in vitro with efficiency equal to controls 
indicating that LRP is not required by Plasmodium  sporozoites to enter the hepatocytes 
(Marshall el al., 2000).
Thrombospondin related adhesion protein (TRAP) which is found in the micronemes as 
well as on the surface of salivary gland sporozoites (Rogers et al., 1992,) has also been 
shown to be involved in sporozoite motility and hepatocyte invasion (Rogers ei al., 1992, 
Gantt et a l, 2000). Sporozoites of P. berghei with a disrupted TRAP gene were not 
capable of gliding motility or hepatocyte invasion (Kappe et a l ,  1999, Sultan et a l, 
1997). Recently, Plasmodium falciparum  erythrocyte membrane protein 3 (PfEMP3) 
knob-associated protein was found on the surface of sporozoites and in the cytoplasm of 
the liver stages (Grilner et a l ,  2001). Specific antibodies obtained from individuals living 
in malaria endemic areas blocked invasion of P. yoelii yoelii and P. berghei sporozoites 
into hepatocytes in vitro (Grüner et a l ,  2001).
Within the hepatocytes, sporozoites develop and replicate forming the liver schizont, 
which ruptures releasing merozoites into the circulation. Depending on the Plasmodium  
species, 100-30,000 merozoites are released from the initial hepatoschizogony (reviewed 
by Meis and Verhave, 1988). The pre-erythrocytic cycle varies in duration among the 
different species taking 5.5-6 days for P. falciparum , 10 days for P. vivax and 2 weeks for 
P. malariae (reviewed by Meis and Verhave, 1988).
Sporozoites of some species including P. vivax and P. ovale can lie dormant within the 
hepatocytes and hence called hypnozoites (Krotoski, 1985). Hypnozoites persist in the 
hepatocytes as a small uninucleate form 4-5mm in diameter until reactivation with a 
subsequent relapse of the disease (reviewed by Meis and Verhave, 1988). What causes 
the reactivation of these hypnozoites is still unknown.
Invasion of red blood cells;
The merozoites released from the hepatocytes invade red blood cells. Different species 
may have different preferences with respect to the age of red blood cell invaded. For 
instance P. vivax invades reticulocytes, P. falciparum  can infect erythrocytes of any age 
but prefers young ones (Pasvol et a l ,  1980) and P. malariae infects mature erythrocytes. 
Early work on P. yoelii and P. gallinaceiim  showed that the process of invasion involves 
several steps beginning with the parasite initially making contact with the host red blood 
cell membrane and reoriantating itself so that its anterior end comes in contact with the 
erythrocyte. At this site of contact a depression is formed in the red cell membrane, which 
deepens as the merozoite moves inwards. Eventually the parasite is internalized within a 
vacuole inside the erythrocyte called the parasitophrous vacuole (Ladda ei a l ,  1969). The 
entire process of erythrocyte invasion takes less than 30 seconds (Pasvol et al., 1995). 
From the above description, it looks that the process of invasion is not that of a 
penetration but rather of invagination resembling the implantation of a human zygote into 
the uterine wall.
It was previously thought that the initial contact between the parasite and the red blood 
cell did not require specific red cell receptors since treatment of red blood cells with 
trypsin, chymotrypsin and neuraminidases did not affect the ability of the parasite to 
invade these cells (Sherman, 1966). Now we know this is not true and indeed the 
presence of specific molecules on the red blood cells are required to allow invasion to 
occur. For example, in the case of P. vivax, Duffy blood group antigens are required for 
the process of invasion and this explains why those Africans negative for Duffy antigens 
are resistant to P. vivax infection (Miller el al., 1976). In Duffy negative individuals, the 
initial attachment of the merozoites to the erythrocyte membrane does occur, but the 
merozoites are unable to form a junction with the erythrocyte membrane (Spencer et al., 
1978). P. falcipavum, on the other hand, requires the presence of glycophorins which are 
carbohydrate rich glycoproteins traversing the erythrocyte membrane, since monoclonal 
antibodies against an epitope on glycophorin A markedly inhibited red cell invasion by 
merozoites in vitro (Pasvol et al., 1982, Thompson et /., 2001). Sialic acid residues of 
glycophorin A have been identified as invasion receptors for P. falciparum  (Miller et al., 
1977, Pasvol et a l, 1982). The parasite ligand for sialic acid residues is the erythrocyte 
binding antigen-175 kDa (EBA-175) (Camus and Hadleye, 1985). In vitro studies, 
however, have shown that some clones of P. falciparum  can invade erythrocytes using 
sialic acid-independent pathways (Dolan et a l, 1994). P. falciparum  field isolates were 
also commonly found to use erythrocyte invasion pathways that are independent of sialic 
acid residues of glycophorin A (Okoyeh et a l ,  1999).
The merozoite membrane proteins involved in erythrocyte invasion include, the 
merozoite surface protein-1 (MSP-1) and ring stage surface antigen (RESA) which 
interact with spectrin (Herrera et a l ,  1993, Foley et a l ,  1991), apical membrane antigen-1 
(AM A-1 ) (Triglia et a l, 2001), erythrocyte binding antigen (EBA-175) which binds to 
glycophorin A (Sim et a l,  1994) and acidic-basic repeat antigen (ABRA) which interacts 
with Band 3 (Kushwaha et a l ,  2002). Microtubules of P. falciparum  have also been 
shown to take part in the invasion of merozoites into erythrocytes since colchicin which, 
inhibits polymerization of microtubules inhibited erythrocyte invasion by P. falciparum
in vitro (Bejon et al., 1997). Other proteins identified on the surface of P. falciparuin- 
infected erythrocytes that are involved in the process of invasion include P. falciparum  
rhoptry protein homologous PfRH2a and PfRH2b (Rayner et a l ,  2000, Triglia et al., 
2001). Parasite proteases are also thought to play a part in erythrocyte invasion and 
erythrocyte rupture during schizogony (Rosenthal et al., 1998). Proteases from P. 
falciparum, P. chabaudi and P. berghei have been identified to interact with and cleave 
erythrocyte proteins such as Band 3, glycophorin, ankyrin, protein 4.1 and spectrin 
(Raphael et al., 2000, Braun-Breton et al., 1992, Roggwiller et al., 1996)
Following Invasion of red blood cells
Following invasion of the red blood cells each Plasmodium  species induces characteristic 
morphological changes, both within and on the surface of infected cells, related to the 
development of the parasite. Some of these changes include the appearance of membrane 
bound clefts called M aurer’s clefts in the cytoplasm of the erythrocytes infected with P. 
falciparum  (Aikawa, 1988). M aurer’s clefts connect to the membrane of the 
parasitophorous vacuole and appear to increase in number as the parasite matures 
(Mackenstedt et ah, 1989). Another change is the formation of knobs by the asexual 
erythrocytic stages of P. falciparum. These knobs start appearing approximately 24hr 
following merozoite invasion and may cover as much as 5% of the surface of the infected 
cell (Gruenberg, Allerd, and Sherman, 1983). Under scanning electron microscopy, the 
knobs are seen to vary in size and density, being sparse on trophozoite containing cells 
and more numerous and of smaller size on schizont-infected cells (reviewed by Sherman, 
Crandall and Smith, 1992). The role of the knobs is not really known for they were 
initially thought to be essential in the phenomenon of cytoadherence and electron 
microscopy clearly showed P. /n/c/parnm-infected red cell cytoadhering to the 
endothelium via their knobs (Aikawa, 1988). It has also been shown, however, that P. 
malariae which does not cytoadhere, does form knobs and vice versa in the case of the 
rodent parasite P. chabaudi (Cox, Semoff and Hommel, 1987).
Once inside the red blood cells the parasites can take one of two directions, asexual 
proliferation or differentiation into sexual forms (KiHick-Kendrick and Warren, 1968). In 
the process of asexual proliferation, the young ring stage parasites develop into 
trophozoites and then into the dividing schizont, which ruptures giving 6-32 merozoites 
depending on the Plasmodium  species. The released merozoites invade more erythrocytes 
and the whole cycle is repeated. The escape of merozoites from the erythrocytes has been 
shown to occur in two steps. The first step involves the release of merozoite bound by the 
parasitophorous vacuolar membrane (PVM) from the erythrocytes and then the escape of 
the merozoites from the PVM (Salmon et al. 2001). Both these steps are protease 
dependent, since treatment of P. /cnrnv/es'i-infected erythrocytes with chymostatin allowed 
the development of the parasites but not their release from the erythrocytes (Hadely et al., 
1983). Also, culture of P. falciparum  schizonts-infected erythrocytes in the presence of 
the cysteine protease inhibitor, L-transepoxy-succinyl-leucylamido-(4-guanidino) butane 
(E64) resulted in the accumulation of extraerythrocytic merozoites locked within a thin, 
transparent membrane which was shown to be derived from the PVM (Salmon et al., 
2001). The asexual cycle varies in duration among the species, for example being 24 hr 
long in the case P. chabaudi and 48 hr in P. falciparum  (reviewed by Meis and Verhave, 
1988). The other option for the parasites is to develop into microgamétocyte males or 
macrogamétocyte females. The gametocytes are taken up by the feeding mosquito along 
with other forms during a blood meal. The signals that determine whether a merozoite 
will develop asexually or sexually in vivo are not known although several stimuli were 
proposed such as increase in asexual parasitaemia per se, rising immunity to asexual 
stags, a fall in immunity against sexual stages, a change of spleen pH, presence of parasite 
cell debris and sub-curative levels of anti-malarial drugs like quinine (reviewed by 
Sinden, 1983). In vitro work, on the other hand, has shown that, dilution of ring stage- 
infected erythrocyte cultures with fresh erythrocytes suppressed gametocytogenesis 
(Carter and Miller et al., 1979), while addition of cAMP may increase it (Kaushal et al., 
1980). There is some evidence, however, that in P. falciparum  a given erythrocytic 
schizont contains either all sexual or asexual merozoites indicating that the trigger for 
differentiation precedes invasion. The rate al which the merozoites differentiate into
gametocytes varies considerably during successive rounds of schizogony. In P. 
falciparum, gametocytogenesis takes about 10-12 days which is much longer than the 2 
days of the asexual cycle (reviewed by Sinden, 1983). Most of the lifetime of gametocytes 
in P. falciparum, the immature gametocytes are sequestered, possibly in the bone marrow 
(Smalley et al., 1981).
As the mosquito sucks blood of the host, it takes in various forms of the parasite. Once 
inside the midgut of the mosquito, the asexual forms are digested together with the red 
blood cells, while the sexual ones undergo the process of gametogenesis. This is triggered 
by a drop in temperature below 30°C with subsequent rise in pH and unidentified 
mosquito midgut factors (reviewed by Sinden, 1983). With respect to mosquito midgut 
factors, a factor referred to as gametocyte-activating factor (GAP) was found in the 
midgut of female mosquitoes and is thought to be the natural inducer of Plasmodium  
gametogenesis (Garcia et al., 1997, Billker et al., 1997). Fusion of the two sexual forms 
in fertilization leads to the formation of the diploid zygote, which is the only diploid form 
of the parasite throughout its entire life cycle. The zygote, which is a non-motile round 
body, undergoes a rapid meiosis leading to the generation of the haploid mobile, 
elongated ookinetes (Gilles and Warrell, 1993) These newly developed ookinetes have to 
escape the hostile environment of the blood meal which contains antibodies, leukocytes 
and complement (Lensen et al., 1997, Tirawanchai et al., 1991). Ookinetes penetrate the 
midgut wall into the haemocele (Sinden et al., 1996). In vitro culture systems showed 
ookinetes of P. berghei to invade the midgut cells at their lateral apical surface followed 
by invasion of neighbouring cells with the invaded cell dying rapidly by apoptosis (Zieler 
and Dvorak, 2000). Circmsporozoite-and TRAP-related protein (CTRP) an ookinetes 
microneme protein (Yuda et a i ,  1999) was shown to be essential for this invasion. 
Disruption of its gene in P. berghei reduced ookinte gliding motility on glass surface, and 
inhibited invasion of mid gut wall as seen by absence of oocyts (Dessen et al., 1999). On 
the outer side of the midgut wall, ookinetes mature into oocysts which begin to develop in 
the vector 24-72hr post ingestion of infected blood meal (Meis and Verhave, 1988). 
Depending on the parasite species and the temperature, thousands of sporozoites are
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released from the mature oocyts into the haemoeoele within 7-15 days of blood meal 
(Awono-Ambene et al., 1998). Sporozoites travel to the salivary glands of the mosquito. 
When the mosquito feeds on blood, the sporozoites are injeeted into the host circulation 
and the whole life cycle is repeated.
During the parasite life cycle within the host, three phenomena have been reported with 
significance in the disease severity. These are, antigenic variation, cytoadherence and 
rosetting, which are mentioned here because of their importance.
Antigenic variation
Antigenic variation refers to a process of controlled phenotypic variation of surface- 
exposed antigenic determinants without introducing changes in the genome. It is a prime 
immune evasion mechanism employed by a number of pathogens such as Plasmodium  
and Trypanosoma to maintain a chronic infection (Borst and Greaves, 1987, Miller et al., 
1994). In P. falciparum, protein PfEM Pl which is expressed on the surface of infected 
erythrocytes and which mediates adhesion to other erythrocytes and to endothelial cells, is 
clonally variant (Baruch et a i, 1995, Rowe et a l ,  1997, Chen et a i, 1998). This protein is 
encoded by a set of var genes which are distributed through out all the 14 chromosomes 
of the haploid Plasmodium  genome and each parasite contains approximately 50-150 var 
genes (Su et al., 1995, Rubio et al., 1996, Fischer et a l ,  1997, Hernandez-Ri vas, 1997). 
Infected erythrocytes express only a limited number of var gene variants at any given time 
and var gene switching occurs at a rate of approximately 2% per generation in vitro 
(Roberts et a l ,  1992, Smith el a l ,  1995, Rowe et al., 1997, Chen et al., 1998), Two 
additional variant proteins are expressed on the surface of infected erythrocytes and 
undergo clonal variation. They are encoded by the rif and STEVOR genes (Kyes et al., 
1999, Fernandez et al., 1999). A technique established for examining var gene expression 
has shown that ubiquitous transcription of all var gene variants occur in early ring stages. 
In trophozoite stages, var gene expression is tightly regulated by a silencing mechanism 
(Scherf et al., 1998). The clinical importance of antigenic variation is that it imposes a
great challenge on the host’s body which constantly has to recognize new antigens and 
therefore start an immune reaction all over again.
Cytoadherence
Cytoadherence is the process whereby red blood cells infected with mature parasites bind 
to endothelial cells in post-capillary venules (Udeinya et al., 1981). Erythrocytes infected 
with mature asexual stages (trophozoites and schizonts) of P. falciparum  bind to 
endothelial cells of post-capillary venules of many organs such as the brain, heart, lungs, 
small intestine and in the placenta in humans (Aikawa et a l ,  1990, Pongponratn et al.,
1991). In ihQ Aotus monkeys they are found primarily in the heart, adipose tissue, skeletal 
muscle and submucosa of the small intestine (Miller, 1969). This phenomenon is 
responsible for the presence of ring and non-pigmented young stages only in the 
peripheral blood as reported by Bignami and Bastinelli in 1890 (reviewed by Crandall and 
Sherman, 1994).
Cytoadherence is thought to help the mature erythrocytic forms avoid splenic filtration 
(Langreth and Peterson, 1985, Barnwell, 1989). It must be emphasized, however, that 
those parasites that do not exhibit cytoadherence like P. malariae also manage to undergo 
successful proliferation. Another suggested function for cytoadherence is to provide 
relatively low oxygen tension and high carbon dioxide tension found in post-capillary 
venules which are beneficial for the development of P. falciparum  in in vitro culture 
(Scheibel et a i ,  1979).
Cytoadherence is thought to play a vital part in the pathogenesis of severe malaria 
including cerebral malaria (Berendt et al., 1994) through causing mechanical obstruction 
to blood flow and subsequent hypoxia (Aikawa et a i,  1990). Another suggested 
mechanism for damage caused by cytoadherence is the localisation of any released 
parasite toxins or indeed proinflammatory damaging cytokines in a particular area (Pasvol 
et a i ,  1995). Furthermore, local release of nitric oxide by cerebral endothelial cells is
thought to interfere with the normal neiirotransmission leading to coma (Clark et al.,
1992). f
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In the case of P. falciparum  several endothelial proteins have been identified as receptors 
for the infected red cells, among these are intracellular adhesion m olecule-1 (ICAM-1)
(Berendt et al., 1989), vascular adhesion molecule-1 (VCAM) (Ockenhouse et al., 1992), I
CD36 (Barnwell et al., 1989, Oquendo et al., 1989), thrombospondin (Rock et a i ,  1988),
E-selectin (Ockenhouse et al., 1992), the syneytiotrophoblast chondroitin sulphate 
(Rogerson et al., 1995) and hyaluronic acid (Beeson et a l, 2000). The parasite-infected 
red cell surface molecule which mediates this binding is the variable Plasmodium  
falciparum erythrocyte membrane protein 1 (PfEM Pl) (Howard et a l ,  1988, Leech et a l ,
1984, Reeder et a l ,  1999) which can bind to any of the above receptors simultaneously 
through its multiple adhesion domains. Variability in the disease severity among infected 
individuals has been attributed to variation in both the parasite adherence capacity to the 
host endothelium and to the ICAM-1 polymorphism in the host. For instance, a certain - |
mutation in ICAM-1 has been shown to be associated with a greater risk of cerebral .!
malaria in Kenyan children although no such association was found in Gambian children 
(Fernandez-Reyes et a l ,  1997, Bellamy et a l, 1998). This is thought to be due to the P. 
falciparum  isolates from Kenya having a greater binding tendency to ICAM-1 than the 
isolates from Gambia (Adams et a l ,  2000). 7
Cytoadherence also occurs in the immature developing sexual stages of the parasite but 
they preferentially adhere to the vasculature of the spleen and the bone marrow (Smalley 
et a l ,  1976). These forms start to adhere within 24hr following red cell invasion and 4
remain there for 8-10 days until reaching stage V of their development when they re-enter 
the circulation and are capable of transmission through mosquitoes (Berendt et a l ,  1990).
Cytoadherence of the sexual forms is thought to be important for their development into 
the mature stages. Among the receptors used by the sexual forms to bind to the 
endothelium are ICAM-1 and CD36 (Rogers at a l ,  1996) while Band 3 has been
suggested to be the ligand on the infected red cells responsible for cytoadherence 
(Crandall et al., 1993, Rogers et al., 1996 ).
Resetting:
Rosetting describes a phenomenon in which uninfected erythrocytes adhere to trophozoite 
and schizont-infected erythrocytes in in vitro conditions. Up to 10 uninfected erythrocytes 
can be seen attached to a single infected erythrocyte and giant rosettes made of 20-30 
cells have occasionally been reported. Rosetting was originally noticed in the simian 
malaria parasite P. fragile (David et al., 1988) and later seen in several Plasmodium  
species including P. falciparum  (Handunnetti et al., 1989, Udomsangpetch, 1989), P. 
coatnely (Udomsangpetch et al., 1991), P. vivax (Carlson et al., 1990) and P. chabaudi 
(Udomsangpetch et al., 1995). The molecules involved in rosetting include, CD36 and 
PfEM Pl (Handunnetti et a i ,  1992).
The clinical significance of rosetting was investigated by several groups and the results 
were not always in agreement with each other. In the case of cerebral malaria in children 
from Papua New Guinea, no correlation was found between the degree of rosette 
formation and disease severity (Al-Yaman et al., 1995) while a positive correlation was 
noted in children with cerebral malaria in Gambia (Carlson et a i ,  1990) and in patients 
from Malagasy (Ringwald et a l ,  1993). In the ease of malaria in pregnancy, it was found 
that rosette forming-isolates are rarely found in the placenta indicating that rosetting did 
not correlate with disease severity here (Rogerson et a i,  2000).
It must be emphasized, however, that rosette formation is an in vitro phenomenon and its 
occurrence in vivo has not been reported yet. Hence results obtained from studies of 
rosetting must be interpreted with caution.
Recently another phenomenon was described and thought to be involved in determining 
disease severity. This is the agglutination of infected erythrocytes through platelets (Pain 
et a i , 2001). This platelet-dependent clumping of infected erythrocytes was found to 
occur through the platelet surface protein CD36. It was also found to be common in field 
isolates of P. falciparum  from Kenya and to be associated with severe malaria (Pain et 
a i ,  2001)
Epidemiology:
Occurrence of a disease is described by two main terms, epidemic and endemic. Epidemic 
malaria describes a sharp rise of the incidence of malaria among a population in which 
the disease was not known or an increase in clinical malaria in an area moderately 
endemic, due to some introduced factor. Endemic malaria is used when there is a 
consistent measurable incidence both of cases of the disease and of its natural 
transmission in an area over a succession of years. It is classified in the following way: 
Holoendemic representing constant high exposure (perennial transmission of high degree 
resulting in a considerable degree of immune response in a large proportion of adults), 
hyperendemic describing high but seasonal exposure (immunity here is insufficient to 
prevent the effects of malaria on all age groups),
mesoendemic is found typically among small rural communities in the subtropical zones 
with varying intensity of transmission depending on local circumstances and 
hypoendemic where there is little transmission and the effects of m alaria on the general 
population are unimportant (Gilles and Warrell,1993).
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Clinical Malaria:
Malaria can present in a wide spectrum of clinical features ranging from asymptomatic 
parasitaemic individuals to death due to multi organ failure. Among clinical conditions 
caused by malaria are:
Anaemia
Severe malaria is one of the complications of falciparum malaria. W HO has defined 
severe malaria as a Hb concentration of < 50g/L or a haematocrit < 0 .1 5  in the presence 
of a Plasmodium falciparum  parasitaemia > 10000 parasites /pi in a normocytic blood 
film. (Warrell, D. A. et a l, 1990).
The anaemia of malaria is multifactorial, involving both increased destruction and 
decreased production of erythrocytes. Destruction of the infected erythrocytes occurs at 
the time of schizont rupture (Greenwood et al., 1991) and also there is premature removal 
of non-infected red cells by the spleen (Maggio-Price et al., 1985). In addition, there is 
bone marrow suppression although the haematopoetie growth factors such as IL-3 and 
erythropoietin are normal or even elevated (Villeval et a i ,  1990).
The relative contribution of the above mechanisms in the development of anaemia in 
malaria depends on the age of host, pregnancy status, anti-malarial immune status, 
genetic background of the host and the endemicity of the disease. In general it is thought 
that haemolysis plays the bigger part in non-immune children with acute malaria, while 
dyserythropoeisis is seen in individuals experiencing recurrent or frequent falciparum 
malaria although in any one individual several mechanisms are likely to operate 
(reviewed by Medez, Fleming, and Alonso 2000).
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Cerebral malaria
Cerebral involvement in the form of convulsions or impaired consciousness in falciparum 
malaria can arise due to several factors. These are; side effects of chemotherapy, 
electrolyte imbalance due to vomiting, fever and hypoglycaemia (due to severe malaria 
per se or quinine therapy). All the above factors can impair consciousness and/or induce 
epileptic fits.
The term cerebral malaria (CM), however, is restricted to unarousable coma in P. 
falciparum  positive patients and after excluding other causes of encephalopathy. Cerebral 
malaria occurs in approximately 1% of patients infected with P. falciparum  and carries a 
mortality of approximately 15 % in children and 20% in adults (Warrell et a l, 1997, 
Allen et a i, 1996, Hien et a l, 1996).
At one point CM was thought to be due to changes in the blood brain barrier (BBB) 
permeability leading to intracerebral oedema (Maegraith and Fletcher 1972). Based on 
this hypothesis, patients with cerebral malaria were given a dexamethasone infusion but 
contrary to the expectations then, there was no difference in mortality between the treated 
and the untreated gi'oups while coma was prolonged in the treated group. This led to 
abandonment of ancillary corticosteroid therapy and rejection of the permeability 
hypothesis (reviewed by Warrell, 1997). Post-mortem examination of brains of 
individuals who had died of CM, revealed cerebral pigmentation due to haemozoin 
deposition resulting from haemoglobin breakdown and some petechial haemorrhages 
around capillaries. The rest of the brain appeared relatively normal with little 
extravascular pathology (MacPherson et a i ,  1985). Mechanical obstruction of cerebral 
vessels by adherent parasites was also thought as a mechanism causing cerebral malaria. 
Indeed post-mortem studies have shown plugging of capillaries with infected erythrocytes 
(Warrell, 1990, Aikawa et a i ,  1990). Carotid angiography, done on some patients with 
post-eerebral malaria stroke, however, revealed that only a portion of the patients had 
large vessel obstruction while the others had clear vessels (Gille and W arrell, 1993). The
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other cases in which no vascular obstruction is found, neurological deficit was thought to 
be due to cerebral infarction caused by an imbalance between the energy demands of the 
cerebral tissue, especially during convulsions, and the shortage of energy supply due to 
hypoglycaemia and anaemia (reviewed by W hite and Ho, 1992). Another mechanism 
suggested to play a role in the pathogenesis of cerebral malaria is local nitric oxide (NO) 
production by cerebral endothelium with a consequent disturbance of neurotransmission 
(Clark CÏ a/., 1992).
Most of the survivors recover fully but some 5% of adults have remaining neurological 
sequelae (Warrell et al, 1982) including psychosis, extrapyramidal features, hemiparesis, 
neuropathies including the cranial nerves, focal epilepsy and Guillian-Barre syndrome 
(Gilles and Warrell, 1993), whereas 10% or more of the affected children do show 
sequelae (Brewster et al, 1990). Common sequelae in children include hemiplegia, 
behaviuoral disturbanees, tremors, mental retardation and epilepsy (reviewed by Warrell, 
1997).
In the murine model of CM, P. berghei ANKA infection in C57B1/6 mice leads to 
paralysis, coma and then death after 6-9 days (Rest et a l,  1982). There are differenees 
noticed between the human cases and the murine model of CM. These include, the 
infiltration of the miee cerebral capillaries with mononuclear cells rather than 
erythrocytes (Rest et al., 1982, Polder et a i ,  1988). Also in the murine CM, cerebral 
oedema has been demonstrated by the reduced brain density and break down of the BBB 
by Evans blue (Thumwood et a i,  1988). Two types of histological changes were reported 
in P. berghei ANKA-infected mice. Type I seen in acute lethal cerebral malaria 
characterized by widespread microglial activation, endothelial cell damage, and 
microvascular disruption in the brain tissue. Type II was seen in animals looking normal 
clinically, characterized by focal mononuclear cell inflammation without endothelial 
damage. The authors suggested that the same might be true for human cerebral malaria 
(Jennings g/ c/f, 1998).
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Recently it was shown that tumor necrosis factor a  receptor 2 (TNFaR2) expression on 
brain tissues is required for the development of experimental cerebral malaria (Stoelcker 
eî aL, 2002). Also it was shown that during CM there is increased expression of TNFR2 
on brain vascular endothelium (Lucas et a i,  1997). Mice deficient in TNFR2 were 
protected from the lethal syndrome and did not increase expression of ICAM-1 on brain 
microvascular endothelial cells (Erickson e /a f ,  1994)
Malaria-associated problems in pregnancy
The prevalence of low birth weight, spontaneous abortions and stillbirths has been 
reported to be higher in pregnant women infected with P. falciparum  malaria than healthy 
pregnant women (McGgregor, W ilson and Billewicz, 1983, W atkinson, Rushton and 
Lunn, 1985, Stekette et al., 1996a). Congenital malaria is a rare condition defined as 
finding parasitizes erythrocytec in the blood of a neonate of < seven days of age (Djibo 
and Cénac, 2000). The mechanisms for this are not known but it could be possible that 
there is trans-placental transfer of the recently-discovered forms, the merophores (Landau 
et al., 1999).
Other manifestations of falciparum malaria include black water fever, multi-organ failure, 
coagulopathies, respiratory distress and hypoglycaemia. In most adults who die from 
falciparum malaria, there is multi-organ failure. The principal causes of death are 
pulmonary oedema, acute renal failure, metabolic acidosis and circulatory collapse (Gillis 
and W arrell, 1993).
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Factors affecting the disease severity in malaria:
Several factors play a part in determining the clinical presentation of falciprum malaria 
and its severity. Among these are endemicity of disease, factors inherent in the pathogen 
and factors inherent to the host.
Disease Endemicity
It has been noted that in holoendemic areas (constant exposure), anaemia predominates in 
young children, while in hyperendemic areas (seasonal exposure) cerebral disease is 
commoner (Pasvol et al., 1995).
Pathogen factors
Pathogen-related factors include tendency of parasitized erythrocytes to cytoadhere to 
endothelial cells and to form rosettes (Pasvol 1992). Studies examining the effect of these 
factors on disease severity have not produced conclusive results. Details are mentioned 
under cytoadherence and rosetting.
Host factors:
These include genetic factors such as T N Fa promoter polymorphism (McGuire et al.,
1994) and haemoglobinopathies, diet, age, sex, pregnancy and parity, social factors such 
as education, health seeking behaviour and the availability of health facilities both in 
peace and war (Prusty, 2001). Details will follow under immunity against malaria.
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Immunity against malaria:
In malaria endemic areas, it has been reported that immunity against non-cerebral severe 
disease is acquired at a young age after possibly two attacks of the disease (Gupta et al.,
1999). Immunity to the disease in general, however, develops after many years. This state 
of acquired immunity is established after several years of living in endemic areas and is 
referred to as premunition (Trape et al., 1994, Bottius et al., 1996) and probably 
represents a balance between the host and the pathogen, which allows survival of both. 
The chronicity of infection is thought to be due to several features of the malaria parasite 
including antigenic polymorphism in different isolates and antigenic variation (Hommel 
and Semoff, 1988). Recently another mechanism for malaria chronicity was suggested 
following the discovery of new forms of the parasite hitherto unknown. Impression 
smears of organs and lymphatics of infected animals showed structures referred to as 
merophores containing merozoites which have resisted lysis seen with other asexual stage 
parasites. Their number was found to be proportional to the number of maturing 
schizonts. The discovering team suggested that they could play a role in the 
recrudescence and chronicity of rodent malaria. (Landau et a l, 1999).
The protection gained by the host is thought to be due to a mechanism involving an 
interaction between IgG and monocytes referred to as antibody-dependent cellular 
inhibition (ADCI) (Lunel & Druilhe, 1989, Bouharoun-Tayoun et a l, 1990). This 
mechanism requires the presence of a certain level of merozoites in the circulation to 
trigger it, hence the persistence of a very low level of parasitaemia. It is also thought to be 
non-selective for any particular antigenic variants, otherwise the level of parasitaemia 
would show large fluctuations which is not the case in chronic disease (Druilhe and 
Peri g non, 1997).
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Age
The risk of malarial disease is significantly reduced during the first quarter of infancy 
across a wide range of transmission intensities (Snow et a l ,  1998). This early protection 
is attributed to the presence of maternal malaria-specific IgG in the foetal circulation 
(McGregor 1956), presence of haemoglobin F (Pasvol, 1977) and riboflavin and p- 
aminobenzoic acid (PABA) deficiency in infants diet (Bates, 1982). During the second 
quarter of infancy the risk of malaria severity seems to depend on the transmission rate, 
being high in areas of high transmission. In such areas, however, the risk declines after 
the sixth month of age, implying that clinical immunity is acquired at a very early age 
(Snow et al., 1998). McGregor described an antitoxic immunity in the age group of 2-3 
years exposed to heavy infection since birth. In this group asexual parasitaemia is high 
and yet without apparent illness (McGregor, et al. 1956). The general consensus is that in 
sub-Saharan Africa P. falciparum  predominantly affects children < 5 years old among 
whom mortality is greatest (Marsh, 1992).
Diet
Perhaps the importance of diet in malaria infection was an accidental finding. It was 
noticed that rats fed a milk diet were difficult to infect with P. berghei. The protective 
role of milk was subsequently confirmed by Maegraith, Deegan and Sherwood Jones 
(1952) who reported suppression of parasitaemia in rats infected with P. berghei and fed 
on cow, human or reconstituted dried milk. The reason for this resistance was found to be 
the lack of p-aminobenzoic acid (PABA) in milk and indeed this suppression was 
reversed with the addition of PABA (Hawking, 1954).
Later studies showed the involvement of other dietary agents like cod liver oil which was 
found to prolong survival of P. berghei infected mice despite the presence of p- 
aminobezoic acid in their diet. This suppression was, however, reversed on addition of 
antioxidants vitamin E, C or tetraethylthiuram disulfide (Godfrey, 1957). The authors
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suggested that unsaturated fatty acids of the cod liver oil were oxidized by the host to 
peroxides creating a hostile pro-oxidant environmenl to the parasite. Vitamin E, which is 
an anti-oxidant, prevented peroxidation and so provided parasite friendly conditions. 
Also, vitamin E deficient diets enriched with fish oils were shown to suppress lethal P. 
yoelii infections in athymic mice and led to survival without developing detectable 
parasitaemia in SCED/bg mice infected with non-lethal P. yoelii. (Taylor el al., 1997).
Restriction of dietary protein intake in mice and rats reduced severity of P. yoelii, P. 
berghei and P. vinkei infections (Ibekwe and Ugwunna, 1990). It has also been noticed 
that severe malaria is extremely rare in children with protein-energy malnutrition such as 
Kwashiorkor and marasmus, and that nutritional supplemental on in malarious patients 
exacerbates the disease (Marsh, 1995). It is worth mentioning that traditional medicine 
of some communities involves reducing red meat protein intake and replacing it with fish 
protein in any acute illness characterized by fever and lethargy including malaria 
(personal experience, my mother). Furthermore, it was shown that the addition of m-3- 
fatty acids of fish origin inhibited the development of P. falciparum  in vitro 
(Kumaratilake et a l,  1992).
Effect of a combination of diet and red cell abnormalities was seen in the case of eating 
fava beans in patients with G6PD deficiency. Vicine and convicine constituents of fava 
beans produce potent pro-oxidants upon hydrolysis. These products increase phagocytosis 
of malaria-infected erythrocytes especially G6PD deficient cells (Ginsburg et a l, 1996).
Pregnancy
During pregnancy, previously immune women become suseeptible to malaria infection 
and tend to suffer severe disease. Prim gravi da seem to be at a higher risk than 
mutligravida in both prevalence and severity of disease (McGregor et a l ,  1983, Fleming 
et a l ,  1989, Kasumba et a l ,  2000). The increased susceptibility to malaria during 
pregnancy is not due to reduced humoral immunity since no significant drop in the levels 
of malaria-specific antibodies was found in the state of pregnancy (McGregor et a l .
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1984). It is thought to be due to the sequestration in the placenta of a subpopulation of 
isolates which preferentially bind to placental molecules such as chondroitin sulphate A 
(Fried and Duffy, 1996, Beeson et al., 2000) and hyaluronic acid. Also, Non-immune IgG 
were recently shown to bind to the Duffy binding-like (DBL) domain of the PfEM Pl 
molecule on the surface of infected erythrocytes and anchor them to the 
syneytiotrophoblast through binding to Fc receptors (Flick et al., 2001). Resistance in 
multigravida, on the other hand, has been attributed to the presence of antibodies against 
a wide range of placental parasite isolates (Beeson et al., 1999, Freid et al., 1998).
Genetics; 
Polymorphism in red blood cells
Involvement of host genetic makeup in susceptibility to malaria was noted by Haldane 
who suggested that the very high frequency of thalassaemia in the Mediterranean region 
was not due to high frequency of mutations but rather due to resistance the heterozygous 
state of thalassaemia confers against malaria (reviewed by Weatherall, 1997). Also, early 
studies reported that HbS provided protection against P. falciparum  (Allison, 1954) and 
subsequent studies confirmed that indeed > 90% of Gambian children with HbAS were 
protected against severe P. falciparum  disease (Hill et a l ,  1991).
The mechanisms of this protection are still not fully elucidated though several hypotheses 
have been put forward. Among these are, sickling and rapid removal by phagocytosis in 
the spleen of parasitized red blood cells with HbAS (Luzzatto et a l, 1970), reduced 
ability of parasitized red blood cells with HbAS to grow under low oxygen tension 
environment (Pasvol et a l,  1978) and release of toxic substances to malaria parasite from 
infected red blood cells with HbAS upon sickling (Orjih et al., 1985). Also, Low rosetting 
tendency was thought to play a part in protection from malaria in individuals with sickle 
cell trait. This idea, however, proved to be wrong since HbAS red cells had similar 
tendency of rosette formation in vitro as those with HbAA (Udomsangpetch et al., 1993). 
W hile reduced cytoadherence and rosette formation was suggested to be the mechanism
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of protection from P. falciparum  malaria in individuals heterozygous for thalassaemia- 
P and thalassaem ia-a (Udomsangpetch et al., 1993, Carlson et al., 1994).
HLA system:
Studies in the Gambia, West Africa, revealed an inverse correlation between HLA-B53 
and disease severity with reduced frequency of HLA-B53 in children with cerebral 
malaria and in those with severe malaria (Hill et al., 1991). Since erythrocytes do not 
express HLA molecules, it was thought the protection conferred by the HLA B53 
molecule could not be related to the parasite’s invasion into erythrocytes. Subsequent 
studies showed that the HLA-B53 was involved in antigen presentation of the hepatic 
stage antigen LSA-1 to the C D 8^ T cells (Hill et al., 1994). Class II molecules HLA- 
D R B land DQB which are common in West Africa but rare in other racial groups were 
also found to be associated with protection against falciparum malaria with a magnitude 
similar to that produced by HbAS (Hill et al., 1991, 1992).
Tumor necrosis factor alpha (TNFa) promoter
Polymorphism of TN Fa gene promotor region has been reported to play a role in disease 
severity in P. falciparum  malaria. Gambian children homozygotes for TNF2 allele, which 
is a variant of the T N Fa gene promoter region, were found to have a relative risk of 7 for 
death and severe neurological sequelae from cerebral malaria (McGuire et a l ,  1994). The 
authors suggested that this could be due to increased levels of T N Fa production by TNF2 
allele, which was reported to be associated with higher constitutive and inducible T N F a 
transcription levels (Wilson et al., 1994).
Polymorphism in NOS2 promotor region
Polymorphism in inducible nitric oxide synthase 2 (NOS2) promotor region affecting 
malaria severity have been described. A 1173 C-T polymorphism was found to be
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associated with increased nitric oxide (NO) production and protection against cerebral 
malaria and severe malaria anaemia in Tanzanian and Kenyan children (Hobbs et al., 
2002). Also a 954 G to C polymorphism was associated with mild malaria in Gabon (Kun 
et al., 1998).
CD36
CD36 is one of endothelial receptors for adhering parasitized erythrocytes (Rogers et al., 
1996). It also, however, mediates uptake of non-opsonised parasitized erythrocytes by 
human monocytes and its activation on monocytes by phagocytosis of infected red cells 
does not induce the release of T N F a (McGilvary et a l.,1999). Individuals deficient in 
CD36 were found to be more susceptible to severe and cerebral malaria (Aitman et al., 
2000). The authors suggested that the protective role of CD36 was through increase 
phagocytosis of infected cells and reduced T N F a production.
Immunity against pre-erythrocytic stages:
Neither the sporozoites nor the hepatic stages cause any clinical disease, nevertheless host 
immune response develops against them. In fact the amount of immune response against 
the hepatic stages has been shown to determine the susceptibility of the host to the 
infection. For example in BALA/c mice it has been shown that resistance and 
susceptibility against the hepatic stage of two related species, P. berghei and P. yoelii is 
determined by the size of hepatic response mounted against each parasite. In the case of 
P. yoelii to which BALB/c mice are susceptible, there is little cellular response and 
significant histopathological changes within the liver are not observed until after hepatic 
schizonts have begun to rupture at around 44 hr post-injection of sporozoites. In contrast 
to this is the development of substantial cellular response and histopathological changes 
within the liver by 24 hr post-injection of P. berghei sporozoites against which the mice 
are resistant (Khan and Vanderberg, 1991).
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Several surface proteins expressed during the hepatie stages have been shown to be the 
target for an immune reaction. Among these are circumsporozoite protein (CSP), 
thrombospondin related adhesion protein (TRAP), liver stage antigen-1 (LSA-1) and liver 
stage antige-3 (LSA-3).
Mature sporozoites in the mosquito’s salivary glands and in the host circulation have a 
major surface protein referred to as the circumsporozoite protein (CSP). It contains three 
regions, the central region consisting of immunodominant multiple repeat sequences that 
are species specific. The two flanking regions, I and II, seem to be highly conserved 
among different species. CSP is secreted from the apical end of the sporozoite and 
translocated posteriorly during its motility (Stewart and Vanderberg 1988, 1991). Also 
region II of the CSP has a high degree of structural homology to thrombospondin (Cerami 
et a l ,  1992) an adhesion molecule also involved in the process of cytoadherence. Hence it 
has been suggested that the CSP may be involved in binding the sporozoites to the 
hepatocytes via this region. Once inside the hepatocytes, substantial amounts of the CSP 
are shed into the hepatocyte cytoplasm (Khan, Ng and Vanderberg, 1992) and as the 
parasite develops inside the hepatocytes, the CSP becomes localized around the periphery 
of the parasite. The importance of these events in parasite development or stimulation of 
the host’s immune response is not known yet. The immune response against this surface 
protein involves both antibody-dependent and independent mechanisms as demonstrated 
in both murine and human malaria (Mazier et al., 1988).
Antibody-dependent immunity against pre-erythrocytic stages
In murine malaria, the involvement of antibodies to pre-erythrocytic stages was evident 
when serum from mice immunized with P. berghei irradiated sporozoites inhibited the 
invasion and development of exo-erythrocytie forms in vitro (reviewed by Chatterjee et 
al., 1996). Similar results were obtained in vivo when antibodies recognizing the repeat 
region of the CSP from mice immunized with irradiated sporozoites of P. berghei or P.
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yoelii protecled recipient mice against a homologous sporozoite challenge (Polocnjak ei 
a l ,  1980, Charoenvit (?/r//., 1991).
Antibodies to other sporozoite surface proteins have also been reported to inhibit invasion 
into hepatocytes. Among these are antibodies recognizing a 17kDa protein found on the 
parasitophorous vacuole membrane of hepatocytes or erythrocytes infected with P. yoelii. 
These antibodies were found to inhibit the development of intrahepatic forms of P. yoelii 
in vitro (Charoenvit et al., 1995). In P. falciparum  thrombospondin related adhesion 
protein (TRAP) which, is found in the micronemes as well as on the surface of salivary 
gland sporozoites also seems to be involved in the sporozoite invasion into the 
hepatocytes (Robson et a l ,  1995) and in the motility of the sporozoites. Antibodies raised 
against TRAP inhibited hepatocytes invasion in vitro (Rogers et a l ,  1992a, Muller et a l, 
1993). Also, antibodies against P. falciparum  knob-associated PfEMP3 which is 
expressed on the exo-erythroeytic stages as well as in asexual blood stages have recently 
been shown to inhibit the invasion of hepatocytes by P. falciparum  sporozoites in vitro 
(Gilmer et al., 2001).
Cross-species protection to the pre-erythroeytic stage has been reported in several studies. 
M ice immunized with P. falciparum  sporozoites were protected against P. berghei 
sporozoite challenge (Sina et a l ,  1995). Sera from these animals recognized 
circumsporozoite protein 2 (CSP2) protein in both P. falciparum  and P. berghei and 
inhibited P. falciparum  and P. berghei sporozoite invasion of hepatoma cells in vitro 
(Sina et a l ,  1995). LSA-3 specific human antibodies exert 100% inhibition of invasion of 
P. yoelii into mouse hepatocytes in vitro (Brahimi et a l, 2001).
The mechanisms by which anti-pre-erythrocytic stage antibodies protect the host are not 
clearly defined but more than one mechanism could be involved. Anti-CSP antibodies, 
for instance, have been shown to inhibit the entry of sporozoites into hepatocytes (Mazier 
et a l ,  1987, Nudlemann et a l ,  1988). Some studies, however, have reported an 
enhancement of hepatocytes invasion by sporozoites by these antibodies. Low titers of
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anti-CSP antibodies of P. falciparum  (Hollingdale et al., 1988) and of P. yoelii 
(Niidelmann et al., 1988) showed an increase number of hepatic form of the parasite.
Anti-CSP antibodies have also been shown to play a part post-hepatocyte invasion. In P. 
falciparum  anti-CSP antibodies were found to interfere with the sporozoite attachment to 
the hepatocytes membrane and subsequent intrahepatocytic development of the parasite 
(Mazier et al., 1988). It was thought that since CSP persisted throughout hepatic 
schizogony then anti-CSP antibodies bound to the parasite could block translocation of 
the CSP to the parasitophrous vacuole membrane increasing therefore the acidity inside 
the vacuole with a subsequent lysosomic digestion of the trophozoites hence reduce 
intrahepatic parasite development (reviewed by M azier et al., 1988).
Antibody-independent mechanisms
T cell involvement in immunity against pre-erythrocytic stages was demonstrated when 
Chen induced protection with irradiated sporozoites in B cell deficient mice (Chen et al., 
1977). Adoptive transfer of cytotoxic T cell clones recognizing an epitope contained 
within amino acids 249-260 of P. berghei CSP provided a high degree of protection in 
naive mice against sporozoite challenge (Romero et a l ,  1989). The protective immunity 
induced by irradiated sporozoites was shown to be CDS'*" T cells-dependent (Weiss, et al., 
1988, Schofield et al., 1987). Depletion of CDS’*" T cells abrogated protection achieved 
by vaccination with attenuated vaccinia virus (NYVAC) recombinants expressing the 
CSP (Lanar et a l, 1996). The cellular response in the liver of mice infected with P. yoelii 
was shown to vary according to the method of immunization. Irradiated sporozoites 
induced a significant increase in CDS'*' T cells while live sporozoites led to an increase in 
polymorphonuclear cells, monocyte/macrophages, B cells and a range of T cells (Faure et 
a l,  1995). The mechanism suggested for this protection by CD8^ cells involves IFNy 
(Schofield et al., 1987, Weiss et al., 1992) which is produced by CDS'*' T cells upon 
activation (Weiss et a l ,  1988). Systemic adiuinistration of IFNy protects rhesus monkeys
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against a P. cynomolgi B sporozoite challenge (Maheshwari et al., 1986). The sterile 
immunity observed in mice immunized with irradiated sporozoites is abrogated following 
anti-IFNy neutralizing antibody treatment (Schofield et al., 1987b, Seguin et a i ,  1994). 
Immunization of mice with P. berghei sporozoites induces IFNy production (White, 
Jarboe and Ki'zych, 1994). IFN-y and IL-1 were shown to inhibit strongly P. falciparum  
sporozoites development in hepatocytes in vitro but neither exerts any effects directly 
which means that they lead to effecter mechanisms. IL-1 was shown to inhibit at a very 
early stage of infection (Mellouk et al., 1987) and its inhibitory effects was shown to be 
due to its induction of C-reactive protein (CRP) production by hepatocytes which 
inhibited P. yoelii (Pied et a l ,  1989). IFNyproduced its inhibitory effects intra- 
hepatically (Mellouk et al., 1987).
Production of IFNy, however, could not be the only role of CD8^ T cells in immunity 
against the sporozoites since the presence of CD8^ T cells was found to be essential in 
protection against P. berghei sporozoites. Mice lacking p2-maeroglobulin (do not express 
MHC class I molecules) and hence are deficient in CDS’*' T cell function, failed to be 
protected against P. berghei sporozoite challenge despite the fact that this challenge did 
stimulate the production of IFNy along with IL-2 and anti-CSP IgG (White et al., 1996).
The role of CD4^ T cells in immunity against the exo-erythrocytic stages appeared later in 
literature than that for CD8  ^T cells. It was shown that a CD4^ T cells clone which had a 
cytotoxic activity in vitro mediated protection against a P. berghei sporozoite challenge 
(Tsuji et al., 1990). CD4^ T cell clones isolated from mice infected with a synthetic 
peptide corresponding to the amino terminal segment of P. yoelii CSP were found to 
eliminate liver stage parasites from hepatocytes in vitro in an MHC restricted manner 
which (Rénia et al., 1993) and following their adoptive transfer, could protect naive mice 
against sporozoite challenge apparently by direct killing (Rénia et al., 1993). Activation 
of CD4'*' T cells in response to CSP of P. falciparum  in individuals from Papua New 
Guinea has been observed (Doolan et al., 1994). CD4^ T cells responses against the pre- 
erythrocytie stages of the parasite does not seem to be restricted to CSP but other
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sporozoite proteins could be involved. Active immunization with synthetic linear peptides 
derived from P. yoelii protein PySSp2 (Wang et a l, 1996) or PyH epl? (Charoenvit et a l ,
1995) confers solid protective immunity, which is mediated by CDW T cells and is 
absolutely dependent on IFNy (Reviewed by Good and Doolan 1999).
Apart form T cells, immunity against exo-erythrocytic (EE) stages involves others cells 
too. Immunity against sporozoites of P. berghei involves infiltrations around infected 
hepatocytes by neutrophils and macrophages (Jap et a l ,  1982). The explanation of this 
infiltration is that after 47 hr, when some EE stages start to rupture, their products leak 
into the circulation for the infected hepatocytes are permeable and these products attract 
phagocytes (Meis and Verhave, 1988). Also, it was shown that dendritic cells may have a 
role in antigen presentation to the CD8^ T cells during the hepatic stages of the P. yoelii 
(Bruna-Romero and Rodriguez, 2001).
NO was shown to play an important role in immunity against intra-hepatic stages of the 
parasite. Inhibition of NO production led to failure of accumulation of CDS"*" T cells 
around infected hepatocytes (Scheller et a l ,  1997). The source of NO in Brown Norway 
rats challenged with P. berghei sporozoites was found to be the hepatoeytes which 
expressed increased levels of iNOS (Klotz et a l ,  1995). The authors also found that 
higher proportion of infected hepatocytes displayed iNOS activity in immunized rats 
compared to the naive ones after challenge and that eliminating the liver forms by 
primaquine significantly reduced the ability of immunized mice to express iNOS. The 
results therefore suggested that hepatic iNOS expression was dependent upon the 
presence of attenuated sporozoites. The inhibitory effects of IFNy on P. falciparum - and 
P. berghei-mï&ci&à hepatocytes in vitro was found to be mediated through NO (Green et 
a l,  1990, Mellouk et a l ,  1994).
It is now believed that protection in mice induced by immunization with irradiated 
sporozoites of P. berghei (Schofield et a l ,  1987, Seguin et a l,  1994) or P, yoelii (Doolan
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et a l ,  1996b) is dependent on CDS'*' T cells, IFNy and NO suggesting that activated CD8^ 
T cells secrete IFNy which subsequently activates iNOS (Doolan et al., 1996).
Role of the acute phase reactants
Both IL-1 and IL-6 have been shown to inhibit the intrahepatic stages of the parasite 
directly and indirectly (Mellouk et al., 1987, Pied et al., 1991). Both cytokines induce the 
synthesis of CRP (Heinrich et al., 1990) which is a major acute phase reactant. CRP was 
found to inhibit P. yoelii sporozoites invasion into hepatocytes in vitro. This inhibition 
was also seen in vivo when rats with high serum CRP due to prior treatment with 
turpentine oil were found to be largely protected against P. yoelii sporozoites challenge 
by not developing the blood stages (Pied et a l, 1989).
Inuiiunity against asexual erythrocytic forms: 
Innate immunity
Innate immunity to any infection involves various elements of the immune system 
including the mechanical barriers of the skin and mucous membranes, hostile 
environment produced by chemicals controlling the pH, phagocytic cells, and other 
proteins such as those of the complement system. Various studies investigating innate 
immunity in malaria have been done. Results of some of this work is presented.
Role of macrophages;
Macrophages were found to play an important role in the elimination of asexual blood 
stage parasites in rodent malaria. Administration of 3 mg of silica (blockades 
macrophages) to P. c AS-infected resistant C57B1/6 abrogated protection resulting in host 
mortality and delay in parasite clearance. Silica was injeeted on days -1 or day 6 post
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infection. It was shown that macrophage treatment with silica on day 6 was more 
efficient than on day-1 in suppressing protection leading to 70 % mortality. On the other 
hand administration of macrophage activating agents, such as muramyl dipeptide or 
liposome-encapsulated muramyl dipeptide glycerol dipalmitate resulted in significant 
survival of susceptible A/J mice (Stevenson et al., 1989). In vitro studies have shown that 
macrophages are capable of killing P. falciparum  (Ockenhouse et a l ,  1984, Ferrante et 
al., 1990). The work done by Ferrante group also confirmed the importance of non­
antibody mediated meehanisms against blood stages since the macrophage effectiveness 
was not affected by the presence of antibodies or complement (Ferrante et al., 1990). 
M acrophages had also been implicated in antibody-dependent cellular inhibition (ADCI) 
of P. falciparum. It was shown that the ADCI of P. falciparum  was mediated by factors 
produced by macrophages such as TNF (Bouharoun-Tayoun et al., 1995).
Role of neutrophils
In vitro studies have shown that upon contact with P. falcipaimm-'mfect&d red cells, 
neurtophils NADPH oxidase becomes activated with the production of oxygen reaetive 
entities which had been reported to be toxic to P. falciparum, P. yoelii and P. berghei 
(Wozencraft et a l,  1984, Dockrell and Playfair, 1984). It appears that this toxicity 
requires the presence of antibodies and that cytokines like T N F a upregulate the 
expression of Fc receptors on the neutrophils (Ferrante et al., 1990). On the other hand 
neutrophils have also been implicated in the pathology of malaria. Their sequestration 
in the brain and other organs is seen in histological slides of rodent malaria. It was found 
that treating P. 6erg/reCinfected mice with anti-PMN monoclonal antibodies abolished 
PMN sequestration in the lung and partially reduced monocyte sequestration in the lung 
and brain (Senaldi et al., 1994).
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Role of dendritic cells
It has been shown that the infected red blood cells actually bind to dendritic cells and by 
doing so, inhibit their maturation and the subsequent T cells stimulation (Urban et a l ,
1999). This was thought to be one of the ways the parasite evades the host immune 
system and results in chronic infection. Recently, however, it was shown that 
internalization of haemozoin by dendritic cells may actually activate them (Coban et a l,
2000) with subsequent activation of specific immunity through activation of T cells and 
of innate immunity through the production of IL-12 and interferons (1999, Mellman and 
Steinman, 2001).
Role of natural killer (NK) cells
It was shown in murine malaria that, on their own, NK cells from primed spleens of P. c. 
AS infected C57B1/6 could not transfer protection to naive mice. NK cell deficiency, 
however, resulted in higher mortality in deficient mice than controls. This does indicate a 
role for NK cells in protection albeit not essential (Kitaguchi et a l,  1996). It has also been 
shown that the major expanding lymphocyte population during murine malaria are the 
intermediate TCR (TCR'"*) cells, N K l.L  and N K l.D  cells (Pied et a l ,  2000, 
Weerasinghe et a l, 2001) which constitute part of the innate immunity. It was shown that 
depletion of N K l.R  cells resulted in a prolonged parasitaemia but the mice did recover 
from their infection (Mannoor et a l ,  2001) indicating therefore the role o f N K l.L  cells in 
resistance against murine malaria.
Role of Complement
Several studies have indicated a role for complement in protection against both human 
and rodent malaria. Complement was shown to kill both human and rodent malaria 
parasites at different stages of the life cycle in vitro in the presence of specific antibodies 
(Healer et a l, 1997, Pang & Horii, 1998). Complement was also shown to promote P.
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falciparum  killing by the monocytic cell line THP-1 in vitro (Kumaratlike et a i, 1997). In 
P. berghei-mf&ct&d rats complement depletion by injection of cobra venom caused rapid 
and higher parasitaemia and a higher mortality than the controls (Ward et a l, 1981). In 
P, c. c. AS-infected mice depletion of C lq  (a component of the classical pathway) by 
gene targeting resulted in a higher peak of primary parasitaemia. M ore importantly, 
however, the mice were susceptible to a secondary challenge with the same parasite 
indicating a role for C lq  in the development of immunity to reinfection (Taylor et a i,  
2001).
Specific Immunity:
In general specific immunity refers to immune responses involving T cells (cell-mediated 
immunity which is the predominant form against intracellular pathogens and B cells with 
their immunoglobulins (humoral immunity) which are predominant against extracellular 
pathogens. Again a wide range of experimental work has been done investigating the role 
of this arm of the immune system against asexual erythrocytic stages of malaria.
Role of T cells
T lymphocytes are characterized by the presence of the surface receptor CDS’*" and are 
subdivided into 2 main groups according to the surface markers CD4^ and CD8^ T cells. 
CD4’’’ T  cells are further divided into T helper 1 (T hl) cells producing IL-2, IFNy and 
TNF-(3 and Th2 cells producing IL-4, 5, 6 and 10 upon activation (Mosmann et al., 1986, 
1989, Cherwinski er n/., 1987)
A rich pool of evidence exists regarding the importance of T cells in malaria immunity. In 
rodent malaria, the importanee of T cell was demonstrated in early experiments using 
thymectomised animals, which developed a more severe disease than intact animals
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(Brown et al., 1968, W einbanni et al., 1976, Jayawarda et al., 1977, McDonald and 
Phillips, 1978b). Transfer of immunity to asexual blood stages was achieved by transfer 
of splenic and lymph node cells from immune animals (Phillips, 1970, Kasper and Aglar, 
1973). Moreover, it was reported that the appearance of crisis forms (which represent 
intraerythrocytic degeneration of parasites) in P. c AS-infected resistant C57B1/6 mice is 
T cell dependent (Stevenson et al., 1990).
Regarding the part played by different subclasses of T cells, the vast majority of 
experimental work has pointed out to the importance of CD4^ T cells in immunity against 
asexual blood stages. CD4^ T cells have been found to increase in the spleens of 
malarious mice (Weidanz et al., 1990). Their role in particular was demonstrated in 
experiments transferring splenic CD4^ T cells from immune donor mice and leading to 
resolution of acute infection in non-immune infected mice (Cavacini et al., 1986, Kumar 
and Miller, 1990). Furthermore, depletion of CD4'*' T cells by monoclonal antibodies in 
P. chabaudi infected-C57Bl/6 mice led to a significantly higher parasitaemia than the 
control mice and failure to reduce parasitaemia below 20% (Suss et al., 1988).
The importance of CD4^ T cells was initially thought to be for helping in the production 
of specific antibodies (Brown et a i, 1971). Indeed it was shown that P. chabaudi-inf&clcd 
C57B1/6 mice and depleted of CD4^ T cells by monoclonal antibodies early during 
infection (day7 or 12 post-infection) failed to clear the parasites, while those treated later 
(day 19) were successful in resolving the infection and that the resolution of infection was 
associated with the appearance of malaria specific IgG antibodies (Langhorne et al., 
1990). Production of specific antibodies, however, could not be the only function of 
CD4^ T cells since in P. chabaudi nc/nmFinfected mice, immunity was achieved by 
adoptive transfer of T cells although the mice were B cell-deficient (Grun et al., 1981, 
1983).
Another role suggested for CD4^ T cell was the activation of macrophages through the 
production of IFNy (Stevenson et al., 1990). Human macrophages stimulated with IFNy
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have been shown to kill P. falciparum  asexual blood stages in vitro (Okenhouse, 
Schulman & Shear 1984) by releasing reactive oxygen and nitrogen intermediates 
(Okenhouse e/n/., 1984, Rockett e /n /., 1991).
During a primary blood stage infection of mice with P. chabaudi chabaudi, the T helper 1 
and 2 (Thl and Th2) subsets of CD4^ T cells functions appear sequentially. Circulating 
IFNy, which is a Thl cytokine, peaks 2-3 days prior to peak parasitaemia. T hl cells, 
therefore, are thought to be important in controlling the primary parasitaemia. CD4^ Th2 
cells, on the other hand, seem to be more important later (day 28) when the parasitaemia 
has declined to sub-patent levels, to clear the infection (Langhorne et ah, 1989, 
Langhorne et a i ,  1989). This sequence was confirmed in experiments showing that CD4^ 
T cells obtained from P. chabaudi chabaudi-n\îc.ciQ.6. NIH mice on days 16 or 20 post 
infection had Thl characteristics in vitro, while those obtained from re-infected mice had 
Th2 characteristics (Taylor-Robinson and Phillips, 1992, 1993, 1994a).
Langhorne and colleagues suggested the following scheme of interaction between the Thl 
and Th2 cells in acute P, chabaudi chabaudi AS malaria. Thl cells are thought to 
recognize P. chabaudi chabaudi peptides presented in association with MHC class II 
molecules on antigen presenting cells and are then stimulated to produce IL-2 and IFN- 
y (Mosmann & Coffman, 1987). IL-2 and IL-4 act as growth factors for Th2 cells. These 
cells in turn after encountering antigens help B cells to produce specific antibodies 
(Mosmann & Coffman, 1987). IFNy on the other hand upregulates the expression of 
MHC class II molecules on macrophages and consequently increase antigen presentation 
and phagocytosis and release of down stream mediators such as T N F-a and reactive 
oxygen radicals (Nathan et a i ,  1983). This indicates that the Thl effects early during 
infection are mainly non-specific (Langhorne et a i, 1989). This was evident from the 
work of Jarra and Brown who showed that re-infection of mice 1 day after the peak of 
primary parasitaemia with the same or different strain of P. chabaudi AS led to a non­
specific protection against the heterologous eh all ange while specific mechanisms became 
evident when re-infecting later (Jarra and Brown, 1989).
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In falciparum malaria in people, it was found that circulating T cells are reduced during 
the acute attack of malaria and that the reduction correlates with disease severity, being 
highest in cerebral malaria. The drop affected CD4^ T cells frequency most markedly. 
(Hviid et al., 1997). The reduction in peripheral T cells is thought to reflect redistribution 
of T cells into the site of infection.
yô T cells were also found to play a role in immunity to malaria, yô T cells were found to 
increase in the spleens of mice during acute malaria (Bordessoule et al., 1990, van der 
Heyde et al., 1993, Ho et al., 1990, Roussilhon et al., 1990). In P. c. AS-infected mice, it 
was found that the majority of splenic T cells were a[3 in their normal proportions of 
CD4^: CDS"  ^ T cells, but that there was an 8-10 fold increase in the yÔ T cell population 
(Langhorne el a l, 1993). P. chabaucli-n\ïe.cie^d TCRô chain knock-out mice (TCRô'^') 
cleared primary parasitaemia with a slight delay but had a significantly higher 
recrudescent parasitaemia than the wild type. Depletion of a(3 cells, on the other hand, led 
to a failure to clear the infection and had a low malaria-specific antibodies level. These 
results clearly showed that yô T cells alone were not efficient in providing help for 
antibody production which is required for the clearance of the infection (Langhorne, 
Mombaerts and Tonegawa, 1995). yô cells in P. chabaudi aJam i-infected C57B1/6 mice 
proved to be essential for the suppression of infection. yÔ depleted mice by monoclonal 
antibodies were unable to suppress infection although their levels of splenic CD4^ a{3 T 
cells were similar to controls (van der Heyde et al., 1995).
In human malaria yÔT cells (Vyl, Vy2) were found to increase in the peripheral 
circulation of humans during acute P. falciparum  malaria and remain elevated for weeks 
following successful chemotherapy (Chang et al., 1992, Ho et al., 1994, Ho et al., 1990, 
Roussilhon et al., 1990). Moreover, in vitro studies revealed that proliferation of human 
peripheral T cells from malaria non-exposed individuals to erythrocytic stages of P. 
falciparum  is dominated by T cells expressing yô receptors (Goodier et al., 1992, Behr et 
al., 1992, Goerlich et al., 1991). Cloned yô T cells were cytotoxic for P. falciparum in
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vitro (Elloso et a l,  1994). Subsequent studies, comparing T cell responses to P. 
falciparum  schizont-extracts and live schizonts, revealed that T cell response to parasite 
extracts is predominantly a p  while live parasites are required for yô T cell expansion 
(Waterfall Black and Riley, 1998). This is in agreement with results obtained from the 
rodent malaria P. yoelii infection which had shown that only infection with live parasites 
causes a yô cellular expansion in the spleens of BALB/c mice infected with P. yoelii 
(Kopacz and Kumar 1999). yÔ T cells from non-immune donors, were recently found to 
produce T N Fa and IFNy within 18 hr post contact with P. falciparumAnÎQCtQd 
erythrocytes in vitro suggesting a role for yô T cells in the early non-specific immunity 
against asexual blood stages (Hensmann and Kwiatkowski, 2001).
CD8"  ^ cytotoxic T lymphocytes recognize antigens presented to them by antigen 
presenting cells in association with MHC class I molecules (Townsend and Bodmer,
1989). Studies investigating their role in immunity against asexual blood stages of rodent 
malaria have yielded controversial results. Adoptive transfer of CD8^ T cells from 
immune to non-immune mice had very little impact on the severity of the disease 
following challenge of the recipients (Kumar and Miller, 1990), and their depletion with 
the use of anti-CD8^ antibodies had slight or no effect on the course of the disease (Suss 
et al., 1988, Kumar et al., 1989). Other studies, however, have shown that CDS'*' T cell 
depletion by monoclonal antibodies in P. chabaudi ar/ami-infected C57B1/6 mice resulted 
in a significantly higher primary parasitaemia than the untreated mice (van der Heyde et 
a i,  1993). The same group, on the other hand, found that p2-microglobulin deficient- 
mice which lack functional CDS'*" T cells resolved P. chabaudi adami, P. chabaudi 
chabaudi and P. yoelii 17X malaria indicating that CDS'*' T cells are not required to 
suppress these murine malarias (van der Heyde et al., 1993).
In human malaria, several studies have reported increased numbers of CD8^ T cells in the 
peripheral circulation of patients who have recently recovered from an acute attack of 
malaria (Hoffman et al., 1984, Troy-Blomberg et al., 1984). CDS'*" T cells have been
suggested as playing a part in the immunosuppression observed in acute malaria. 
Depletion of CD8^ T cells from peripheral PMN cells obtained from individuals 
recognized as poor responders to soluble malaria antigen preparation in vitro, increased 
their PM proliferation and IFNy production in vitro. No such effect, however, was 
observed in PMN obtained from individuals responding well to these antigens (Riley et 
a i, 1989).
Apart from their role in protection against malaria, T cells, however, have also been 
implicated in the pathogenesis in malaria. For example depletion of CDS'*" cells prevents 
cerebral malaria in mice (Flermsen et ciL, 1997). Also depletion of P. berghei ANKA- 
infected C57B1/6 mice of CDS"  ^ T cells by monocloncal antibodies protected them from 
cerebral oedema, respiratory distress and lactic acidosis (Chang et al., 2001). yÔ cells 
were also found to play a pathological role in murine cerebral malaria. Mice depleted of 
yô cells by monoclonal antibody treatment and infected with P. berghei ANKA did not 
develop cerebral malaria, while mice lacking yô T cells from birth (0°^ )^ did develop 
cerebral malaria, indicating the importance of yô T cells in pathology if present since birth 
(Yanez et al., 1999). Deletion of T cells bearing V|38.1 TCR with the use of monoclonal 
antibodies protects susceptible BALB/c mice infected with P. berghei ANKA from 
developing cerebral malaria (Gorgette et al., 2002, Boubou et a l, 1999).
Role of B cells and Immunoglobulins
The role of B cells varies in different species malarias. B cell-defecient mice and chickens 
infected with P. yoelii and P. gallinaceiun respectively died of fulminanat malaria 
(Roberts et a l, 1977, Weinbaum et a l, 1976). In B cell-deficient mice infected with P. 
chabaudi chabaudi, infection followed a normal course during the primary peak of 
parasitaemia but the animals were not able subsequently to clear the parasites (Taylor- 
Robinson & Phillips 1996, Langhorne et a l ,  1998). In the case o f f .  chabaudi adami-
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infected mice, on the other hand, immunity has been reported as being antibody- 
independent (Grun and Weidanz, 1981).
Several functions have been suggested for B cells and antibodies in protection against 
malaria. B cells have been implicated in the switch from Thl to Th2 cells which is 
necessary as the disease progresses to the clear parasitaemia (Langhorne et al, 1989). In 
P. chabaudi chabaudi-h\fc.cic,d, B cell-deficient C57B1/6 mice (either by life long
treatment with anti-p antibodies or B cell knock out mice) the CD4^ T cells retained a
predominant T hl-like response to malaria through out the primary infection. Adoptive 
transfer of B cells to these mice resulted in the development of Th2 response needed to 
clear the parasitaemia (von der Weid and Langhorne, 1993, Langhorne et a i ,  1998, 
Taylor-Robinson and Phillips 1996).
Another mechanism of antibody-mediated immunity demonstrated in P. chabaudi. AS- 
infected CBA/Ca mice is the opsonisation of parasitised red blood cells during crisis 
period. IgM, IgGl and IgG2a immunoglobulins were found to increase during this period 
and enhance phagocytosis of parasitized erythrocytes by macrophages in vitro (Mota et 
al., 1998). In P. yoelii infection, however, protection was found to be directly mediated 
by antibodies and does not require Fc receptors (Rotman et al., 1998).
In the case of human malaria, the role of immunoglobulins in protection against malaria 
was evident when immunoglobulins from adults living in endemic areas given to children 
infected with P. falciparum  malaria transferred protection to them (Cohen, McGregor and 
Carrington, 1961).
Among mechanisms proposed for antibody-mediated protection in humans is inhibition 
of invasion of red cells by merozoites. Antibodies against M S P I 19 fragment have been 
found in children in natural infections. These antibodies inhibit the secondary processing 
of the M SPl protein required for invasion of red cell by merozoites. Antibodies against 
MSP 11 9 o f P. falciparum  have been shown to inhibit red cell invasion in vitro (Blackman
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et a l, 1994, O ’Donnell et a l, 2001). The role of these antibodies in natural protection 
against malaria has been questioned since no correlation was found between their serum 
levels in Gambian children and protection against the disease (Dodoo et al., 1999).
Another suggested mechanism for antibodies is in the antibody-dependent cellular 
cytotoxicity (ADCC). It was found that IgG transferred from immune African Adults to 
P ./a /d p am m -in fec ted  non-immune Thai patients although protected the recipients, they 
were not on their own inhibitory to the parasites in vitro. The same antibodies, however, 
did exert inhibitory effect on the parasites growth when normal blood monocytes were 
added to the culture (Luiiel & Druilhe, 1989, Bouharoun-Tayoun et al., 1990).
Among antibodies found in the circulation of individuals living in malaria endemic areas 
are agglutinating antibodies to parasite-encoded variant surface antigens PfEM Pl. These 
antibodies have been shown to correlate with protection from malaria in Ghanian children 
(Dodoo et al., 2001, Ofori et a l ,  2002) suggesting that protection against malaria is at 
least partly mediated by variant antigen-specific antibodies. A strong correlation was also 
found between protection against malaria and levels of specific anti-GLURP antibodies 
(Oeuvary et a l ,  2000, Dodoo et a l ,  2000). Immunization of saimiri monkeys with 
purified complexes of rhoptry-associated protein 1 (RAP-1 ) and RAP-2 have been shown 
to confer partial protection against P. falciparum  infection (Ridley et a l ,  1990). IgG 
reactivities to RAP-1 have been found to be inversely correlated with parasite density in 
Tanzanian children <5 y of age which suggests that immune recognition of RAP-1 is 
associated with control of parasitaemia (Jakobsen et a l ,  1996).
Role of IgE
The involvement of IgE in malaria was investigated because of the fact that IL-4 
stimulates the B cells to switch from IgM to IgE (King et a l ,  1993) and because it had 
been demonstrated that at least in the case of murine P. chabaudi A S  malaria there was
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a general switch from Thl to Th2 cells (Langhorne et a l ,  1989) which secret IL-4 |
(Mosmann et a l ,  1986). In the case of human malaria, it was found that 85% of donors 
from highly endemic areas of P. falciparum  had elevated levels of total and malaria 
specific IgE in their sera. Also it was found that higher levels were found in patients with 
cerebral malaria or severe malaria than in uncomplicated malaria (Perlmann et al., 1994,
Perlmann et a l ,  1997). High levels of IgE in severe falciparum malaria were seen to Î
parallel an elevation in circulating T N Fa levels and the authors also showed an ability of 
IgE to induce T N Fa in vitro from peripheral blood mononuclear cells. The authors 
suggested that IgE induction of T N Fa could also occur in vivo and so contribute to 
malaria pathology (Perlmann et a l, 1997) by causing high levels of circulating 
T N F a which have been implicated in disease severity (Grau et a l ,  1989).
Role of cytokines:
The role of various cytokines has been studied in various parasite-host combinations with 
results indicating that cytokine involvement is greatly influenced by the system involved. 
Roles of TN Fa, IFNy and 11-4 are described in chapters 4, 5 and 6 respectively
Role ofTGF-P:
Transforming growth factor P is a member of structurally similar polypeptides referred to 
as the transforming growth factor superfamily. The bioactive form is a homodimer and 
there are three isoforms that have been identified in mammals. TGFp can produce 
opposite effects on the same cells depending on their environment at the time. Some of its 
biological functions include regulation of cell proliferation, control of extracellular 
protein turnover and modulation of cellular responses (Barnard et al., 1990, Massague,
1990). It is secreted by a number of cells including lymphocytes, macrophages and 
platelets. Among other functions there is the inhibition of IL-2-dependent T cell
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proliferation (Kehrl et a i, 1986, Wahl et a i ,  1988), B cell proliferation and 
immunoglobulin secretion (Kehrl el a i ,  1986), IFNy enhancement of NK cell activity 
(Rook el al., 1986), ablation of the respiratory burst of activated peritoneal macrophages 
(Tsunawaki et al., 1988) and suppression of NO release (Vodovotz et al., 1993).
In murine malaria it was shown that high circulating levels of TGFp early during 
infection were associated with susceptibility of BALB/c mice to P. c.c. A S  infections 
with a relative lack of IFNy and NO, while low levels of TGFP were seen in resistant 
mice which exhibited high levels of IFNy and NO (Tsutsui and Kamiyama, 1999). Also, 
both circulating levels of TGFp and its production in vitro by splenocytes were found to 
correlate inversely with disease susceptibility (Omer and Riley, 1998).
Role of IL-10
IL-10 is a pleotropic cytokine that was initially described as a cytokine produced by Th2 
cells capable of inhibiting the synthesis of many Thl cytokines in response to stimulation 
with antigen or concanavalinA, and accordingly named cytokine synthesis inhibitory 
factor (CSIF) (Fiorentino, Bond and Mosmann, 1989).
IL-10 can be produced by a variety of cells. It is produced by B cells (Go et al., 1990), 
cells of monocyte/macrophage lineage (Fiorentino et al., 1991), T helper cells (Howard et 
al 1992, Moore et al., 1993), mast cells (Thompson-Snipes et al., 1991), cytotoxic T cells 
(Chen et al., 1991) and thymocytes (MacNeil et al., 1990).
The role of IL-10 was studied in P. yoelii malaria in C57B1/6 mice which were infected 
with either the non-lethal or the lethal strain of the parasite. It was shown that IL-10 was 
produced during the first week of infection in mice infected with the lethal strain. 
Splenocytes of these mice also produced IL-10 during the first week of infection in 
response to malaria antigens in vitro. IL-10 was not detectable in the first week in animals
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infected with the non-lethal strain of the parasite. The authors suggested that their results 
agreed with the general concept of Th2 responses early during infection being associated 
with a lethal outcome (Kobayashi et al., 1996).
In the case of P. chabaudi chabaudi AS malaria, it was shown that female IL-10 knock 
out mice had a more severe disease with a greater hypoglycaemia, hypothermia and 
weight loss and greater mortality compared to their wild type counterparts during the 
acute phase of illness. The knock out mice produced more IFN-y, T N F a and IL-12p40 
mRNA than the wild type animals (Li et al., 1999). In experimental cerebral malaria 
significantly higher levels of IL-10 mRNA were found in the spleens and brains of 
resistant animals (Kossodo et al., 1997). The above results indicate a protective role for 
IL-10 in malaria.
In the case of human malaria, it was shown that plasma levels of IL-10 correlated with the 
severity of P. falciparum  malaria, with high levels being found in cerebral and severe 
malaria, while mild malaria was associated with low levels. It was also found that levels 
fell within 7 days of starting therapy with anti-malarials by which time the clinical 
features of malaria have disappeared (Peyron et a i ,  1994).
IL-10 was suggested to downregulate a proinflammatory process in acute falciparum 
malaria (Ho et al., 1998). PBMC from patients with acute disease were shown to secrete 
T N F a and IL-6 , 2-4 hr post stimulation with malaria antigens, while IL-10 was detected 
8 hr post stimulation. This suggested that as IL-10 was secreted and increased, it 
suppressed the T N Fa and IL-6 . Addition of exogenous IL-10 was found to suppress 
T N F a and IL - 6  mRNA and this suppression was maximum when IL-10 was added in the 
first 2hr of stimulation (Ho et al., 1998). Moreover, faster parasite clearance rates were 
found in association with in vitro production of IL-10 by acute phase PMBC in response 
to both liver and asexual blood stage antigens (Luty et al., 1998).
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The role of IL-10 in the development of anaemia in malaria caused by P. falciparum  was 
studied. Anaemia in malaria has been shown to be due to several factors but not due to a 
reduction in the level of erythropoeitin which has been found to be normal or even 
increased (Kurtzhals et al., 1997). The study conducted on African children with severe 
anaemia, cerebral malaria and uncomplicated malaria showed significantly lower levels 
of IL-10 in the severe anaemia than the other groups. It was also found that although 
T N Fa was higher in cerebral malaria, the ratio of T N F a to IL-10 was lower in conscious 
patients with severe anaemia than the other groups. The authors explained this by the fact 
that T N F a is known to suppress the bone marrow function and since IL-10 is a counter 
regulatory cytokine to TN Fa, then IL-10 should lift up some of this suppression. Indeed 
IL-10 has been shown to stimulate marrow cells in vitro and countract anaemia in mice. 
Therefore low levels of IL-10 would allow the marrow suppressive effects of T N Fa to 
appear (Kurtzhals et al., 1998).
Recently it was shown that IL-10 may play a role in resistance to P. falciparum  after 
eradication of parasitaemia (Kurtis et a l ,  1999).
Role of IL-12
Interleukin-12 is a disulfide-linked 70kDa (p70) heterodimer glycoprotein composed of a 
40kDa (p40) and a 35kDa (p35) subunits. Both subunits together are required to produce 
the biological effects of IL-12 (Schoenhaut et a l ,  1992). IL-12 is produced by a number 
of cells including dendritic dells (Heulfer et a l ,  1996), neutrophils (Romani et a l, 1997), 
microglial cells (Aloisi et a l, 1997) and monocytes/ macrophages which are the major 
source of IL-12 (Trinchieri et a l ,  1995). IL-12 was originally identified as NK cell 
stimulatory factor and shown to have pleotrophic effects on T cells, B cells and NK cells, 
(reviewed by Trinchieri, 1998).
There is evidence that IL-12 plays a central role in the differentiation of CD4'*' ThO cells 
into T hl phenotype (Manetti et a l, 1993, Schmitt et a l,  1994, Heulfer et a l ,  1996) with
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subsequent production of IFNy which in turn leads to production of T N F a and reactive 
nitrogen intermediates (Stevenson et al., 1995). IL-12 is also thought to form a link 
between innate and specific immunity. Not only does it enhance cell mediated immunity 
but also influences humoral immunity by inducing isotype switching through both IFNy- 
dependent and independent mechanisms (Metzger et al., 1997). IL-12 mediates several 
biological activities of human T and NK cells, including induction of IFNy production, 
and enhancement of NK cell-mediated cytotoxicity (Kobayashi et al., 1989).
In mice infected with P. chabaudi AS, IL-12 was shown to be protective against blood 
stage malaria (Stevenson et al., 1995). In these animals it upregulated extramedullary 
erythropoeisis in the spleen, preventing therefore fatal anaemia associated with the 
infection. Also, in vitro production of IL-12 by splenic macrophages obtained from 
resistant B 6  mice infected with P. chabaudi AS was significantly higher than that 
produced by splenic macrophages of susceptible A/J mice (Stevenson et al., 1998). 
Moreover it showed a beneficial effect when combined with chloroquine in the treatment 
of A/J mice infected with P. chabaudi AS. These animals had a more than 15 fold 
reduction in parasite load and a 100% survival (Mohan et a l, 1999).
Role of spleen
In P. falciparum-owdomic areas, splenomegaly is a characteristic finding in children. It 
seems to regress with time for it is unusual for the spleen to remain palpable in adulthood 
(Gillis and Warrell, 1993).
The spleen has been shown to play several roles in malaria. It has been shown be 
involved in the phenomena of parasite sequestration and antigenic variation because both 
these phenomena are lost in P. chabaudi chabaudi obtained form splenectomised 
CBA/Ca mice (Gilks, W alliker and Newbold, 1990). Weiss described a vigorous splenic 
response in P. yoelii malaria. He reported branching of fibroblastic stromal cells (which
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he termed barrier cells) and their fusion with one another forming extensive irregular 
membranous sheets providing a variety of barriers. These barriers trapped parasitized 
erythrocytes and macrophages and hence increased phagaocytosis of the parasitised 
erythrocytes. In the non-lethal P. yoelii malaria, these barriers protected splenic 
reticulocytes from parasitization while in the lethal infection no such protection was seen 
(Weiss, 1989). Antibody-coated parasitized erythrocytes are removed by Fc receptor- 
mediated interactions with splenic macrophages. This function is increased in acute 
malaria (Lee el al, 1989, Ho et. al., 1990a). The spleen has also been suggested to be 
involved in a process called pitting. In this process infected red blood cells are cleared of 
their parasites without any damage to the red cells. It was observed in P. falciparum  
malaria that during acute infection, the circulation contained red cells rich in ring-infected 
surface proteins (PI 5 5/RES A) but the cells were devoid of any parasites and the spleen 
was suggested to be responsible for this mechanism of parasite clearance (Angus et al.,
1997). Spleen is also a site for extramedullary erythropoeisis. During acute malaria, the 
red pulp of the spleen expands and splenic erythropoeisis was evident in the first 24hr 
post infection with P. yoelii in BALB/c mice (Weiss, Johnson & W eidanz, 1989). 
Another role the spleen plays in P. chabaudi AS infection is the help in switching into 
Th2 response required to clear the infection. It was seen that during the primary peak 
parasitaemia, there is an expansion in the splenic non-B non-T (NBNT) cells which 
produce IL-4, helping therefore, the ThO cells to develop into Th2 cells (Helmby et al.,
1998). In P. chabaudi adami infection it was shown that antibody-independent immunity 
to reinfection was spleen dependent (Grun, Long & Weidanz, 1985).
Immunity against sexual stages
Studies on the parasite’s fate in the mosquito have reported the existence of a number of 
mechanisms aiming at reducing parasite population inside the vector. Tens of thousands 
of gametocytes can be ingested into the mosquito blood meal but normally just 50-100 
ookinetes are produced, from these typically <5 survive to produce oocyts on the midgut
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wall. Of 50,000 sporozoites produced. Only 15-80 might be inoculated by the feeding 
mosquito into the host (reviewed by Sinden and Billingsly, 2001).
Both antibody-dependent and -independent mechanisms have been described to play a 
role in immunity against the sexual stages. There are a number of antigens on the surface 
of the P. falciparum  sexual forms which can mediate humoral immune response. 
Antibodies directed against surface proteins of gametes or gametocytes of malaria 
parasites have been shown to modify infectivity to mosquitoes (Carter et al., 1988). 
Antibodies to the glutamate-rich repeat region of Pfl 1.1 in the presence of complement 
were found to suppress transmission in the mosquito (Feng et al., 1993). Complement 
mediated-lysis of gametes has also been shown with antibodies to the gamete surface 
protein Pfs230 (Quakyi et al., 1987, Healer et al., 1997). Other surface proteins that have 
been found to mediate antibodies capable of blocking transmission include Pfs48/45 
(Kaslow, 1993) and Pfs25 which is found on the surface of the zygote and early ookinetes 
(Kaslow et al., 1991). Antibodies have been shown to block transmission by both 
interfering with the process of fertilization and sporogony and by antibody mediated 
complement-dependent lysis of the parasites (Ponnudurai et a l, 1987, Read et al., 1994). 
Also they have been reported to oppsonize the gametes inside the mosquito midgut and 
enhance their phagocytosis by leukocytes (Lensen et al., 1997).
Antibody-independent mechanisms have been reported for P. vivax and are thought to be 
mediated by TNFa. Reactive nitrogen intermediates (RNI) were found to reduce 
gametocyte infectivity in mosquitoes (Motard et al., 1993). The components of the 
alternative pathway in the mouse serum have been shown to reduce but not totally 
eliminate the infectivity of P. yoelii to Anopheles stephensi. This reduced infectivity was 
largely due to the inability of the zygote to transform into the ookinete (Tsuboi et al., 
1995).
Al-Olayan and colleagues, found that >50% of P. berghei midgut parasites die by 
apoptosis before invasion (Al-Olayan et al., 2002). It was shown that during the stages of
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ookinetes invasion of the midgut epithelium and during invasion of the sporozoites of the 
salivary glands a set of immune genes was transcriptionally activated both locally and 
systemically in the fat body (reviewed by Dimopoulos, 2001). Tn A. slephensi, iNOS 
expression was detected in midgut soon after midgut invasion by the parasite and also 
later during the release of sporozoites. Circulating nitrates and nitrites were significantly 
higher in parasite-infected mosquitoes. Dietary supplementation of A. stephensi with L- 
arginine (NO substrate) reduced parasite infection in the vector, while NOS inhibitors 
increased infectivity (Luckhart et al., 1998). Several antimicrobials were isolated from A. 
gambiae. They are induced by natural and experimental infections. Among them are 
cecropins, defens in and gambicin. They are effective against bacteria, some fungi and 
gamibicin is marginally lethal to P. berghei (Vizioli et at., 2001).
Diagnosis of malaria
In some countries endemic for malaria local people recognize the disease by its episodic 
rigors (personal experience). Laboratory diagnosis for malaria, however, is divided into 
microscopic and non-microscopic tests.
Microscopic tests include examination of blood smears. Thick films are made first to 
detect parasitaemia. Their sensitivity is of 5 parasitized red blood cells (pE)/pl, while thin 
films which are made to identify the particular type of parasites have, sensitivity of 2 0  
pE/pl. Microscopic tests have the disadvantages of requiring costly tools like 
microscopes, electricity and personnel with experience in examining blood films. They 
are also labour-intensive and time consuming.
During the past ten years, however, there has been the development of rapid diagnostic 
tests (RDTs) that are based on the detection of antigens derived from malaria parasites in 
lysed blood, using immunochromatographic strips. They are divided into two groups 
according to their major P. falciparum  specific antigen targets, histidine-rich protein 2
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(HRP2) and parasite lactate dehydrogenase enzyme (pLDH). Field studies have reported 
sensitivity of >90% approaching 1 0 0 % with at high parasite density and specificity of 
>90%. These tests can be performed in 15 minutes, do not require heavy equipment and 
do not require long training of the personnel with the consequent advantage of making a 
rapid diagnosis of malaria and early treatment. The tests, however, are more expensive 
than microscopy ($ 2-4/ test) and are not quantitative nor can they differentiate between 
the different parasite species (Wongsrichanalai, 1999).
A novel method for diagnosing malaria is based on detection of haemozoin in peripheral 
blood monocytes by automated flow cytometry instrument while counting the full blood 
count. The test is designed to diagnose malaria even in the absence of clinical suspicion 
of the disease. Field studies in South Africa reported a sensitivity of 72% and specificity 
of 96%, while in Portugal; sensitivity was reported to be 95%. The disadvantage is that 
the test requires heavy expensive equipment and therefore is not suitable for poor 
endemic countries. It is more suitable for areas where physicians do not encounter malaria 
often and therefore may not suspect it clinically. Another disadvantage is that it can give 
rise to false positive results due to the persistence of haemozoin containing monocytes in 
the circulation for 2-3 weeks following cure (reviewed by Hanscheid, 2000)
Control of Malaria
Several factors are responsible for the inability to control the disease including lack of an 
effective vaccine, resistance of parasites to chemotherapy and insects to insecticides, 
poverty and civil strife. Poverty is linked with malaria in a vicious circle. Malaria- 
associated morbidity imposes a huge burden on endemic countries economy, which in 
turn results in shortage of tools such as antimalarial drugs and bed nets required to 
combat the disease. Refugees’ movement due to civil strife can result in the appearance of 
malaria in previously malaria-free areas (Greenwood & Mutabingwa, 2002).
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In the 1950s and 1960s, WHO had a global malaria eradication project. The project was 
abandoned due to its high cost and the appearance of DDT resistant luosquitoes (Shiff, 
2002). In the late 1990s a new programme (Roll Back Malaria) was set with more 
realistic objectives for malaria control. The objectives were to reduce malaria related 
mortality and morbidity to half by 2010 and half it again by 2015 (Nabarro and Tayler,
1998). The programme is a partnership between malaria endemic countries, UN agencies, 
research community, private sector and media. The technical strategy of the programme is 
based on early detection and prompt treatment of malaria cases, detection and control of 
malaria epidemics, mosquito control and prevention of malaria in pregnancy (WHO, Bull, 
2000).
WHO also aims to develop sensitive indicators to detect epidemic risks in areas with 
different levels of epidemicity. Satellites are in use to detect climatic changes favouring 
mosquito breeding in order to give an early warning to the health authorities in the areas 
concerned about a potential increase in the frequency of the disease (Rogers et al., 2002)
Several measures could be used to control malaria, these are:
Vaccines
There are two major problems in the development of vaceines against malaria, first the 
number of different stages that exist in the complex life-cycle of the parasite and secondly 
the antigenic variation of the asexual blood stages. It follows, therefore, that for a vaccine 
to be successful it needs to include epitopes from different stages of the parasite’s life 
cycle and to include those epitopes which are more or less highly conserved among 
different isolates such as the cross-reactive epitopes of PfEM Pl molecule (Gamain et al., 
2 0 0 1 ) and are immunogenic.
M alaria vaccines are classified into three types according to the parasite stage they target.
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Pre-erythrocytic stage vaccines
Several studies have shown a role for pre-erythrocytic stage proteins in protection of the 
host and hence a potential role in the synthesis of antimalaria vaccine. Irradiated 
sporozoites elicit protection to challenge with live sporozoites in mice (Nussenzweig et 
a l,  1967), humans (Clyde et a l,  1975, Egan et a l ,  1993) and monkeys (Collins, & 
Contacos, 1972). The advantage with these vaccines is that there seems to be some cross 
reactivity between species of the parasite. This was evident in the high protection rate 
(>60%) achieved in P. beghei-mfociod mice that previously had been inoculated with 
irradiated sporozoites of P. falciparum  (Sina et a l ,  1993). Although complete protection 
can be achieved with irradiated sporozoites, this method does not seem to be practical 
because of the large number of infected mosquitoes required for each individual 
(reviewed by Phillips, 2001).
A chimeric protein consisting of a fusion between the CSP and the hepatitis surface 
antigen (HbsAg) named RTS,S has gone through a field trial in The Gambia. It resulted in 
a significant reduction in the rate at which adult males were infected after vaccination 
(Bojang et a l ,  2001).
A DNA vaccine including epitopes from six different P. falciparum  pre-erythrocytic 
antigens fused to the full sequence of TRAP has been studied in Gambia since year 2000 
with encouraging results (Ferry, 2000). Also a recombinant anti-CSP vaccine was found 
to produce protection to naïve humans (Kestr et a l ,  2001).
Vaccines against pre-erythrocytic stages are thought to act by inhibiting hepatocyte 
invasion by the sporozoites or inhibit intra-hepatic development of the parasite, and 
consequently stop disease development (Richie and Saul, 2002).
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Asexual erythrocytic stage vaccines
The potential of blood stage antigens as vaccines was demonstrated in early experiments 
using crude antigen preparations in animal models (Phillips et a l ,  1992). Several asexual 
blood antigens have been used in vaccine development. Immunization with purified 
rodent malaria M SP-1 was successful in protecting mice (Holder et al., 1982). In phase 1 
trial of M SP-11 9 , immunization of non-exposed human volunteers induced high levels of 
antigen-specific Thl and Th2 cytokines, the bias of which could be regulated by adjusting 
the antigen dose and number of immunizations. Since the responses produced to M SP-11 9  
in the vaccinees were also found in adults living in malaria endemic areas, the authors 
concluded that vaccination by M SP-11 9 could boost the naturally acquired immunity in 
the semi-immune individuals (Lee et al., 2002). AMA-1 was found to produce protection 
in monkeys (Collins et al., 1994) and in rodents (Anders and Saul, 1998). A synthetic 
PfAMA-1 ectodomain was found to induce the production of antibodies that inhibited red 
cell invasion by P. falciparum in vitro (Kocken et al., 2002).
Transmission blocking vaccines
In the rodent malaria P. berghei it was found that immunization of mice with Pbs21 (a 
protein expressed in mosquito midgut stages) could elicit antibody responses that totally 
blocked the development of parasites in the midgut of mosquitoes (Margos et al., 1993). 
In the case of P. falciparum, several sexual stage antigens (Pfs230, Pfs48/45) and zygote 
ookinete antigens (Pfs25, Pfs28) have been identified as potential targets for antibody- 
mediated transmission blocking immunity. Such vaccines, although not beneficial to the 
host directly, are aimed at blocking effective transmission of the parasites into the 
mosquito i.e. break the parasite’s life cycle and hence prevent transmission of infection 
into more individuals (Richie and Saul, 2002).
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A major difficulty facing production of an effective vaccine against malaria is the short 
term protection achieved by the vaccines tested so far (Stoute et a l ,  1998). Several 
adjuvants have been used to prolong immunity, among these are the in situ expression of 
the vaccine through attenuated strains of salmonella, developing chimera of the vaccine 
and hepatitis B surface antigen (RTS,S vaccine) (reviewed by Richie and Saul, 2002) and 
co-administration of haemozoin with a DNA vaccine encoding Pfs25 which was found to 
enhance IgG2a responses (Coban et al., 2002).
Chemotherapy
Several classes of drugs are in use against P. falciparum. Among these are: -
1) Arylaminoalcohols: derived from the Cmchona bark and including quinine, 
mefloquine and halofantrine
2) 4-aminoquinolines including chloroquine, amodiaquine
3) 8 -aminoquinolines such as primaquine
4) Artemisinins: include several semi synthetic derivatives of artemsisin (the active 
ingrediant of the Chinese herb ‘qinghao’), artemether, arteether, and artesunate.
5) Antifolates
6 ) atovaquone/proguanil
7) antibiotics such as doxycycline, clindamycin and tetracycline (Gilles and Warrell, 
1993, Ridley, 2002).
Resistance has been reported to almost all antimalarials (Wellems et al., 2001, White et 
oL, 1998). A recent report regarding sporozoite rates in An, gambiae s. I  and An. funestus 
in Tanzania has shown a marked increase and this has been attributed to the wide spread 
chloroquine resistance (Mboera and Magesa, 2001)
Recently a new approach for malaria control has been reported using the currently 
available drugs. Prophylactic administration of Fansidar at the time of routine
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vaccinations in Tanzanian infants reduced the incidence of malaria and anaemia in 
children substantially (Schellenberg et ciL, 2001). Also, administration of 
sulfadoxine/pyrimethamine once during the second and once during the third trimester of 
pregnancy protected pregnant women against severe anaemia and improved birth weight 
(Shiûman et al., 1999).
The search for new novel drugs to join the armory of drugs against malaria is continuing 
and several new formulations have been reported to exert a good effect and hence carry 
good potential. Among these are antihistamines ketotifen and cypoheptadine which 
inhibit development of hepatic stages of P. yoelii (Singh and Puri, 1998). Extracts of 
Cassia occidentalis root bark, Morinda morondoides leaves and whole plants of 
Phyllanthus niruri have recently been shown to suppress parasitaemia in P. berghei 
ANKA-infected mice (Tona et a l ,  2001).
A new class of drugs has been developed which targets membrane synthesis by the 
parasite. Following invasion of erythrocytes, parasites synthesize membranes essential for 
their development while such activity is absent from mature erythrocytes. This new class 
of drugs therefore specifically targets the parasites and has shown promising results. 
Compound G25 inhibited in vitro growth of P. falciparum  and was 1000 fold less toxic to 
mammalian cell lines. Also very low doses of the same compound completely cured 
monkeys infected with P. falciparum  or P. cynomolgi (Wengelnik et al., 2002).
Coiubination of anti-malarials is useful to decrease the chance of resistant parasites 
emerging and also to treat patients infected with virulent, resistant strains (Bloland et al., 
2000). In parts of south-east Asia for instance, combinations of quinine plus tetracycline 
and quinine plus doxycyline are commonly used.
Educating mothers how to treat their children correctly and training shopkeepers in the 
importance of selling a full course treatment both seemed to have produced promising 
results (reviewed by Greenwood and Mutabingwa, 2002)
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Other methods
Several other techniques have been implemented for the control of malaria globally. 
Among those are the use of bed nets particularly those impregnated with pesticides, 
covering any sources of still fresh water, regular spraying of houses with insecticides and 
the use of biological control represented by use of larvivarous fish feeding on the vector 
larvae in fresh waters (Gilles & Warrell, 1993).
Use of animal malaria models
It would be better if human diseases could be studied entirely in the human population but 
this is not possible for ethical reasons. In the case of malaria, one is faced with multiple 
problems including inability to observe the disease progress without medical intervention, 
inability to check the effect of a possible drug against an untreated control group and 
difficulties surrounding working with children and pregnant women. Add to this the 
problem of longitudinal follow up of populations constantly on the move due to civil 
strife. Anothei- crucial point is the very early phase post infection and before the 
appearance of the clinical features. This cannot really be studied in the humans since 
people present to health personnel at variable times post infection. For these reasons, it 
was essential to conduct studies on animal models which have proved to be extremely 
beneficial not only in the case of malaria but also in other diseases.
Plasmodium chabaudi chabaudi AS infection in mice has been studies by several groups. 
It is a reasonable model for the human P. falciparum  malaria because of a number of 
features they share. Like P. falciparum, P. c. chabaudi AS  has been shown to sequester in 
the post-capillary venules (Cox et al., 1987) although with a different site of 
sequestration. In the case of P. falciparum, the asexual stage-infected erythrocytes tend to 
sequester in the heart, brain, lungs, kidneys, small intestine and liver (Aikawa et a l ,  1990, 
Pongponratn el a l ,  1991) while P. chabaudi chabaudi AS-infected erythrocytes 
preferentially sequester in the liver. Like P. falciparum, P. chabaudi also infects mature
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erythrocytes. P. chabaudi infection is also characterized by the occurrence of one or 
more recrudescence of patent parasitaemia. Finally, both P. falciparum  and P. chabaudi 
AS exhibit antigenic variation during asexual erythrocytic stage (Melean, Pearson and 
Phillips, 1986a).
Aims of project.
This project follows my previous work with Professor Alexander and Dr. James Brewer 
at the University of Strathclyde. The previous work involved investigating the effects of 
pre-infection treatment with empty non-ionic surfactant vesicles (NISV) on the weight 
loss of BALB/c mice infected with Toxoplasma gondii. The work also involved 
measurements of plasma T N Fa levels in the NISV-treated and untreated mice. The 
results of the previous project were promising in that the treated mice lost less weight and 
had lower plasma levels of TN Fa.
Empty NISV were used in this project in P. chabadui chabaudi AS-infected BALB/c 
mice with a number of hypothese to be tested. The hypothese included:
1. To test if pretreatment of P. chabaudi chabaudi-mf&cXod BALB/c mice with 
empty NISV had any beneficial effects on the clinical course of the disease 
including the amount of weight loss in the infected animals.
2. The second aim was to test the effects of pretreatment with empty NISV on 
the circulating T N Fa levels in the treated and infected animals.
3. To determine the mechanisms involved in the above two effects if they 
were true.
4. To determine if pretreatment with empty NISV had any immunomodulatory 
effects in the infected animals by measuring the circulating levels of other 
pro and anti-inflammatory cytokines such as IFNy and IL-4.
5. Experiments were also performed to investigate the NISV effects on 
splenocyte proliferation and the production of T N Fa and NO in response to 
various stimulating agents in vitro.
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6 . Finally it was decided to investigate the effect of haemolysis on the 
measurement of circulating cytokine levels by ELISA. This was achieved by 
first attempting to measure circulating cytokine levels in whole lysed blood 
and then to compare them with levels obtained using plasma or serum 
samples
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Mice:
Inbred male BALB/c mice were used in most experimental infections. As the place of 
work was changed during the course of the research, the animals were obtained from two 
different sources. One group was bred at the Todd Center, University of Strathclyde 
(Glasgow) and the other group was purchased from Harlan Oak (Bicester, UK). All mice 
were fed on pelleted CRM(p) Breeder diet (Labsure Ltd). Water was given ad libitum. In 
all experiments, unless otherwise stated, the animals used were 8 - 1 2  weeks of age and 
weighed around 25g. For the mice purchased from Harlan, it was routine to receive them 
at a younger age (6 - 8  weeks) and to allow them to acclimatize in the animal house for 1 - 2  
weeks prior to use.
In order to compare the effect of sex on the course of a malaria infection female BALB/c 
mice were used in some experiments. These again were 8-12 weeks of age, kept in 12 
hour artificial light, fed on pellet CRM (p) diet and given food and water ad libitum.
For some preliminary in vitro experiments, female ICR mice were used
Parasites:
Plasmodium chabaudi chabaudi AS strain was originally isolated from adult thicket rats 
(Thamnomys rutilans) in 1969 by Professor David W alliker (University of Edinburgh) 
from La Maboke, Central African Republic. The strain was subsequently established in 
laboratory mice and cloned by the limiting dilution method (Walliker, Carter and Morgan, 
1971). Stabilates of parasites, derived from the original AS parent clone, were maintained 
by cryopreservation in liquid nitrogen and subpassage through mice.
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Cryopreservation of blood:
Infected blood, at a parasitaemia of 5-10% containing ring stage parasites, was collected 
by cardiac puncture from mice sacrificed in a CO 2  chamber into a syringe containing 
sodium heparin (1000 i.u. /ml) in phosphate buffer saline (PBS, pH 7.2) as an 
anticoagulant at 10 i.u. heparin per ml of blood. The infected blood was diluted with an 
equal volume of a sorbitol-glycerol solution (38% glycerol, 2.9 % sorbitol, 0.63% NaCl). 
200pl aliquots were dispensed into 1.2 ml cryopreservation vials (Nunc) and labelled 
with the species of parasite and a code. The vials were snap frozen by immersion into 
liquid nitrogen and stored until needed.
Maintenance of P. chabaudi chabaudi AS
For long term preservation, cryopreservation vials (Nunc) of blood infected with P. 
chabaudi A S  parent were kept in liquid nitrogen (-196”C). Infected blood was recovered 
for experimental use by allowing the vials to thaw at room temperature. Once defrosted, 
an equal volume of a 17.5% sorbitol solution was added slowly with frequent mixing. 
The diluted blood was administered by i.p. injection into one or two recipient naïve mice 
from which the experimental groups were infected once the parasitaemia reached 2 0 - 
30%.
Challenge infections
The infected blood was obtained from the donor mouse by cardiac puncture. The level of 
parasitaemia was determined from Giemsa’s (Gurr, BDH Ltd) stained thin blood smears. 
Appropriate dilutions were made with PBS (pH 7.2) to reach a concentration of 5 x 10  ^
parasitised red blood cells (pRBC)/ ml. The recipient mice were placed in a warm box at 
30° C for 5-10 minutes to encourage vasodilation. Mice were infected with 1x10^ pRBCs 
administered i.v. via the dorsal tail vein as a 2 0 0 pl inoculum (using a 1 ml syringe fitted
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with a 26 gauge needle). In case of failure of i.v. inoculation, i.p. inoculations were 
carried out to minimise stress and its effects on the animals.
Preparation of thin blood smears:
Individual mice were bled by gently piercing the dorsum of the tail with a clean lancet 
(Sherwood) and spreading the drop of blood formed onto a clean glass slide (BDH Ltd). 
The slides were fixed in absolute methanol (AnalaR, BDH Ltd) for few seconds and 
stained in Geimsa's stain (1:10 of Giemsa's stain [Gurr], in phosphate buffer saline, pH 
7.2, see Appendix) for 15 min. Following removal from the stain, slides were washed 
under running tap water for a few seconds to remove excess stain and allowed to dry 
before examining under the light microscope.
Determination of parasitaemia levels:
The level of parasitaemia of infected mice was determined by daily examination of 
stained thin blood smears. Samples were taken at approximately the same time of day for 
each experiment by pricking the tail with a clean lancet. A new lancet was used for each 
cage. Following staining and fixation, slides were examined under oil immersion using x 
100 objective and x 10 eyepiece of a Leitz S. M Lux binocular microscope. Percentage 
parasitaemia was determined by counting both total RBC and pRBC in a total of at least 
10 fields containing around 300 RBC /field. In the time period during the infection when 
mouse blood was hypocellular (increased plasma: cell ratio) and some of the RBC were 
haemolysed, as many as possible fields were counted. Means and standard errors of 
percentage parasitaemia of each group were calculated daily and plotted.
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Preparation of empty Non-ionic surfactant vesicles (NISV):
A mixture of 49.6 mg of monopalmitoyl glycerol (Sigma), 16.4 mg of dicetyl phosphate 
(Sigma) and 46.6 mg of cholesterol (Sigma) was made in a sterile pyrex glass test tube 
pre-heated for 4 hours at 180° C to minimize the effects of endotoxin. The tube was 
covered with a piece of aluminium foil and inserted in a heating block at 130°C until 
melted. Under sterile conditions, 5 mis of warm filter sterile PBS (pH 7.2) were added to 
the mixture while manually shaking the tube. The tube was covered and immediately 
transferred onto a vortex (Gallenkamp) for vigorous mixing for one minute. The tube 
was then left in a shaking waterbath (Gallenkamp) at 60°C and shaking speed of 5 
(graded knob) for two hours. A sample was then taken and examined under the light 
microscope, using x 40 objective lens, to check the morphology of the formed vesicles. 
The rest of the mixture was transferred into a plastic centrifuge tube and subjected to five 
cycles of freezing by immersing into liquid nitrogen and thawing by immersing into the 
water bath. After the final step of freezing, the vesicles were stored at -70°C until further 
use (personal communication, Dr. J. Brewer).
Administration of NISV :
Prior to use, NISV were allowed to defrost in a waterbath at 60° C at shaking speed of 5 
for two hours and then stored at 4°C overnight. 100 pi /mouse of NISV were administered 
subcutaneously just above the tail.
For short time storage, the vesicles were kept at 4°C for up to a week, after which they 
were discarded.
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Preparation of parasitised and normal red blood cell lysates:
For in vitro stimulation of splenocyte suspensions, soluble crude Plasmodium chabaudi 
AS antigens was prepared. The donor mice were kept in a reverse light box (12 hr light 
between 2000-0800 hr) for about a week prior to blood donation. This was done in order 
for schizogony to occur during daytime instead of the normal time which is at 0 1 0 0  hr 
(Jarra & Brown, 1985). With this system schizogony did occur between 1100-1300 hr and 
mice were sacrificed at peak parasitaemia and bled through cardiac puncture into 
heparinised PBS (10 i.u./ml) at 0800-0900 hr, when most parasites were at the late ring 
stages. After washing twice in 5% FCS-supplemented Rosewell Park Memorial Institute 
(RPMI) 1640 medium (Gibco) at 250g for 5 minutes, erythrocytes were resuspended to a 
10% haematocrit in the same medium and cultured using the candle jar method (Trager 
and Jensen, 1976). 15ml of the 10% v/v suspension of the infected blood in medium were 
dispenced in 10mm Petri dishes (Greiner) which were placed together with a candle in a 
humidified glass dessicator.The candle was lit and the lid put on with the stopcock open. 
When the candle flame extinguished the stopcock was closed. This procedure provided a 
gas phase of 3% C 0 2  and 15-17% 0 2  (Trager, 1987). The candle jar was placed in a 
37°C incubator until the parasites had reached the schizont stage; parasite maturation was 
monitored every 30-45 min by examination of Giemsa’s stained thin blood smears. The 
ccultured parasites were washed in 5% FCS RPMI 1640 medium at 200g for 10 minutes 
and re-suspended to the original volume in sterile PBS (pH 7.2). The suspension was 
filtered through a sterile W hatman C F ll  powdered cellulose paper column to remove 
leukocytes (Bentier et a i,  1976) and the filtrate was subsequently washed. The pellet 
containing the malaria parasites was restored to its previous volume in PBS (pH 7.2) and 
then freeze-thawed five times by snap freezing in liquid nitrogen and immediately 
defrosting in a 37°C water bath (Gallenkamp). The disrupted parasitized red blood cells 
were centrifuged at 1500g for 10 minutes and the supernatant was collected. This was 
labeled as pRBC lysate and stored in 20-50(il aliquots at - 20°C until use. The above 
procedure was also used to prepare lysate from non-infected erythrocytes excluding 
culture of cells for few hours. This lysate was termed nRBC and stored as above.
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Determination of protein concentration:
The total protein concentration of both pRBC and nRBC lysate was determined by an 
adaptation of a method described by Smith et a l, (1985). Standards of known protein 
concentrations were prepared by diluting 2mg/ml stock BSA standard (Pierce Chemical 
Co) in PBS (pH 7.2) to give a range from l-25jtig/ml. Dilutions of unknown protein 
lysates were prepared in PBS (1:100, 1:1000, 1:10000). 100 pl/well of standards and 
samples were added to a 96 well plate (Immulon^ 4HBX, Dynex). IGOpl of Coomasie 
Protein Assay Reagent (Pierce) was added to each well. The plate was read at 570 nm on 
an MRX plate reader and the protein concentration was determined by plotting the results 
against the graph of known protein standards using Biolinx software (Dynatech).
Collection of plasma samples:
Mice were warmed in the warm box for 5 min to encourage vasodilation. Up to 100 pi 
blood samples were collected from the tail vessels. At certain time points, however, two 
animals were sacrificed from each group and blood was obtained by cardiac puncture.
Variable degrees of disease severity were noted among animals of the same group at any 
time point, with some animals being very ill and others looking relatively well. To 
minimize errors resulting from picking these outliers, samples were collected from a 
number of animals representing the predominant degree of disease severity across the 
whole group at each time point. In order to obtain plasma from blood, blood was 
collected in Eppendorfs containing sodium heparin [(1000 i.u./ml) in phosphate buffered 
saline (PBS, pH 7.2)] as an anticoagulant at 100 i.u. heparin per ml of blood. Samples 
were centrifuged at 9000g for 5 minutes and plasma was pooled for each group into 
Eppendorfs and frozen at -  20°C until use.
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Collection and storage of blood samples for cytokines:
Animals were bled through either cardiac puncture or from the dorsal tail vein as 
described above and the blood samples obtained from animals in the same group were 
pooled. lOOjal of de-ionized distilled water (ddHiO) were added to every 1ml of whole 
blood (in order to haemolyse the blood) and stored at -20°C until further use.
Collection of serum samples:
Animals were sacrificed in CO2  and bled by cardiac puncture. Approximately the same 
amount of blood was obtained from each mouse and samples were pooled for each group. 
The blood was allowed to clot, loosened from the edges of the container and allowed to 
contract overnight at room temperature. The serum was harvested and the contaminating 
erythrocytes were removed by centrifugation for 5 min at 9000g. Samples were then 
stored at -20°C until use.
Cytokine ELIS As using plasma samples:
Plasma samples were collected as described previously and assayed for the presence of 
cytokines TN Fa, IFN7 , IL-10, and IL-4. Capture monoclonal anti-antibodies 
(PharMingen) were diluted to the required concentration of 2jag/ml in coating buffer 
(sodium bicarbonate buffer, pH 8.2-see Appendix). 50 pi of capture antibody per well 
were added to ELISA plates (ImmulonR 4HBX Dynex) and incubated overnight at 4°C. 
On the following day, the plates were washed carefully (allowing at least 30 seconds for 
each wash and minimising bubbles) three times with 0.05% Tween 20 (Organics, BDH 
Ltd), PBS, pH 7.2 washing buffer (see Appendix 1). After the final wash, the plates were 
pounded on dry paper towels to remove any excess antibodies. 2 0 0  pi of blocking buffer 
(10% heat inactivated FCS in PBS, pH 7.2) were added to each well and plates allowed to
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incubate for 1 hr at 37°C to block any non-specific binding sites. The plates were washed 
three times as described above. Fifty pi of appropriate standards (PharMingen) and 
samples were added to each well. In the case of supernatants of spleen cell cultures, neat 
concentrations were used as samples while in the case of blood and its derivatives and 
due to their small available amounts, dilutions were first made in blocking buffer. 
Following 2-3 hr incubation at 37°C, the plates were washed 4 times and dried as 
described previously. Fifty pi of secondary biotinolated secondary monoclonal antibody 
(PharMingen) diluted in blocking buffer to 2pg/ml were added to each well and plates 
were incubated for another hour at 37°C. Following this incubation step, plates were 
washed 6  times and dried before 100 pi/ well of streptavidin-peroxidase (SABU) were 
added and plates incubated for a further 1 hour at 37°C. The plates were now washed 8  
times and dried as above before 100 pi /well of 3,3’,5,5’-tetramethylbenzidine (TBM) 
substrate (KPL) warmed to room temperature were added. The plates were Incubated at 
room temperature while wrapped in aluminum foil to avoid light for at least twenty 
minutes or until the reaction had fully developed. The plates were read at 630 nm with a 
reference filter at 405 nm on an MRX plate reader (Dynatech). The results of the 
unknown samples were calculated against a standard curve of known concentrations 
using Biolinx software (Dynatech).
Measurement of Weights of Animals:
Individual mice were weighed daily at approximately the same time and using the same 
scales for each experiment. Individual mice were identified by drawing circular bands 
around their tails using a permanent marker pen (Sanford). Each mouse was briefly 
covered with a known weight beaker while on the scale to minimize fluctuations resulting 
from movement. Percentage of weights was obtained by dividing the means of daily 
weights by the means of weights on day zero (day of infection).
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Clinical monitoring of animals:
Mice were examined daily and the degree of their activity and self hygiene was noted for 
each individual mouse. A scoring system was developed to quantify the health status of 
each mouse. The means of health scores of all mice in each group were obtained and 
plotted in a graph.
The following score was used to quantify animals health status.
Hassan Health Status Score (HHSS):
CF/ score 1 2 3 4 5
pilo erection severe mild-
moderate
nil
activity nil occasional
movement
walking
slowly/drag
ging
walking fast climbing/run 
ning fast
back hunched straight
perianal area dirty clean
eyes shut partially shut open and 
bright
extension head down sniffs/curious neck only V2 body full, frequent
urine bloody/dark normal
rate of chest 
wall
movement
slow rapid normal
The rate of chest wall movement was included in the score and taken to represent a 
combination of both heart rate and respiratory rate. This is because it was difficult to
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separate between the chest wall expansion representing respiratory rate and movement 
due to hyperdynamic circulation of the rapid heat rate. Had a Pulsoximeter been 
available, it would have been possible to measure the heart and the respiratory rate 
separately. The rate of chest wall movement ranged from a very rapid rate (180 or >/min) 
to very slow (20 or </min). Certain features were used as indicators for dying including 
very slow chest wall movement, which clinically represents exhaustion and the head held 
down with the eyes shut. Also some features such as urine output (+/- haematuria) and 
bowl function were observed initially but had to be omitted subsequently because they 
could not always be observed during the time period of attending the animals.
Splenocyte cultures:
Spleens were obtained aseptically from the sacrificed mice and dissociated by pressing 
them with a 5 ml syringe plunger through a sterile stainless steel tea strainer to make a 
single cell suspension in RPMI 1640 medium (Gibco) supplemented with 10% sterile 
heat-inactivated foetal calf serum (FCS) referred to as complete medium. The cells were 
centrifuged at (280g) for 5 minutes. To remove the erythrocytes 3m 1 of freshly prepared 
Boyl’s solution (Tris, Boehringer Mannheim, NH4CI AnalaR, BDH, 1:9, see Appendix) 
were added and allowed to stand for 3-5 minutes at room temperature for red cell lysis to 
occur. The cells were again centrifuged as above and the supernatants removed to wash 
off the Boyl's solution. The pellet was re-suspended in 5 ml of complete medium and 
washed twice more at 1500 rpm (2B0g) for 5 minutes. After the last wash, cells were 
suspended in 2 ml of complete medium and counted with the use of a haemocytometer 
and trypan blue (Gurr, BDH Ltd).
The cell suspension was finally diluted to 5x10*  ^ cells/ml in complete medium and lOOp.1 
containing 5x10^ cells were added to each well of a 96 well flat bottomed tissue culture 
plates (Iwaki). lOOpl of complete medium or antigen were added to appropriate wells to
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give a total volume of 200 \x\ /well and the plates were incubated at 37° C in 5% CO 2 in 
air for various lengths of time according to the assay done.
Proliferation assay:
Cell suspensions were prepared as described and adjusted to a final concentration of 5 x 
10*^  cells/ml in 10% FCS RPMI 1640 medium (Gibco). 100 |Ll1 of cells/well were 
aliquoted into a 96 well flat bottomed tissue culture plate (Iwaki) with 100 fxl of 10% 
FCS RPMI 1640 medium, or a range of stimulants including ConA, pRBC lysate, nRBC 
lysate, pRBC and nRBC. The plate was incubated at 37° C, 5% CO 2 in air for 72 hours. 
Each well was pulsed with O.SjaCi of ^H-methyl-thymidine (IjtiCi /ml, specific activity 
5Ci /mmol, Amersham) in a 10 |al volume of 10% FCS RPMI 1640 medium and the plate 
was incubated for a further 18 hours at 37° C. The wells were harvested with a semi­
automatic cell harvester (Titertek, Flow) onto glass fibre filter paper (FG /A W hatman) 
and air dried. Each filter disc corresponding to a specific well was transferred to plastic |3 
vials (LKB) and 2ml non-aqueous scintillation fluid (Optiscint safe, LKB) added. The |3 
activity present in each sample was detected during 1 minute using a scintillation counter 
(LKB W allac 1219 Rackbeta) and the counts per minute (cpm) calculated using the 
Ultroterm III software package. All samples were set up in triplicate to enable an 
arithmetic mean of the cpm, representative of the proliferative response, to be calculated.
Culture of liver macrophages:
Livers were obtained from naive mice under sterile conditions. They were dissociated 
with the plunger of a 5 ml syringe by pressing through an autoelave-cleaned metal tea 
strainer in 5 ml of RPMI 1640 (Gibco) supplemented with 10% FCS (this is referred to as 
RPMI complete medium). The suspension was washed at 600g for 5 minutes once and 
the supernatants discarded. The pellet was re-suspended in 2-3 ml of freshly prepared
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Boyl’s solution (ImlTris: 9m 1 ammonium chloride) and washed again at (600g) for 5 
mills. After 2 further washings the pellet was finally suspended in a known volume of the 
complete medium (20ml) and transferred onto a 10 mm petri dish (Greiner). Following 2 
hour of incubation at 37°C in 5% CO 2  in air, the supernatants and any floating cells were 
discarded, while the adherent cells were scraped off the bottom of the dish with a plastic 
Pasteur pipette and washed once at 600g for 5 mins. Finally the cells were resuspended in 
2 ml of complete medium and counted with in a haemocytometer (Improved Neubar). 
The final dilution of IxlO^ cells / 600pl/ well was made and the cells were plated in 24 
well flat-bottomed plates (Iwaki).
Preparation of Macrophages from bone marrow:
Bone maiTOW-derived macrophages were obtained from a culture of bone marrow cells 
collected from the femurs and tibiae of naïve mice. The bones were removed aseptically 
and the distal ends of the femurs and the proximal end of the tibiae were cut. A 26 gauge 
needle was inserted into the opposite ends (proximal end of femur and distal end of tibia, 
since in adults blood cell formation occurs at distal ends of femurs and proximal ends of 
tibiae while the rest of the marrow is replaced with adipose tissue) and the marrow was 
flushed out with 5 ml of ice cold Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) 
supplemented with lOOmg/ml streptomycin, lOOU/ml penicillin, 50 inM 2-b- 
mercaptoethanol, 20% HI-FCS, 2mM L-glutamine, and ImM pyruvate (Sigma)). The 
cells were centrifuged at 600g for 10 mins at 4°C and re-suspended in DMEM 
supplemented with 30% supernatant of L-929 cells and 20% HI-FCS. The cells were 
transferred to a 100 mm tissue culture dish (Greiner) and incubated at 37°C in 5% CO 2  in 
air for 7 days. The non-adherent cells were discarded and the adherent cells were 
collected by rinsing the dish with ice cold filter sterilized PBS for 10 minutes and also 
scraping the bottom of the dish with a plastic Pastuer pipette. These cells were 
centrifuged at 600g for 10 minutes and re-suspended in complete DM EM . A sample was 
removed to count the cells which were then adjusted to a concentration of 5xlO*^/ml.
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Following incubation overnight, the non-adherent cells were removed and fresh complete 
DMEM (Dulbaco modified Eagles medium, Gibco) was added along with the antigens to 
be tested. The final volume of each well was 200|il. The cells were then left to incubate 
for either 3 or 6 hr and the supernatants were collected to assay for T N F a and NO. The 
samples were stored at -20°C until further analysis.
Determination of nitric oxide production:
The level of nitric oxide production in vitro was determined by the measurement of the 
end product, nitrite, using the Griess reaction described by Migliorini et al., (1991). 
Nitrite standards were prepared by diluting O.lg of the stock powder of sodium nitrite 
(Fisons) in 10ml of de-ionised distilled water. The mixture was diluted to a final 
concentration of lOj-tg of sodium nitrite /ml of 10% FCS DM EM  medium. The 
concentration of the standards ranged from 10-0.156p.g /ml nitrite. Fifty pi of freshly 
prepared Griess soultion (1:1 mix of 0.1% (N-l-napthyl)ethyl-enediamine, (Sigma) and 
1% sulphanilamide, (Sigma) in 5% orthophosphoric acid, Fisons) were added to 50pl of 
culture supernatant or standard in an individual well of a 96 well plate (Immulon^ 4HBX, 
Dynex). The plate was incubated for 10 minutes at room temperature and read at 540nm 
on a MXR plate reader. The concentration of nitrite for the unknown samples was 
calculated against a plot of a standard curve using Biolinx software (Dynatech).
(3-(4,5-dimetliylthiazol-2-yl)-2.5 diphenyl tétrazolium bromide) MTT assay:
To each well containing 5x10^ cells /ml, 50pl of 1 mg/ml of [3-(4,5-dimethyl thiazo-2-yl)- 
2,5-diphenyltetrazolium bromide] (MTT), (Sigma) were added and the tissue culture plate 
was incubated in 5% CO 2 in air for three hours. 150pl were removed from each well and 
lOOpl of propane-2-ol (Fisons) were added and mixed vigorously. The plate was read at
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450 nm using an MRX plate reader and the results were calculated against a standard 
curve of known concentrations using Biolinx software.
Cell viability counts
The viability of cell preparations was determined by the trypan blue exclusion method. A 
20pl volume of 0.2% w/v trypan blue (Gurr, BDH Ltd) in PBS (pH 7.2) was added to a 
20pl sample of the cells in PBS (pH 7.2) and mixed thoroughly. 20 pi of the mixture was 
swiftly pipetted onto an improved Neubar haemocytometer (ARH) and the cells were 
counted under phase contrast (x 400) on a light microscope. Viable cells remained clear 
while the dead cells were unable to exclude the dye and stained blue. Five squares (four at 
each corner and the central square) were counted and the proportion of dead to live cells 
gave the percentage viability. From these calculations, appropriate cells concentrations 
for different experimental procedures were derived.
Maintenance of L-929 Cells:
L-929 cells were a kind gift from a colleague (Department of M ateria Medica, University 
of Glasgow) and cultured in sterile flasks (Iwaki) in complete DM EM  (Gibco) 
supplemented with 20 % FCS at 37° C in 5% CO 2  in air. Every fourth day the 
supernatants were collected into sterile uni versais and stored at - 20° C until use while 
fresh medium was added to the cells for further culture.
Statistical analysis:
Results of weights, levels of parasitaemia and health score are expressed as means of the 
groups +/- standard errors. Groups data were compared using Student's t -test. Results 
were considered significant when the p value of < 0.05 was obtained. Results of levels of
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cytokines are expressed as means as measured by the ELISA reader. No standard errors 
are available since samples from each group were pooled together to allow measurement 
of 4 different cytokines plus nitric oxide.
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Chapter 3
Effects of pre-infection administration of non-ionic surfactant vesicles 
(NISV) on the course of P. chabaudi chabaudi AS infection in male 
BALB/c mice.
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Introduction
As m entioned previously, the aim of this project was to investigate the effects of 
preinfection treatment with empty non-ionic surfactant vesicles (NISV) on the course of 
P. chabaudi chabaudi AS in BALB/c mice. The rationale behind using NISV was based 
on an observation made while using empty NISV in mice infected with Toxoplasma  
gondii, details of which are given below.
Non-ionic surfactant vesicles
Non-ionic surfactant vesicles (NISV), also called nisomes, are am phiphilic liposom e­
like vesicles made of non-ionic surfactants (reviewed by Conacher, Alexander and 
Brewer, 1998). NISV as used in the present studies were initially made and used by 
their investigators (Brewer and Alexander, Strathclyde University) to exam ine their 
potential for replacing liposomes as adjuvants in vaccines. The need to replace 
liposomes as adjuvants arose from the fact that liposomes had several disadvantages, 
which required to be dealt with. Among the disadvantages associated with liposomes is 
that they enhance the immune response modestly. This problem could be overcom e by 
form ulating liposomes in combination with other adjuvants such as o f lipid A, 
alum inium  salts, avridine and IL-12 (reviewed by Conacher, A lexander and Brewer, 
1999). Liposome encapsulated synthetic antigens containing repeat sequence epitopes 
from the CSP of P. fa lciparum  were shown to induce a strong humoral immune 
response in rabbits and monkeys (Alving and Richards 1990). Liposomes had another 
problem  relating to one of their components, the phospholipids, which degrade easily in 
air and require special storage conditions and hence makes the liposom es expensive. In 
view of the above disadvantages associated with liposomes, research continued for 
adjuvants better than liposomes. Since the adjuvant action o f liposom es and other 
adjuvants is related to their surface activity (Gall, 1966), which in turn is related to their 
vesicular structure, it was, therefore, thought reasonable to make vesicles from other 
compounds such as non-ionic surfactants.
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Vesicle form ation by non-ionic surfactants has been demonstrated for a number of 
surfactants such as polyglycerol alkethers, crown ethers, polyoxyethylene 
alkether/esters, alkyl glycosides and didodecyldim ethylanim onium  derivatives of 
cholesterol (Brewer, 1993). The vesicles produced were unilam elar or m ultilamellar 
structures and displayed many desirable features of liposomes. M oreover, these vesicles 
exhibited several advantages over the liposomes. They lacked toxicity (Hunter, 
Strickland and Kezdy, 1981) and were devoid of phospholipids -with their costly 
purification procedures and storage requirements- making them, therefore, 10-100 times 
cheaper than liposomes (reviewed by Cochrane, Alexander and Brewer, 1999).
The NISV used here were made from a mixture containing cholestrol, m onopalmitoyl 
glycerol and dicetyl phosphate (details are given in M aterials and M ethods). Their 
manufacturers (Brewer and Alexander, Strathclyde University) initially investigated 
their adjuvant activity in BALB/k mice vaccinated against Toxoplasma gondii. In their 
experiments, toxoplasma soluble tachyzoite antigen (StAg) was entrapped inside the 
NISV and administered to BALB/k mice subcutaneously on days -28 and -14. A group 
of mice was also injected but with empty NISV to act as a positive control. All m ice 
were infected with T. gondii on day 0 and subsequently followed up with respect to 
weight loss. An interesting observation made in these studies was that the infected and 
empty NISV-treated mice lost less weight than the untreated, infected group. The 
authors suggested that perhaps the NISV led to a reduced T N F a  production by 
m acrophages in response to the infection and hence the treated m ice lost less weight 
than the untreated group (Brewer, personal communication). Their suggestion was 
based on the studies reporting the positive correlation between circulating T N F a  levels 
and cachexia (Beutler et a l ,  1985).
The aim of this project was to investigate the effects of pre-infection treatment with 
NISV on anim als’ weights in m alaria and to investigate the above hypothesis regarding 
the mechanism s involved in the actions of NISV by measuring the circulating levels of 
T N Fa. In the work described here, empty NISV were administered following the same 
protocol used by the makers of the NISV (Brewer and Alexander, Strathclyde 
University) to study their effects on the clinical course of male BALB/c mice infected
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with P. c. AS. The clinical parameters followed up are, weight, percent o f parasitaem ia 
and mortality. A health status score was developed to follow up the animals with 
regards to their degree of activity, appearance and hygiene (M aterial and Methods, 
HHSS).
Results
3.1. Effects of NISV on the weight loss of mice infected with P. c. c AS
The work presented here covers four experiments conducted on m ale BALB/c mice at 
two different venues. The first two experiments (S.I and S.2) were conducted at 
Strathclyde University while the last two (G .l and G.2) were conducted at Glasgow 
University.
Inbred m ale BALB/c mice (n = 10, 20, 20 and 25 in experiments S .l , S .2, G .l and G.2 
respectively) were injected subcutaneously with lOOp.1 o f PBS or NISV on days -28 and 
-14 pre-infection and infected with 1x10^ pRBC i.v. on day 0 and were designated as 
groups Pc and PcV respectively (see protocol of NISV administration). Two control 
groups referred to as PBS and NISV containing 10 animals each (in all experiments) 
were injected subcutaneously with lOOp.1 of PBS or NISV respectively on days -28 and 
-1 4  (Table 3.1). Animals were followed up daily at approximately the same time for 
each experim ent and m easurem ent of the weight of each mouse was recorded using the 
same scales for each experiment. In order to obtain weights as accurately as possible, 
each m ouse was briefly covered with a beaker while on the scales to m inim ize its 
movement.
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Table 3.1; Protocol of NISV administration.
Day post 
infection
PBS NISV Pc PcV
-28 lOOpl PBS lOOfil NISV lOOjLtl PBS 100)11 NISV
-14 lOOpl PBS lOO^il NISV lOOjLil PBS 100)11 NISV
0 1x10^ pRBS 1x10^ pRBC
PBS, NISV; groups injected with lOOpl of PBS or NISV respectively on day -28 and 
14, Pc, PcV; groups inoculated with lOOjil of PBS or NISV respectively on days -2 8 , 
14 and infected with 1x10^ pRBC on day 0.
The initial results of weight loss in experiment S .l (n = 10) showed a less weight loss in 
the infected, NISV-treated group (PcV) than the infected and untreated group (Pc). 
Sim ilar results were obtained in experiment S .2 in which a larger num ber of animals 
was used per group (n = 20) (see Appendix 2 for results of individual experiments). 
Both these experiments were conducted at Strathclyde University.
The difference in weight loss between the two groups (Pc and PcV) was significant only 
for a certain period post-infection. The duration and timing of this period, however, was 
not the same in the two experim ents. It was from day 10-15 (p<0.05, at C l of 95%) and 
day 7-1 l(p<0.05, at Cl of 95%) in the first (S .l)  and second experim ent (S.2) 
respectively. Peak parasitaemia in both experiments occurred on day 9 post-infection. 
In experim ent S .l one mouse in the Pc group developed gross oedema from  day 16-22 
post-infection. The mouse was taken out of the group o f the measurem ents in order to 
reduce the impact of this outlier. W ith the data from the two experiments combined, it 
was seen that significantly less weight was lost in the infected, NISV -treated group 
(PcV) on day 6 and days 8-11 (p <0.05, C l -  95%) than the infected, untreated group 
(Pc) (Figure 3.1).
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On repeating the experiment subsequently at Glasgow University in order to collect 
enough blood samples for measuring immunoglobulin profile of the mice, the results on 
weight loss and indeed other param eters did not agree with the previous work. In the 
first (G .l)  of two experiments conducted at Glasgow University, there was a significant 
difference in weight loss on day 8 only but in favour o f the N ISV -untreated group (Pc) 
(p <0.05 at 95% Cl). The peak parasitaemia occurred on days 8 and 9 in the NISV- 
treated and untreated groups respectively.
It was thought that perhaps the NISV used in the above experim ent were not made 
properly and hence led to the contradictory results. The experim ent, therefore, was 
repeated for a fourth time with the NISV being supplied by Dr. J. Brewer, Division of 
hnm unology. Infection & inflammation. W estern Infirmary Glasgow. In this experiment 
(G.2), the infected, NISV-treated group (PcV) had significantly higher weights on days 
6 and 10 than the infected, untreated group (Pc) but the latter group had higher weights 
on days 8, 13, 14 and 15 post-infection than the treated group (PcV) (p <0.05 at 95% 
Cl) (see Appendix for results o f individual experiments). Peak parasitaem ia was on day 
9 and 10 in the untreated (Pc) and treated (PcV) groups respectively. W ith the two 
experiments combined, it was seen that a significant difference in percentage weight 
occurred on day 14 only post infection (p <0.05 at 95% Cl) but in favour o f the infected, 
untreated group (Pc) (Figure 3.2).
In summary, in the first two experiments conducted at Strathclyde University (S .l and 
S.2), the infected, NISV-treated group (PcV) lost less weight than the infected, 
untreated group (Pc), while in the second two experiments conducted at Glasgow 
University (G .l and G.2) the infected untreated group (Pc) lost less weight than the 
infected, NISV-treated group (PcV). W eights of the PBS and NISV groups in each 
experim ent were similar.
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3.2. Effects of pretreatment with NISV on level of parasitaemia:
The course of the parasitaemia was followed in infected mice in all the above four 
experiments. Blood smears were obtained from five mice per group in experiment S .l 
and from all surviving mice in the subsequent experiments. Smears were stained and 
fixed and percent parasitaemia calculated as described in Chapter 2. In the first two 
experiments, conducted at Strathclyde University, percent parasitaem ia in the infected, 
NISV-treated group (PcV) was significantly lower on day 9 and days 5 and 6 in S .l and 
S.2 respectively (p<0.05 at 95% Cl) (see Appendix 2 for individual experiments). W ith 
the two experiments combined the NISV-treated group (PcV) had a lower parasitaem ia 
than the untreated (Pc) group from day 5 to day 10 post-infection but the difference was 
not significant at any point (Figure 3.3).
The results o f parasitaemia in experiments conducted at Glasgow University did not 
agree with those obtained from experiments conducted at Strathclyde University. In 
experim ent G .l, a significantly lower level of parasitaemia was seen in the untreated 
group (Pc) than the treated group (PcV) on day 8, while in G.2 a lower parasitaem ia was 
seen in the NISV-treated group (PcV) compared with the untreated group (Pc) on days 7 
and 9. On day 11 of this experiment, however, the Pc group had a lower parasitaemia 
than the PcV group (p<0.05 at 95% Cl) (see Appendix 2 for individual experiments). 
Again when the two experiments were combined no significant difference was seen 
between the two groups at any time point (Figure 3.4).
An im portant observation made here was that parasitaemia levels were seen to be very 
high in some animals of both groups (Pc and PcV), up to 60% in some animals. High 
parasitaem ia levels on their own, however, carried no prognostic significance since 
some mice made a full recovery. W hat did seem to be im portant in determining 
prognosis was the degree of red cell fragmentation. Anim als with great red cell 
fragm entation seemed to die while the others seemed to recover. If this is true for 
humans as well, then it could perhaps be used to determine which patients to treat with 
a blood transfusion.
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3.3. Effects of NISV on the clinical status of mice 
3.3.i. Mortality
In the first experiment at Strathclyde University (S .l) , the Pc group had 40%  mortality, 
while the PcV group had a mortality rate of 20%. In the subsequent experiments, 
however, rates were seen to be higher (although not significantly) in the infected, NISV- 
treated group (PcV), even in those experiments showing a less severe disease in the 
treated group (Figure 3.5). Furthermore, in one experiment conducted at Strathclyde 
University, 20 % of animals were found dead even before being infected but after 
treatm ent with NISV. There were no signs of injury in these animals to attribute their 
death to fighting and to date it is not really known what caused their death. This 
particular experiment was term inated in case the mice were infected with a pathogen 
present in the animal house.
Among the mice that died some were found to be very warm as if death had occurred 
recently. Upon dissection, it was noted that the majority of these mice had very 
distended bladders (3-6ml) indicating urinary retention for some tim e prior to death.
3.3. ii. HHSS (Hassan Health Status Score):
Apart from mortality rates, a health status score was developed to allow a quantitative 
com parison of the anim als’ health in the two groups. It was based on a table used for 
mice infected with Toxoplasma gondii in which disease is divided into severe, moderate 
and mild (Animal House, Strathclyde University). M ore features were added to this 
table and a score was given to each feature (see Material and M ethods). Initially bowel 
motion and urine appearance were included to describe diarrhoea, and haematuria. 
Subsequently they had to be excluded as these two features were not always observed 
during the period when attending the animals.
8 6
The results shown here represent a combination of two experiments conducted at each 
venue. In the first two experiments (S.l and S.2), the PcV group had a higher score than 
the Pc group on days 11 and 12 post-infection, while in the second set of experiments 
conducted at Glasgow University (G .l and G.2), the Pc group had a higher score than 
the PcV group between days 12-14 post-infection (p<0.05 at 95% Cl) (Figure 3.6.a and 
b).
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Figure 3.1. Percentage weight o f 10-12 week old male BALB/c mice infected with P. 
chabaudi AS. Pc; animals infected with 1x10  ^pRBC on day 0 and received lOOp,! PBS 
s.c. on days -28 and -14. PcV: animals infected with 10^  pRBC on day 0 and received 
lOOpJ NISV s.c. on days -28 and -14. Results represent combined data o f two 
experiments conducted at the same venue (Strathclyde University) containing 10 and 20 
animals per group in experiments S .l and S.2 respectively. The points represent the 
combined means and the bars are the standard errors o f the means.
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Figure 3.2. Percent weight o f 10-12 week old male BALB/c mice infected with P. c AS. 
Pc and PcV are groups infected with 1x10  ^pRBC on day 0 and injected subcutaneously 
with lOOpi o f PBS or NISV respectively on days -28 and -14. Results represent means 
o f combined data o f two experiments conducted at the same venue (Glasgow 
University) and error bars are the standard errors o f the means.
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Figure 3.3. Percent parasitaemia in 10-12 week old male BALB/c mice infected with P. 
c. AS. Pc, PcV; animals infected with 1x10  ^ pRBC on day 0 and received subcutaneous 
injection o f lOOpl PBS and NISV respectively on days -28 and -14. Results represent 
combined data o f 2 experiments conducted at the same venue (Strathclyde University) 
containing 10 and 20 animals per group in experiments S .l and S.2 respectively. The 
points represent the combined means o f the two experiments and the bars are the 
standard errors of the means.
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Figure 3.4. Percent parasitaemia o f 10-12 week maie BALB/c mice infected with P. c. 
AS. Pc and PcV groups were infected with 1x10  ^ pRBC on day 0 and injected 
subcutaneously with lOOpl o f  PBS or NISV respectively on days -28 and -14. Results 
represent means o f combined data o f two experiments G.l and G.2 conducted at same 
venue (Glasgow University) and error bars are the standard errors o f mean
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Figure 3.5.a, b: Percent survival o f 10-12 week old male BALB/c mice infected with P. 
c. AS. 3.5.a. represents data from experiments 8.2), while 3.5.b represents data from 
G.2. Pc and PcV are groups o f mice infected with 1x10  ^ parasitized red blood cells on 
day 0 and received lOOpl o f PBS or NISV respectively on days -28  and -14.
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Figure 3.6 a, b: Health status score o f male 10-12 week old BALB/c mice infected with 
P. c. AS. Pc and PcV are groups o f mice infected with 1x10  ^ pRBC on day 0 and 
injected subcutaneously with lOOpl PBS or NISV respectively on days -28 and -14. 
3.6.a; data from experiment S.2 and 3.6.b; data from experiment G.2
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Discussion:
It can be seen from the experim ents described in this chapter that conflicting results 
with regards to the animals weights, level of parasitaem ia and health status score were 
obtained at the two venues (Strathclyde and Glasgow Universities). If anything then 
these experiments show the importance of repeating experimental work to confirm  or 
refute any conclusions drawn from the initial results.
In these experiments, animals weight is expressed as a percentage of their weights on 
day 0. A better method of expressing weight loss, however, would have been the 
m ethod of pair feeding which involves measuring the amount of food consum ed by the 
ill animals and providing this amount of food to the control animals i.e. to equalize the 
amount of food consumed by both groups. This method would clearly show that despite 
consum ing the same amount o f food, the infected animals were indeed losing more 
weight indicating that the weight loss in them was not only a function of loss of appetite 
but also the catabolic process during their illness. It has to be em phasized, however, 
that the weight measurements in the ill animals is an under estimate o f their catabolism  
since some of this weight is a measure of the enlarged spleen and to a lesser extent the 
liver.
Several possibilities which could explain the contradictory results were suggested. 
Initially it was thought that the NISV used in the third experiment (G .l)  were not made 
properly and so did not produce their desired effects. This possibility, however, was 
overcom e by obtaining the NISV fresh from the makers them selves (Brewer et a l .  
Division of Immunity, Infection and Inflammation, Glasgow) who were confident 
about the NISV although, they no longer checked their m orphology under the 
microscope routinely.
Another possible explanation for the variation of the results was the possible infection 
of some animals with murine hepatitis virus (MHV) giving rise to variable results. This 
possibility too was rejected because the animals used were old enough to have cleared 
such an infection that is thought to affect younger mice. Another possible explanation
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was thaï perhaps animals at the first venue had co-infections with pinworm, which 
could have affected the outcome of their illness, while animals at the second venue 
were claim ed to be free of any such infestations. This was later discarded as some mice 
from the first venue were dissected and examined for worms and were found to be 
clean. This, however, does not exclude infestation by other organisms.
It was also thought that perhaps the amount of PABA taken in the diet by the animals at 
the two venues was different. As m entioned earlier, PABA was shown to have an effect 
on the susceptibility of mice to m alaria infections (Maegraith, Deegan and Sherwood 
Jones, 1952). Both venues, however, used tap water from the same main city supplies 
without adding any PABA. Also both venues used the same pellet diet CRM(p) 
obtained from  the same supplier. This, however, does not elim inate the possibility of 
the water pipes in either venue being colonized by some pathogens causing the above 
variation in the outcome of the illness.
D ifference in the virulence of the parasites used in the different experim ents was also 
thought o f as a possible explanation for the contradictory results but all parasites were 
obtained from the same parasite parents kept in the same place at University of 
Glasgow.
An im portant point to note is that some mice in the first venue (Strathclyde University) 
exhibited clinical features, which were not seen at Glasgow University. Among these 
were gross oedema affecting one m ouse in the infected, untreated (Pc) group which also 
showed lipids in its plasm a suggesting a clinical picture of nephrotic syndrome. In 
humans, nephrotic syndrome (hypertension, oedema, hyperlipidaemia and proteinuria) 
is reported mainly with P. malarias  (Souhami and M oxham, 1998) m alaria rather than 
P. fa lc iparum  while to my knowledge no such condition had been reported in P. 
chabaudi chabaudi AS in mice. Another feature was the developm ent of coprophagia in 
one m ouse during the recovery phase and lasted for many days until the mouse 
eventually died possibly due to malnutrition since it refused to eat its normal diet. One 
last strange feature exhibited in one mouse was the running around in circles, which 
also lasted for several days. It is difficult to say whether it had developed a peripheral or
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central neurological problem since none of the mice was studied by post-m ortem. 
W hether these features were due to P. c. AS or due to some other infection occurring at 
this venue is not known. It is also worth noting that these features were seen later in the 
infection, during and after apparent clinical recovery.
In view of the above results, it becomes evident that the difference in the outcom e of the 
experiments was venue-dependent. This, however, is not entirely true since 
retrospective examination o f the results of more experiments revealed a wider 
variability in the results which were independent of the venue. In one of the 
experiments conducted at Strathclyde University, four mice were found dead shortly 
after the administration o f the second dose of the NISV and before infection. The 
animals did not show any signs of injury to attribute their death to fighting. This 
experim ent was, therefore, term inated in case the animals had been infected with 
another pathogen in the anim als house. Also, the initial experim ent conducted by the 
m anufacturers of the NISV (Brewer, Strathclyde University) showing a reduced weight 
loss in the T. go/Wn-infected mice and treated with empty NISV does not make any 
reference to the presence o f oedem a which could give false positive results with regards 
to the anim als’ weight, nor does it make reference to other clinical param eters to assess 
the anim als (Brewer, 1993). M oreover, in experiment S .l effects o f pre-infection 
treatm ent with NISV was investigated not only on P. c. AS-infected mice but also on T. 
gondii-infQct&d mice using the same batch of the NISV. As m entioned earlier, in this 
experiment, the NISV-treated, P. c. AS infected group developed a less severe disease 
than the untreated group. How ever there was no difference between the NISV-treated 
and untreated, T. gondii-mfQctQd animals.
The difference between the two groups in any experiment could be a mere chance since 
it was also noticed between animals of the same group but in different cages. Also, 
although the difference in parasitaem ia or weight loss between the two groups (Pc and 
PcV) was significant at some time points (p<0.05 at 95% Cl), this by no means 
eliminates false positive results due to chance. This is because p value of <0.05 at 95% 
Cl simply means that the difference between the groups has less than 5% probability of 
being due to chance. M oreover, there was always a mouse which was much worse than
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others of the same group and a mouse which seemed to be hardly affected. In addition, 
one mouse at Strathclyde University had malform ed incisors, while at Glasgow 
University one of the animals had situs in vertus. Both these anim als were eliminated 
from the experimental work. It is obviously possible that the differences seen in weight 
loss and percent parasitaemia could be due to errors made by the observer but this does 
not explain the differences seen in the HHSS for which a bystander from the animal 
house was used as a witness (Jack Keys and David M cGlaughlan at the first and second 
venue respectively). Another point indicating that the difference in the outcome 
between the NISV-treated and untreated, was due to chance is the fact the difference 
between the two groups occurred at different time intervals in the different experiments.
This significance of urinary retention is not known but it could indicate the death of 
these animals from exhaustion due to increased sympathetic drive trying to put up with 
the stress of the disease. The red cell fragmentation observed in mice dying soon 
afterwards is worth investigating in human malaria. This could be useful as a prognostic 
sign and in determining treatment by blood transfusion.
From the above results, it becomes evident that the difference between the NISV-treated 
and untreated male BALB/c mice infected with P. c. A S  was not due to the use of 
NISV. Indeed when the four experiments are combined together, no significant 
difference between the two groups with regards to degree of weight loss or level of 
parasitaem ia is seen at any time point (Figures 3.7, 3.8).
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Figure 3.7; Percent weight o f male BALB/c mice infected with P. c. AS. Results 
represent combined data obtained from 4 experiments. Pc and PcV are 2 groups infected 
with 1x10  ^ pRBC on day 0 received lOOpl PBS or NISV respectively on days -28 and - 
14. Although the NISV treated group shows less weight loss than the untreated group, 
this however is not significant at any time point
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Figure 3.8: Percent parasitaemia in 10-12 week old male BALB/c mice infected with P. 
chabaudi AS. Results represent combined data obtained from 4 experiments. Pc and 
PcV were injected with 1x10  ^ pRBC on day 0 and received lOOpl o f PBS and NISV 
respectively on days -28 and -14.
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Chapter 4
Effects of pre-infection administration of NISV on TNFa levels in 
male BALB/c mice infected with P. chabaudi chabaudi AS.
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Introduction
As m entioned in the previous chapter, pre-infection treatment of P. c. AS-infected 
mice with NISV led to a lower level of parasitaemia, a less degree o f weight loss and 
a higher health status score than the untreated mice in the initial experiments (S 1 and 
52). Since high levels o f T N F a  have been reported to cause cachexia during 
infections (Bcutler et al., 1985), it was decided to measure the T N F a  levels in NISV- 
treated, P. c AS-infected mice and compare them with those in the untreated, infected 
mice.
Tumor necrosis factor:
Tum or necrosis factor alpha (TN Fa) is a m onokine that was discovered by two 
different groups of researchers and accordingly was given two different names. It was 
initially identified in the serum of mice, primed with BCG and injected with LPS two 
hours previously, as a factor capable of causing necrosis of some subcutaneous 
tumors in mice (Carswell et a l ,  1975). It was also discovered and purified by B eu tier 
and colleagues (1985) investigating weight loss during infection o f animals with 
trypanosomes and was, therefore, named cachectin. It was not long before Beutler and 
colleagues noticed that the amino terminal sequence o f the mouse cachectin and the 
human TN F shared a strong homology suggesting that they were in fact the same 
m olecule (Beutler et a l ,  1985). W hen the TN F cDNA was cloned, its sequence 
exactly predicted the amino terminal sequence of the mouse cachectin (Fransen et at., 
1985, Caput et al., 1986). Immunogenic studies and bioactivity m easurem ents of the 
two m olecules confirmed that the two molecules were the same (Beutler and Cerami, 
1988^
T N F a is encoded by a gene located on chromosome 17 in mice, close to the M HC II 
region (M üller et al., 1987, Nedospasov et a i ,  1986), and on the short arm of 
chrom osom e 6 in humans (Nedwin et al., 1985) closely linked to HLA B region 
(Carroll et al., 1987). It is not known whether these locations have any significance.
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T N F a  is initially synthesized as a non-glycosylated transinem brane protein of 
approxim ately 26 kD. A 17 kD fragment is proteolytically cleaved off the plasm a 
m embrane. This released fragment aggregates in vitro to produce dimers, trimers and 
pen tamers but the bioactive form is thought to be a 52kDa hom otrim er in the shape of 
a pyramid (Eck and Sprang, 1989, Jones et al., 1989). Three receptor-binding sites are 
at the base of this pyramid (Van Ostade et al., 1991) allowing sim ultaneous binding to 
more than one receptor. In addition to the 17kD form, a 26kD m em brane-bound form 
of T N F a  that was detected by anti-T N Fa polyclonal antibodies also exists on 
activated macrophages monocytes (Kriegler et al., 1988). The authors suggested that 
this form is rapidly induced on monocytes at sites of inflamm ation. In fact, 
m em brane-bound form of T N F a  had been identified before by Decker and colleagues. 
They had reported TN Fa-dependent lysis of tumor cells by activated macrophages 
that had been fixed by paraformaldehyde before the addition of the target cells and in 
the absence of any measurable secreted TN Fa. Indirect radioim m unassay studies 
confirm ed the presence of T N F a  on the surface o f activated macrophages. The 
authors suggested that the lytic activity exhibited by these m acrophages occurred 
through direct contact with the target cells (Decker et al., 1987).
T N F a  is mainly produced by m ononuclear phagocytic cells (Old et al., 1985). In 
C57B1/6 mice it was found to be produced by all macrophages tested including 
alveolar, hepatic, peritoneal, bone marrow-derived macrophages and peripheral blood 
monocytes (Decker et al., 1987). Several other cell types have been reported to 
produce T N Fa. Among these are T lymphocytes which produce T N F a  in response to 
phorbol my Estate acetate and calcium ionophore (Cuturi et al., 1987) and NK cell 
produce T N F a  in small quantities (Degliantoni et al., 1985). M ast cells have been 
found to contain T N F a stored in their granules (Gordon and Galli, 1990). Human B 
lymphocytes transformed by Epstein Barr virus have also been reported to secrete 
T N F a  (W illiamson et a l ,  1983).
Apart from LPS, which is the most potent stim ulator of T N F a  production, several 
factors have been shown to induce the production of T N Fa. Certain viruses, 
trypanosomal and plasmodial lysates and certain Gram positive bacteria like 
staphylococci have been reported to induce T N F a  production in vitro although in
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relatively small quantities (Aderka et al., 1986). IFNy, although not capable of 
inducing T N F a  production on its own, increases the rate of T N F a  gene transcription 
when co-administered with LPS (Beutler et al., 1986) and upregulates the expression 
of T N F a  receptors on the target cell (Tsujimoto et al., 1986). IL-2 is also thought to 
increase the rate of T N F a gene transcription (Nedwin et al., 1985). M alaria 
exoantigens have been reported to stim ulate the production of T N F a  from 
macrophages and their active m oiety has been found to be phosphotidylinositol and 
inositol monophosphate since antibodies to these specifically inhibit T N F a  induction 
by m alaria exoantigens (Bate et al., 1992). Glucocorticoids, on the other, hand 
suppress T N F a  biosynthesis in vitro if administered to macrophages prior to LPS. 
Indeed pre-LPS glucocorticoid administration to animals protects them from a lethal 
dose o f LPS (Beutler et al., 1986). Cyclosporin A was reported to inhibit 
T N F a  bioactivity but without inhibiting the expression of T N F am R N A  (Nguyen et 
at., 1990).
T N F a  mRNA concentrations rise within minutes in macrophages exposed to LPS in 
vitro and detectable amounts of T N F a  are secreted within 20-30 m inutes (Beutler and 
Cerami. 1988). T N F a  production, however, is inhibited by addition o f actinomycin D 
indicating that messenger of T N F a  is rapidly induced by LPS (Gifford et al., 1984). 
The levels of mRNA reach their peak 2-3 hr after induction, declining slowly 
thereafter to approach levels seen in non-stimulated cells after 15-20 hr despite the 
continual presence o f the stim ulus (Beutler and Cerami, 1988). T N F a  production 
ceases within 4-6 hr following contact with LPS. In this time period during which 
T N F a  is produced, continual exposure to LPS is essential as removal o f LPS led to 
cessation of T N F a  production which was resumed when LPS was again added to the 
cultures (Gifford et al., 1986).
ïn vivo studies have shown that after endotoxin injection into rabbits, T N F a  appears 
in the circulation within 20 m inutes (Beutler et al., 1985) and reaches peak levels 
between 90 min and 2 hours, declining thereafter to reach basal levels within 5-6 hr. 
In mice, radio-iodinated T N F a  was found to have a plasma half-life of 6-7 minutes 
(Beuter cr n/., 1985).
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Two discrete types of T N F a  receptors of 55 and 75 kDa and o f different affinities 
have been identified at the cell surface of a variety of cell lines including human 
peripheral blood monocytes (Hohman et a i ,  1989, Brockhause et a i ,  1990). There are 
two receptors in mouse too (Lewis et a i ,  1991). The murine TN F-R l and TNF-R2 
have 64% and 62% homology to human TN F-R l and TNF-R2 respectively (Lewis et 
aL, 1991, Goodwin et al., 1991). It has been reported that high affinity receptors are 
found not only on cells sensitive to T N F a cytotoxicity such as L929 but also on cell 
types resistant to T N F a  cytotoxicity such as FS-4 (Tsujimoto et a l ,  1985). The 
majority o f cell types seem to express both types o f the receptors known as p55 and 
p75 (TN F-R l and TNF-R2 respectively). There is no homology between the TN F-R l 
and TNF-R2 in their intracellular portions indicating that the intracellular signaling 
pathways are different (Lewis et al., 1991). The extracellular portions o f both TNF- 
R l and TNF-R2 are shed and retain their ability to bind T N F a  (Engelm an et a l ,  
1989). The majority o f the TNF-m ediated biological activities such as cell death, gene 
induction and cytokine production have been attributed to T N F-R l (Lewis et a l ,  
1991). TNF-R2 is thought to be involved in T cell developm ent and proliferation of 
cytotoxic T cells (Tartaglia et al., 1991, Tartaglia et a i ,  1993). TN F-R2 KO mice, 
however, have been reported to show a normal T cell developm ent and activity, an 
increased resistance to TNF-induced death and a decrease in tissue necrosis indicating 
that this receptor plays a role in the necrotic effects of T N F a  (Erikson et al., 1994). It 
has been shown that following binding of T N F a to p55, the com plex becomes 
internalized and eventually degraded in lysosomes (M osslem ans et al., 1988, 
Imsnmim et al., 1987).
T N F a  has been found to exert m ultiple effects on a variety of cell types. It has been 
shown to have many metabolic effects including the inhibition of lipoprotein lipase on 
fat cells (Beutler et al., 1985) which causes break down of adipose tissue and 
hypertriglyceridaemia. It also suppresses the differentiation of adipocytes (Torti et al., 
1985). M oreover it antagonises the lipogenic effects of insulin (Pekala et al., 1983). 
Together these effects inhibit storage of fat, leading to wasting.
T N F a  has powerful effects on the activation and differentiation of monocytes 
resulting in further release of T N F a  (Hohmann et al., 1990). Upon activation of
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macrophages there is the stimulation of a pathway leading to the production of NO, 
which has marked parasiticidal activities (Ding et al., 1986, Nüssler et al., 1992). 
T N F a  also stimulates the production of IL-6 and PgE2 by m acrophages and together 
they induce complex intracellular mechanisms, which control the transcription and 
translation of T N F a mRNA (Han, Heuz and Beutler, 1991).
T N F a  is chemotactic for neutrophils in vitro and induces the expression o f ELA M -1 
on endothelial cells, which is a potent inducer o f neutrophil migration. T N Fa, along 
with interleukin-1, has also been shown to enhance neutrophil adhesion to 
endothelium  in vitro (Pohlman et al., 1986, Gamble et al., 1985). It augments their 
phagocytic activity and increases their cytotoxicity to certain microorganisms 
(Shalaby et al., 1985). T N F a  itself has been found to be a weak stimulant of 
neutrophil respiratory burst (Klebanoff et al., 1986). On the other hand it also induces 
the production of IL-6 and IL-8 by endothelial cells. Although these cytokines are 
chemotactic, they have an inhibitory effect on leukocyte adhesion (Gimbrone et al., 
1989).
Recom binant human T N F a was found to increase T N F a receptors on IL-2-stimulated 
T cells. T N F a  also promotes the expression o f IL-2 receptor and HLA-DR antigen on 
lymphocytes and augments the IL-2-dependent IFNy production by the T cells 
(Scheurich et a l ,  1987)
T N F a  is an endogenous pyrogen, causing fever both directly by acting on the 
hypothalamus and indirectly by triggering peripheral production of IL-1. Injection of 
rabbits with human iT N F a  causes a brisk m onophasic fever (Dinarello et al., 1986).
In the case of malaria, it was initially shown that tumor necrosis serum (serum 
obtained from BCG-infected mice, two hr following an intravenous injection o f LPS) 
was toxic to blood stages of P. falciparum  (Haidaris et al., 1983) P. yoelii and P. 
berghei (Taverne et a i ,  1987) in vitro. Rabbit antiserum against partially purified 
TN F protected the intra-erythrocytic forms of P. falciparum  from the effects of the 
BCG-LPS serum (Haidaris et al., 1983). By using rTN Fa, however, it was shown that 
T N F a  itself did not have any toxic effects on the P. falciparum in vitro (Jensen, van
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de W aa and Karadsheh 1987, Taverne et a l ,  1987, Kum aratilake, Ferrante and 
Rzepczyk, 1990) but it rather led to the production of intermediates, which could be 
the effecter molecules in killing the parasites. It was initially thought that the in vitro 
killing o f the blood stage parasites by the tumour necrosis serum was due to reactive 
oxygen intermediates (ROI) since mitogenic stim ulation o f peritoneal macrophages 
14 days following treatment with BCG gave an optimal hydrogen peroxide release 
(Nathan, 1997). Furthermore, hydrogen peroxide had been reported to be toxic to 
blood stage parasites in vitro (Dockrell et a l ,  1983). Reactive oxygen intermediates, 
however, are short lived and their effects could be blocked by antioxidants, which is 
not the case for the parasiticidal activity of tumour necrosis serum. It was, therefore, 
thought that ROI could not be responsible for this toxicity (Geary et a l ,  1986). 
Instead lipid peroxides, which are produced by reaction of plasm a lipoproteins with 
ROI and which are unaffected by antioxidants (Morel et a l ,  1984), were suggested to 
be responsible for the in vitro anti-parasitic activity with perhaps other factors 
(Rockett et a l ,  1988). The authors suggested that if these oxidized lipids were taken 
up by the parasites, they could have a direct toxic effect on the parasite by cross 
linking their proteins or by destabilizing the erythrocyte mem brane. Subsequent 
studies showed that serum of CBAYCaH mice undergoing a successful immune 
response against P chabaudi infection was not toxic to P. falciparum, in culture unless 
the infection and the T N F a levels of the mice were high enough to cause illness. The 
authors, therefore, suggested that the downstream  products o f T N F a  required 
activated macrophages to cause intra-erythrocytic death of parasites (Clark, Cowden 
and Butcher, 1990). A synthetic peptide corresponding to residues 70-80 o f the T N F a  
m olecule (TNFavo-so) was reported to enhance human polym orphonuclear killing of 
P. falciparum in vitro and reduce P. chabaudi parasitaemia in m ice (Kum aratilake et 
a l ,  1990, 1995). The TNFavo-so peptide did not increase the expression o f adhesion 
molecules on endothelial cells and inhibited the T N Fa-induced increase in P. 
falcipatmm-ïnîœtoà  erythrocytes binding to endothelial cells. The authors suggested 
that the protective effects o f T N F a could be retained while toxic effects are 
elim inated by using selected characterized subunits of T N F a  (Kum aratilake et a l ,  
1995). Furthermore, a recent report has shown that addition of T N F a  to cultures of 
human m onocytes and P. falciparum  infected erythrocytes increased the phagocytic
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index of the monocytes from 3.8-7.8 in the presence of serum  containing P. 
falciparum  antibody (M uniz-Junqueira et a l ,  2001).
In vivo studies revealed both a protective and a harmful effect for T N F a  in malaria. A 
protective role for T N F a  was evident in male CBA/CaH mice infected with P. 
chabaudi adami and treated with human rT N F a via an osmotic pump. These animals 
developed a lower parasitaemia, earlier crisis forms and an earlier decline in 
parasitaem ia than the untreated group (Clark et al., 1987). Treatm ent with 10^-10^ 
units o f human rT N F a also resulted in 80% survival and significant decrease in the 
peak parasitaemia in susceptible A/J mice infected with P. c. AS. M oreover, all the 
surviving mice recovered by week 4 and were completely protected against a 
challenge infection. An important finding in these mice was that a higher T N F a  dose 
was needed to produce protection as the infective dose of pRBC increased. Giving the 
same treatm ent to resistant C57B1/6 mice, on the other hand, did not produce any 
effect except that a dose of T N F a  higher than 10  ^ U resulted in 100 % mortality 
(Stevenson and Ghadirian, 1989). This indicated that the resistant m ice did produce 
enough T N F a  to protect them selves and exceeding a certain levels o f T N F a  resulted 
in harmful effects. Furthermore, treatment of P. berghei K173-infected female 
C57B1/6 mice prevented the developm ent of experimental cerebral m alaria (ECM) 
and also reduced parasitaemia in those mice that did not develop ECM  but not in 
those that did developed it (Postm a et at., 1999). Repeated injection o f murine rT N Fa 
into P. yoelii 17X-infected out bred mice reduced their parasitaem ia and significantly 
prolonged their survival (Taverne et a l ,  1987). Transgenic mice carrying a modified 
human T N F a  P-globin chain and infected with P. yoelii had a 10 fold lower 
parasitaem ia at its peak than the wild type mice and those infected with P. chabaudi 
had even a lower level of parasitaem ia than their wild type counteiparts. The decrease 
in parasitaem ia was thought to be due to enhancem ent of m acrophage activity against 
parasitized red blood cells by the human T N F a  (Taverne et a i ,  1994).
Recent work on T N F a receptor double knock out (p55, p75) resistant B6 x 129 mice 
did not, however, lead to any alterations in the parasite levels or in their clearance. 
The authors suggested that TNFcr therefore was not critical for resolving blood stage 
infection with P. chabaudi AS m alaria and its absence did not affect the early IL -12
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production and T hl response (Sam et a l ,  1999). Other studies, on the other hand, 
have reported that although T N F a  R1 may not be essential for the control of primary 
parasitaem ia re-infection in such animals was as severe as the prim ary infection 
indicating that TN F-Rl was necessary for the developm ent of memory responses (Li 
and Langhorne, 2000).
Other studies showed that both the timing and site o f T N F a  generation during 
infection were important. T N F a mRNA in the liver and spleen was found to be high 
early during infection in resistant C57B1/6 mice infected with P. chabaudi AS, while 
high levels were found in the liver of susceptible A/J mice late during infection in 
whom  circulating T N F a was also high during this period (Jacobs et al., 1996).
On the other hand several studies indicated a role for T N F a in m alaria pathology. 
Serum T N F a  levels were found to be significantly higher in P. berghei ANKA- 
infected m ice that developed cerebral malaria (CM), than those that did not develop it 
(Grau et al., 1987c). In the animals that developed CM, local T N F a  was also found 
by imm unohistochem ical staining, while it was absent in the anim als that did not 
develop CM. Indeed treating the infected animals with a neutralizing anti-T N Fa 
antibody before the appearance of CM dropped CM from 80-90% to 8.3%, but it did 
not protect them  from death which was due to severe anaem ia (Grau et al., 1989). In 
addition, P. berghei K173-infected C57B1/6J mice exhibited increased sensitivity to 
T N F a  and doses as low as 2.5pg on days 8-10 were lethal. Depletion o f m acrophages 
which are the usual source o f T N F a also prevented the developm ent o f cerebral 
m alaria (Curfs et al., 1993). Treating these mice with sublethal doses of T N F a  
(l.Oug/ml), however prevented the development of CM indicating dose-dependent 
effects o f TN Fa. Also, transgenic mice expressing high levels o f T N F a  receptor 1 
fusion protein were markedly protected from death by cerebral m alaria after infection 
with P. berghei (Garcia et al., 1995).
Furthermore, injection of rTNFa into naive mice induced systemic changes found 
in malaria such as hepatic midzone necrosis, hypoglycaemia and neutrophil adhesion 
to pulmonary blood vessels. No cerebral changes were seen, however, and the blood 
brain barrier which is interrupted in CM remained intact. The authors suggested that
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the changes seen in CM in mice infected with P.berghei ANKA could in fact be due 
to locally produced T N F a from monocytes sequestered in the cerebral circulation 
rather than due to systemic T N F a  levels (Clark et a l ,  1990). Indeed work on murine 
cerebral m alaria showed that T N F a  is locally produced by m icroglia and astrocytes 
few days before the appearance of clinical features (Jennings el al., 1998).
T N F a  is thought to play at least a part in the murine m alaria associated-anaemia. 
Treatm ent of P. berghei female BALB/c mice with rhuT N Fa via an implanted 
osmotic pum p led to reduction of pluripotent stem cells and erythroid progenitors in 
the bone marrow, splenomegaly and reduced incorporation o f iron into erythrocytes. 
Treatm ent o f these mice with anti T N F a serum lead to partial recovery o f the bone 
marrow with an increase in the stem cells and erythroid progenitors plus increased 
incorporation of iron (Miller et al., 1989). The role of T N F a in m alaria-associated 
anaem ia was also seen in transgenic mice for the human T N Fa-p  chain which excrete 
human T N Fa. These mice were shown to develop anaemia thought by the authors to 
be due to increased erythrophagocytosis (Taverne et al., 1994).
Circulating T N F a levels were also seen to correlate with CM in humans. In a study 
conducted on Gambian children it was shown that T N F a  levels was twice as high in 
those who developed CM and 10 times higher in fatal cases than those with 
uncom plicated m alaria (Kwiatkowski et al., 1990). Serum T N F a  levels were shown 
to correlate positively with the severity and mortality rates o f P. falciparum  in 
children in Malawi (Grau et al., 1989, Kern et al., 1989). Here high circulating T N F a 
levels were associated with hypoglycaemia, hyperparasitamia and age under 3 years 
(Grau et al., 1993). Also higher T N F a and IL-6 were found in the circulation of 
patients with CM or complicated m alaria than in patients with uncom plicated malaria 
(Ringwald et a l ,  1993), and levels of both cytokines were found to be useful markers 
for P. falciparuml  severity (Kern et a l ,  1989). In one study, depletion of T N F a  with 
the use of anti-TN Fa monoclonal antibodies in Gambian children with cerebral 
m alaria did not alter mortality but instead increased the neurological sequelae in the 
survivors. This was explained by the possible extended retention of T N F a  in the
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circulation by the antibodies and therefore prolongation of its effects (van Hensbroek 
el al., 1996).
As m entioned earlier, T N F a  is an enodogenous pyrogen (Dinarello et al., 1986). In 
m alaria fever has been attributed to TN Fa. Fever in Gam bian children with 
uncom plicated m alaria was associated with moderately elevated levels of circulating 
T N F a  (Kwiatkowski, 1990). Indeed neutralizing anti- T N F a m onoclonal antibodies 
have been shown to inhibit fever in Gambian children with cerebral m alaria 
(Kwiatkowski e t a i ,  1993).
In view of the above studies, it becomes evident that T N F a  has dual 
protective/pathological effects depending on its levels. Certain T N F a  levels are 
required to produce protective effects, but beyond these levels the pathological effects 
appear.
Inbred m ale BALB/c mice were infected with P. chabaudi AS. A group of these 
animals was treated with NISV prior to infection. The aim was to test the hypothesis 
that NISV suppress T N F a  production from the macrophages (Brewer and Alexander, 
personal communication). The animals were followed up clinically (chapter 3), and 
with regards to various cytokines, IFNy (chapter5), IL-4 (chapter 6) and T N Fa, the 
results o f which are presented here.
Results
4.1. Effects of NISV on plasma TN Fa levels of P. c AS -infected mice.
The results shown here are from three experiments, the first two (S .l and S.2) 
conducted at Strathclyde University while the last one (G .l) was conducted at 
G lasgow University. Inbred male BALB/c mice were infected with 1x10^ pRBC of P. 
chabaudi AS (n = 10, 20 and 20 in experiments S .l, S.2 and G .l respectively) on day 
0. They had received lOOpl subcutaneously of either PBS or NISV on days -28 and - 
14 and referred to as the Pc and PcV groups respectively. Age and sex-m atched
animals were also injected with PBS and NISV but received no infection and were 
referred to as PBS and NISV. Animals were bled into heparinised capillary tubes and 
samples of the same group were pooled and stored at -20°C  until analysis.
In experim ent S .l, no T N F a was detected early during the infection. T N F a  was only 
detected in the Pc group late in the infection, on days 37-42 (Figure 4.1). It was 
therefore decided to reduce the amount of T N F a  used in the starting standard from 
20ng/ml. This was done serially until some levels were detected in the samples 
against standards starting from 2ng/ml. In experiment S.2, higher levels of 
T N F a  were seen in the Pc group than the PcV group on days 9, 12 and 13 post­
infection. T N F a  peaked twice in the Pc group, on days 9 and 12 while in the PcV 
group it peak once only on day 9 post-infection (Figure 4.2). In this particular 
experiment, the peak parasitaemia occurred on day 9 while animals w eight reached its 
nadir on day 8 post-infection. In both S .l and S.2 experiments, the PcV group 
exhibited a less severe disease than the Pc group in terms o f percent parasitaemia, 
percent weight loss and health status score (see Appendix 2). In experim ent G .l, 
T N F a  also peaked twice in the Pc group on days 9 and 10 and was significantly 
higher than the PcV group which showed one peak only on day 9 post-infection 
(Figure 4.3). In contrast to the previous two experiments, however, the PcV group 
exhibited a more severe disease (higher parasitaemia, more weight loss and lower 
health status score) than the Pc group in this particular experiment (see Appendix 2). 
No T N F a  was detected in groups PBS and NISV (Figure 4.3).
4.2. Effects of pretreatment with NISV on whole blood TNFa
W hole blood was collected in one experiment only (G.2). Twenty five inbred male 
BALB/c mice per group were infected with P. c AS and treated with NISV or PBS as 
described above. Blood was collected from two or five animals per group via cardiac 
puncture or via the tail vein respectively at selected time points judged by the clinical 
status of the animals. Samples from the same group were pooled and lOOpl of ddH 20 
were added to each 1ml of blood in order to break any clots prior to freezing. Samples 
were then stored at -20°C  until further analysis.
T N F a  was detected in both groups from day 3 until day 11 post-infection. On day 12 
T N F a  was seen in the PcV group only, while on day 14 it was detected in the Pc 
group only (Figure 4.4). T N F a  was slightly lower in the PcV group on days 3, 6, 7 
and 8 and slightly higher on days 4, 10 and 11 than the Pc group. T N F a  levels 
peaked to around 400U/ml on day 21 (following recovery from primary parasitaemia) 
in both Pc and PcV groups with slightly higher levels seen in the Pc group. T N F a  was 
measured in the PBS and NISV groups at one time point only (day 21 post infection). 
No T N F a  was detected in the PBS group, while low levels (30U/ml) were seen in the 
NISV group. Since this experim ent was done once only, it cannot be com pared with 
other results. In this particular experiment, the PcV group exhibited a worse disease 
(see Appendix 2).
4.3. Effects of pre-infection treatment with NISV on ex-vivo splenic levels of 
TNFa
Results shown here cover two experiments (G .l and G.2). Two anim als per group 
from groups of inbred male BALB/c mice infected in the above experim ents were 
sacrificed at selected time points during infection judged by the appearance of clinical 
features (days 1, 4, 7, 10 and 16 and days 6, 8, 10, 11, 14, 17 and 21 post-infection in 
experiments G .l and G.2 respectively). Spleens were rem oved aseptically and 
exposed to various stim ulating or control agents including ConA, parasitized red 
blood cells, non-infected red cells plus complete RPMI. Splenocytes were incubated 
at 37°C in 5% CO 2  in air for various periods (4hr, 6hr, 18hr and 24hr) because of the 
difficulty in detecting TN Fa. Supernatants were stored at ~20°C until further analysis.
T N F a  was detected in only one experiment (G. 1) and only at 4 hr incubation while all 
other attempts of detecting it in the other experiment (G.2) and at other time points 
failed despite the use of the same antibodies (Figure 4.5). The PBS and NISV groups 
were found to produce T N F a  in response to ConA and pE on day 10 post-infection, 
while low levels were detected in response to ConA on day 1. T N F a  was detected in 
the two infected groups (Pc and PcV) on day 1 post-infection when it was more than 
double in the Pc group (25U/ml) than the PcV group (12U/ml) and on day 10 in
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response to ConA, pE and nE, but with higher levels in the PcV than the Pc group 
(Figure 4.5). Some T N F a (6U/ml) was also detected in the PcV group on day 4 post- 
infection in response to nE. Peak parasitaemia occurred on days 8 and 9 in the PcV 
and Pc groups respectively. In this particular experiment, the PeV group developed a 
more severe disease than the Pc group in terms of percent parasitaem ia, percent 
weight loss and health status score (see Appendix 2).
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Figure 4.1 (experiment S.l); TNFa levels in the plasma o f 10-12 week old male 
BALB/c mice infected with P. c. AS. Pc and PcV are mice infected with 1x10  ^
parasitised red blood cells on day 0 and received lOOpl o f PBS or NISV respectively 
on days -28  and -14. Results represent pooled samples o f 5 animals per each time 
point.
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Figure 4.2 (experiment S.2): TNFa concentration in plasma samples o f 10-12 week 
old male BALB/c mice per group infected with P. chabaudi chabaudi AS. Pc and 
PcV groups were injected intravenously with 1x10^ pRBC on day 0 and had received 
lOOpl o f subcutaneous PBS and NISV respectively on days -28 and -14. Results 
represent pooled samples o f 5 animals per group at each time point.
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day post infection
Figure 4.3: TNFa levels in the plasma samples o f 10-12 weeks old male BALB/c 
mice infected with P. c AS. PBS and NISV groups contained 10 animals each and 
received subcutaneous lOOpl PBS and NISV respectively on days -14 and -28. Pc and 
PcV each contained 20 animals, received lOOpl subcutaneously o f PBS and NISV 
respectively on days -28 and -14 and were injected i.p. with 1x10  ^ pRBC on day 0. 
Results represent pooled samples o f 2 mice or 5 mice per group at each time point.
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Figure 4.4; TNFa concentration in whole blood o f 10-12 week old male BALB/c 
mice infected with P. c AS. Groups Pc and PcV were infected i.p. with 1x10  ^ pRBC 
on day 0 and had received lOOpl subcutaneously o f PBS or NISV respectively on 
days -28 and -14. PBS and NISV groups were similarly injected with lOOpl o f PBS or 
NISV respectively but without infection. Results represent pooled samples o f 2 
animals per group at each time point.
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Figure 4.5: TNFa concentration in 4 hr splenic supernatants o f 10-12 week old male 
BALB/c mice infected with P. c AS. Results represent pooled samples o f 2 animals 
per group at each time point. PBS and NISV groups received lOOpl s.c. o f PBS and 
NISV respectively on days -28 and -14. Pc and PcV received a similar treatment as 
PBS and NTVS groups respectively but also received 1x10  ^ pRBC i.p. on day 0. 
Splenic cells were exposed to the following antigens; CM; complete RPMI medium, 
ConA; concanavalin at lOpg/ml, P; parasitized red blood cells, N; red blood cells 
from non-infected donor.
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Discussion:
AS m entioned earlier, T N F a levels were m easured following the initial promising 
results obtained with pre-infection treatment of F. c. AS-infected mice with NISV. 
Plasm a T N F a  levels were measured in three experiments. It must be em phasized that 
the comparison of circulating T N F a  levels and indeed other cytokines (details in the 
subsequent chapters) between the NISV-treated and non-treated groups was done 
without taking standard errors into account. The reason for this is that the samples 
from each group were pooled to allow the m easurem ent of 4 cytokines (TN Fa, IFNy, 
IL-4 and IL-10) plus m easurem ent o f circulating NO. The total amount o f plasm a or 
serum needed for each sample, therefore, is 700 p.1 which was not possible to obtain 
from a single mouse. Ideally it would be better to study samples of individual animals 
of each group separately, obtain their mean and standard errors and then compare 
them with that of the other groups. As seen from experiment S .l ,  no T N F a  was 
detected early during infection (days 1-14: results not shown). To increase the 
sensitivity o f detecting low levels o f TN Fa, lower concentrations of T N F a  were used 
to obtain the standard curve. Dropping the highest T N F a concentration in the 
standards from 20ng/ml-2ng/ml was indeed effective in detecting some T N F a  in the 
subsequent two experiments (S.2, G.2). In both these experiments two peaks of T N F a 
were seen in the Pc group while only one was seen in the PcV group with lower 
T N F a  levels. W ith the three experiments taken together it can be seen that pre­
infection treatment of male BALB/c mice with NISV caused suppression of 
circulatory T N F a  levels. This finding is in agreement with the hypothesis o f the 
NISV suppliers (Brewer and Alexander, University of Strathclyde) who suggested 
that NISV suppressed T N F a  production from stimulated macrophages (personal 
communication). Early studies on T N F a  have shown a positive correlation between 
high T N F a  levels and cachexia (Beutler el aL, 1985) In the results presented here, 
however, it can be seen that although NISV suppressed plasma T N F a  levels, they did 
not necessarily suppress m alaria-associated weight loss in the treated mice (greater 
weight loss occurred in the Pc group in experiments S .l and S.2, while in experim ent 
G .l greater weight loss in the PcV group). W eight loss was also greater in the PcV 
group in experiment G.2 (no plasm a T N F a  levels are available for this experiment).
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The discrepancy in the clinical outcom e between the Pc and PcV groups was also seen 
in the percent parasitaemia and health status score (higher percent parasitaem ia and 
lower score were seen in the Pc group in experiments S .l and S .2, while in 
experim ents G .l and G.2, higher parasitaem ia and lower score were seen in the PcV 
group).
The explanation for these results could be several fold. First, it could be that NISV 
cause a non-dose-dependent T N F a  suppression leading therefore to a variable degree 
of T N F a  suppression and consequently a variable clinical outcome. As mentioned 
before, T N F a  has a dual protective/pathological effects in m alaria depending on its 
levels (Curfs et a l ,  1993). It therefore becomes possible to think that if NISV 
suppress T N F a  production by a certain amount, the miee would lose less weight 
(Beutler et a l ,  1985, Pekala et a l ,  1983, Torti et a l ,  1985) while if too much T N F a 
was suppressed then the mice would succumb to the disease. In experim ents S .l and
S.2, T N F a  was measured as ng/ml while in G .l, it was measured as U/ml. This makes 
it difficult to compare the levels of T N F a  in the two experiments and the amount of 
suppression induced by the NISV. One would, however, expect the mice with very 
little T N F a  to die without exhibiting much of the clinical features which are thought 
to be m ainly due to high levels of T N F a (Beutler et aL, 1995). As m entioned in the 
previous chapter, four animals were found dead following adm inistration of the 
second dose of the NISV without any clinical signs of injury and without any signs of 
illness. Their death could not be attributed to any cause. If NISV do cause an 
uncontrollable suppression of T N Fa, then their death could be attributed to the NISV 
causing suppression of T N F a to the extent that mice could not survive and also did 
not show any signs of illness.
Another explanation could be that although T N F a  was suppressed, TN Fp which 
shares many of T N F a properties and its receptors (Flohman et aL, 1990), could have 
been unaffected by the NISV treatment and so produced the pathological effects. 
Indeed lymphotoxin has been shown to be induced by disrupted P. falciparum-  
infected red cells by mononuclear cells in vitro (Ferrante et aL, 1990). Furthermore, 
T N F a  is known to exist in a membrane bound form (Decker et al., 1987, Kriegler el 
aL, 1988) and although the circulatory levels were suppressed, it could be that the
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membrane-bound form was not altered and so pathological effects o f T N F a  were 
produced by this mem brane-bound form.
A third explanation is that the difference seen between the two groups with regards to 
the clinical features was not genuine but merely reflected biological variation among 
the infected animals. Indeed when the experiments were taken together, no difference 
was seen in their weights, parasitaemia and mortality (Chapter 3). This would, 
therefore, mean that T N F a suppression did not produce a significant impact on the 
clinical outcome of the disease in these mice. It would, however, be interesting to test 
the NISV effects on conditions in which suppression of T N F a  by m eans of anti- 
T N F a  m onoclonal antibodies or soluble TNFR have resulted in improved clinical 
outcom e (Grau et aL, 1989, Garcia et aL, 1995).
T N F a  was also measured in whole blood samples. The results showed no significant 
difference between the two groups except on days 12 and 14 when T N F a  was 
detected in one group only. Since this experiment was conducted once only and since 
T N F a  measurements in whole blood have never been reported before, it becomes 
difficult to interpret these results and further work would be required. It has been 
reported, however, that damaged red cell caused the release of T N F a  from human 
peripheral blood mononuclear cells. The TN Fa-inducing activity of dam aged malaria- 
infected erythrocytes was found to be 200 times higher than naïve erythrocytes. 
(Bate et aL, 1994). The T N F a  detected in lysed whole blood here could, therefore, be 
explained by the findings of Bate and colleagues.
The ex-vivo splenic T N F a  also showed suppression in T N F a in the PcV group on 
day 1 post-infection. T N F a was, however, detected only in experim ent G .l while no 
T N F a  was detected in the splenocyte supernatants of experiment G.2 which makes it 
difficult to interpret the results of experiment G .l. The early production o f T N F a 
seen in both groups could be due to IFNy activation of macrophages since early IL-12 
has been reported to induce IFNy production from NK cells (Handa et al 1983, 
Trinchieri et aL, 1995).
In view of the above results and the results presented in the previous chapter, it can be 
concluded that pre-infection treatm ent of P. c. AS-infected male BALB/c mice with 
NISV causes apparent plasm a T N F a suppression but that this suppression does not 
correlate with clinical outcome of the animals. Further work followed to elucidate 
whether this apparent suppression was genuine or a mere reflection of chance (details 
are in the subsequent chapters). Also, had adequate amount o f samples been available 
to allow measurement of standard errors, the question of whether NISV suppressed 
T N F a levels would have been answered better.
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Chapter 5
Effects of pre-infection administration of NISY on the IFNy levels in 
male BALB/c mice infected with P. chabaudi chabaudi AS
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Introduction
In the previous chapter, it was seen that pretreatment of P. c. AS-infected male 
BALB/c mice was associated with a suppression of circulating plasm a T N Fa. IFNy is 
known to activate macrophages to produce T N F a  (Grau et a i ,  1989). In order to 
determine the mechanisms of NISV-induced suppression of T N Fa, circulating IFNy 
levels were also measured, results of which are presented here.
Interferon gamma (IFNy) :
IFNy, a 34kDa homodimer glycoprotein (Greenlund et al., 1992) was discovered by 
two independent groups and so initially was given two names reflecting its biological 
activities namely a) type H interferon and b) macrophage activating factor (MAP) 
(reviewed by Billiau 1996). IFNy was first identified as an antiviral agent in the 
supernatants o f leukocytes cultures stimulated by the mitogen phytohaem agglutinin 
(W heelock, 1965). Subsequently it was realized that antiviral activity was exhibited 
by what are now known as IFN a, fFN(3 and IFNco while IFNy had other distinct 
properties. IFNy was found to have a 10-100 fold lower specific antiviral activity 
com pared with IF N a or IFNp but a 100-10,000 fold higher im m unom odulating 
activity (PacQ et al., 1985).
Both humans and mice contain only a single IFNy gene that is located on 
chrom osom es 12 and 10 respectively (Naylor et a i ,  1983, Naylor et al., 1984). The 
size, amino acid sequence and glycosylation of IFNy, are well conserved among 
various animal species (reviewed by Billiau 1996). IFNy is made up o f two elongated 
17 kD a subunits that are held together in an anti parallel configuration with the amino 
terminus of each chain being juxtaposed to the carboxy term inus of the opposing 
chain. This structure allows IFNy to bind a pair of identical receptor peptides (W alter 
et aL, 1995).
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The main source of IFNy is activated T hl CD4^ T cells (M osmann and Coffman, 
1989), w ith those cells expressing CD30 m em brane antigen as the principal subset 
producing IFNy (Alzona et aL, 1994). This, therefore, means that any factor that 
regulates the polarization of CD4^ cells into T h l and Th2 cells affects the production 
of IFNy. DL-12, for instance favours the developm ent o f naive CD4^ T cells into T hl 
subset while IL-4 inhibits this process (Seder et aL, 1993). IFNy production from 
CD4^ T cells is induced by stimuli such as specific antigen in the context of MHC 
molecules, by direct stimulation of the TCR with anti-CD3 antibodies or with 
mitogens such as phytohaemagglutinin or concanavalin A (Gajewski et al., 1989). 
IFNy production by T h l cells requires the cooperation of accessory cells, which are 
mostly m ononuclear phagocytes. These cells are needed both to secrete regulatory 
cytokines like T N F a and IL-12 (Rothe et aL, 1993, Chan et aL, 1992) and also to 
make contact with lymphocytes through intercellular adhesion m olecules (W ingren et 
aL, 1993). IL-10 inhibits IFNy production by T h l cells (Fiorentino et aL, 1989, Moore 
et aL, 1993) not through direct action on the T h l cells (Fiorentino et aL, 1991) but by 
inhibiting the expression of these accessory molecules (reviewed by Farrar and 
Schreiber 1993).
Follow ing stimulation of T h l cells, IFNy mRNA is first detectable at 6-8 hr, peaks by 
12-24 hr and declines slowly thereafter. IFNy itself is first detected in the extracellular 
environm ent 8-12 hr post-stimulation and peaks at 18-24hr (reviewed by Farrar and 
Schreiber, 1993). In in vitro systems, it is possible to measure the released amount of 
IFNy long (up to 5 days in my experience) after activation of T cells (Langer and 
Pestka, 1988) but in in vivo systems, IFNy can be detected in the hum an or murine 
circulation transiently due to its rapid removal from the plasm a because of the 
abundance o f IFNy receptors (reviewed by Farrar and Schreiber, 1993).
Other sources of IFNy include activated NK cells (Handa et aL, 1983, Perussia, 1991). 
M itogens and microbial products have been shown to induce IFNy production from 
naïve NK cells in vitro and in vivo (Bancroft ef aL, 1987, Bancroft et aL, 1989) with 
the help of TN Fa, IL -12  and macrophages (Bancroft et aL, 1989, Bancroft et aL, 
1992, Trinchieri, 1995). IL-lj3 was shown to be needed for IL-12 to stimulate IFNy
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production by NK cells (Hunter et al., 1995). Also, Gram -positive bacterial 
preparations such as Staphylococcus aureus components have been shown to 
stim ulate IFNy production from NK cells in vitro (Yoshihara et a i ,  1993). CDS'*' 
cytotoxic T cells of the type 1 cytokine phenotype are another source o f IFNy. M ouse 
splenic CDS"*" T cells in the presence of IFNy or IL-12 plus anti-IL-4 antibodies, 
differentiate into CD8^ T cells producing T h l cytokines (IL-2 and IFNy) (Sad, 
M acrotte and M osmann, 1995). IFNy was also shown to be constitutively expressed 
by resting mouse peritoneal macrophages and to up regulate its gene expression in 
them (Di M arzio et aL, 1994).
IFNy interacts with a specific cell surface receptor of high affinity (Finbloom et aL, 
1985), which is ubiquitously expressed on all nucleated cells (Langer and Pestka., 
1988, Valente et aL, 1992). The receptor consists of a 90kD a  chain which is the 
ligand-binding unit (Finbloom et aL, 1985, Aguet et aL, 1988) and a 314 amino acid |3 
chain which acts as an accessory chain required for signal transduction (Hemmi et 
aL, 1994, Masters et aL, 1995). The a  chain is encoded by chrom osom es 6 and 10 in 
humans and mouse respectively (Pfizenmatier et aL, 1988, M ariano et aL, 1987) and 
the P subunit is encoded by chromosomes 21 and 16 in human and m ouse respectively 
(Soh et aL, 1994, Hemmi et aL, 1994).
The signal transduction pathway starts with IFNy interaction with two a  chains 
inducing a  chain dimerization. The two p chains then associate with the IF N y -a  
chain complex leading to phosphorylation and activation o f JAKs. Further steps of 
phosphorylation and activation occur leading finally to the activation o f S T A T la  that 
translocates into the nucleus and binds to IFNy activation region on the DNA and 
initiates transcription. Once signalling has occurred, the IF N y -a  chain complex is 
internalized and dissociates with the free IFNy eventually being degraded in the 
lysosome and the receptor recycling back to the surface of the cells (Anderson et aL, 
1983).
IFNy is a pleotropic cytokine with many functions. Its main cellular target is the 
m onocyte/macrophage cell. IFNy affects the differentiation of imm ature myeloid cells
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into mature monocytes and activates m acrophages by both upregulating the 
expression of MHC H molecules (Basham and M erigan, 1983, Cao et aL, 1989) and 
increasing the levels of several enzymes needed for antigen processing (Allen and 
Seed, 1989). IFNy induces protein 10, which is a chemo-attractant for human 
monocytes and T cells and promotes T cell adhesion to endothelial cells (Taub et al.,
1993)
IFNy increases intracellular killing of parasites (Nathan et al., 1983), enhances 
phagocytosis (Ockenhouse et al., 1984, Shear et al., 1989), enhances tumor killing 
(W einberg and Larrick, 1987) and induces production of T N F a  (Grau et al., 1989, 
M urray et al., 1985) and that o f reactive oxygen intermediates (Nathan et al., 1983, 
Kamijo et al., 1993a). M oreover, it enhances the cytolytic activity of NK cells 
(Gidlund et al., 1978). IFNy was also reported to regulate the differentiation of mouse 
splenic CD8*  ^T cells (Sad, M arcotte and M osmann, 1995).
Several studies have reported a role for IFNy in protection against malaria. IFNy- 
treated monocytes and m onocyte-derived m acrophages killed P.falciparum in vitro 
and resulted in the appearance o f crisis forms (Ockenhouse et al., 1984, Gyan et al.,
1994). This lethal action was inhibited by addition of anti-IFNy antibodies to the 
culture (Ockenhouse et al., 1984). It was also shown that the parasite growth 
inhibition was due to production of NO since addition of the NO synthase inhibitor, 
LNM M A to the macrophages in culture reduced parasite growth inhibition (Gyan et 
al., 1994). Daily treatment of F  chabaudi a<7z(w/-infected CBA/CaH m ice with murine 
recom binant IFNy (rIFNy) starting from day -1 produced a dose-dependent delay in 
the onset of a patent parasitaemia, and an earlier appearance of crisis forms (Clark et 
al., 1987). In mice infected with the lethal strain of F. yoelii (17X), treatm ent with 
rIFNy resulted in a significantly lower peak parasitaemia and increased survival 
(Shear et al., 1989). IFNy was seen to increase transiently in the serum of mice 
infected with F. c. AS about 3-4 days prior to primary peak parasitaem ia (Slade and 
Langhorne, 1989). M oreover, IFNy production in vitro from splenocytes of the 
resistant C57B1/6 mice infected with F. c. AS was seen to peak 2-3 days prior to 
primary peak parasitaemia (Langhorne et al., 1989, Stevenson et al., 1990). Treatm ent 
of F. c. AS-infected resistant C57Bl/10ScN mice with anti-IFNy antibodies resulted in
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a greater parasitaemia 2 days before and at peak parasitaemia (Stevenson et al., 1990). 
Furthermore, treatment of P. berghei-ïnf&clQÔ C57B1/6 mice with rlFNy prevented the 
development of experimental cerebral malaria (Curfs et a i ,  1993). Treatment of 
CBA/JNCrj mice infected with the attenuated P. berghei (PbXAT) strain with anti- 
IFNy antibodies led to failure of resolution of the infection associated with 
suppression in m alaria specific IgG2a levels (W aki et ah, 1995). The above studies, 
therefore, indicate a protective role for IFNy in several host-parasite combinations. 
Subsequent studies have also confirmed this protective role but in addition showed 
that despite its protective role, IFNy was not essential for clearance o f the infection. P. 
c. AS-infected IFNyR-KO mice have a similar level of primary parasitaem ia but fail 
to reduce it to subpatent levels (Baimer et a i ,  2000), have a greater m ortality and a 
higher second peak o f parasitaem ia that their wild type counterparts (Baimer et al., 
2000, Favre et a l ,  1997). Both wild type and IFNyR deficient mice, however, were 
equally protected upon re-infection (Favre et al., 1997). The above studies clearly 
indicate that IFNy deficiency impairs immunity against primary parasitaem ia but does 
not abrogate it. In addition, transient increase in serum IFNy levels were detected in 
both P. c. AS-infected resistant BALB/c (H-2d) and susceptible DBA/2 (H~2d) mice 
(Slade and Langhorne, 1989) indicating that IFNy is not the determ ining factor for 
host susceptibility or resistance to malaria infection. Other studies, however, have 
shown that early splenic IFNy production (24hr post-infection) was the difference 
between two lethal and two non-lethal malaria infections (de Souza et a l ,  1997).
It must be emphasized, however, that IFNy was also shown to m ediate harmful 
effects. Treatment of P. berghePmftciod  CBA/Ca mice with anti-IFNy monoclonal 
antibodies no later than day 4 post-infection markedly reduced the incidence of 
cerebral m alaria and the associated cerebral lesions o f capillary plugging by 
monocytes, lymphocytes and parasitized red blood cells (Grau et at., 1989).
Apart from its role in blood stage infection, IFNy was also shown to play a role in 
immunity against exoerythrocytic stages. IFNy has been shown to inhibit P. 
falciparum  sporozoite development in hepatocytes (Mellouk et ah, 1987) and the 
exoerythrocytic forms of P. berghei in vitro (Ferreira et al., 1986). Systemic 
administration of IFNy protects rhesus monkeys against a P. cynomolgi B sporozoite
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challenge (Maheshwari et a l ,  1986). Furthermore, the immunity observed in mice 
immunized with irradiated sporozoites was abrogated upon treatm ent o f the mice with 
neutralizing anti-IFNy antibodies (Schofield et a l ,  1987c)
In the studies presented in this thesis, male BALB/c were infected with P. c. A S  and a 
group was pretreated with NISV. The animals were followed up clinically (see 
C hapters), and in terms of their cytokine production, T N F a  (Chapter 4), IL-4 
(Chapter 6) and IFNy, that is presented here. The aim was to investigate whether 
NISV-induced suppression o f T N F a (details in Chapter 3) occurred through 
mechanisms involving IFNy.
Results
The work described here represents the results of 4 experiments in which male 
BALB/c m ice were infected with P. c. AS  and treated with NISV pre-infection (days - 
28 and -14). IFNy levels were measured in splenic supernatants and plasm a samples. 
Also a new method of m easuring IFNy in lysed whole blood was tried and is 
described below.
5.1. Effects of NISV on the plasma levels of IFNy
Inbred male BALB/c mice (10, 20 and 20 per group in experiments S .l ,  S.2, and G .l 
respectively) were infected i.v. with 1x10^ pRBCs of P. chabaudi AS on day 0. Two 
groups had received lOOjil of PBS or NISV on days -28 and -14 subcutaneously and 
were referred to as Pc and PcV respectively. Two control groups were injected with 
lOOp.1 of PBS or NISV and referred to as PBS and NISV respectively. Equal volumes 
o f blood were collected from the tail veins of 5 animals (experim ents S .l , S.2) or 
through cardiac puncture of 2 animals (experiment G .l) per group at each time point 
indicated into heparinized capillary tubes. Blood samples were centrifuged at 13000 
rpm (4000g) for 5 minutes and plasma samples of each group were pooled and stored 
at -20"C  until further use.
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In experim ent S .l significantly higher amounts of IFNy was found in the plasm a of 
the NISV-treated group (PcV) on days 13, 15, 17, 25, and 40 post-infection, while 
higher levels were found in the untreated group (Pc) on days 19, 21, 23, 29, 34 and 42 
(Figure 5.1). Peak parasitaem ia in this experiment was on day 9 and the trough of 
weight loss on days 11 and 10 in the Pc and PcV groups respectively (see Appendix 
2). In experiment S.2, significantly higher IFNy levels were found in the plasm a of the 
PcV group on days 15, 16, 19 and 21 post-infection, while higher levels were seen in 
the Pc group on days 9 and 14 post-infection (Figure 5.2). Peak parasitaem ia was on 
day 8 and trough of weight loss was on day post-infection (see A ppendix 2). As 
m entioned previously, the PcV group had a less severe disease than the Pc group in 
these two particular experiments with regards to level of parasitaemia, degree of 
weight loss and health status score (see Appendix 2 for results o f individual 
experiments). In experiment G .l, the animals were followed up for 16 days only when 
they had recovered clinically from the primary parasitaemia. No IFNy was detected 
from day 1-7 except in the PBS group on day 1. IFNy peaked on day 9 post infection 
in both Pc and PcV groups (Figure 5.3), which coincided with day o f prim ary peak 
parasitaemia. No significant difference was seen between groups Pc and PcV at any 
time points. In this particular experiment, the Pc group exhibited a less severe disease 
than the PcV in terms of parasitaem ia levels, and degree of weight loss (see Appendix 
2).
W ith the three experiments taken together, it can be seen that IFNy was never found in 
the plasm a of the infected animals early in the infection and prior to the prim ary peak 
of parasitaemia. It can also be seen that there was no consistent difference in the 
plasma IFNy levels between the NISV-treated and untreated groups. Plasm a IFNy 
levels in the PBS and NISV groups were measured in one experim ent only (G .l)  and 
there were found to be very low (100 U/ml) and there was no difference between the 
two groups.
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5.2. Effects of NISV on the IFNy levels measured in lysed whole blood
Twenty five inbred male BALB/c mice per group were infected as described above. 
Blood samples were collected from either five animals from tail vein (days 3, 4, 5, 7, 
12, 15) or two animals by cardiac puncture per group (days 6, 8, 10, 11, 14, 17, 21) at 
each time point. Samples from each group were pooled together and stored at -20°C 
until further use. ELIS As were done according to the standard m ethod described in 
material and methods. It was noted, however, that by leaving the plate with blood 
samples at 4**C over night and completing the rest of the steps o f ELISA on the 
following day, IFNy (and other cytokines) were detected. W ithout this m odification 
in the ELISA steps, no cytokines were detected in the whole blood samples.
Two im portant observations were made in IFNy levels in whole blood. First, it was 
noted that IFNy was seen early during infection (from day 3-day 8) while during peak 
parasitaem ia it was undetectable but it reappeared afterwards, albeit at much lower 
levels. The second point is that IFNy was slightly higher in the PcV group on days 5 
and 7 post-infection (Figure 5.4). The NISV-treated group exhibited a m ore severe 
disease in this experiment, with regards to level of parasitaemia, degree o f weight loss 
and health status score (see Appendix 2). IFNy measurements in the lysed whole 
blood o f the PBS and NISV groups were done at one time point only (day 21 post­
infection). Low levels of IFNy (approximately 48 U/ml) were detected in both groups. 
W hole blood samples were used in one experiment only (G.2) and so no com parison 
can be made with other results.
5.3. Effects of NISV on IFNy levels in splenocyte supernatants
IFNy in splenocyte supernatants of P. c AS-infected mice was m easured in two 
experiments, both of which were conducted at Glasgow University. Spleens of 2-3 
animals per group were removed aseptically at each time point (days 1 , 4 , 7  and 10 
and days 6, 8, 10, 11, 14, 17 and 21 post-infection in experiments G .l and G.2 
respectively). Splenocytes of each group were pooled together, exposed to various 
stim ulating or control agents including normal medium, ConA, non-infected mouse
131
red blood cells (nE) and parasitized mouse red blood cells (pE), and incubated for 72 
hr at 37°C in 5% CO 2  in air. Supernatants were collected and stored al -20"C until 
further analysis.
IFNy peaked on day 4 post-infection in experiment G .l to all stim ulants used. Low 
IFNy levels were also detected in response to ConA on day 6. IFNy levels were 
slightly higher in the NISV-treated group on day 4 while on day 6 the PcV group had 
a slightly lower levels than the Pc group. Low levels of IFNy were detected in the 
splenocyte supernatants of PBS and NISV at all time points. In the second experiment 
(G.2), high IFNy levels were seen on days 6, 17 and 21 post-infection (Figure 5.6.). In 
experim ent G.2, IFNy measurements in the splenocyte supernatants o f the PBS and 
NISV groups were done at one time point only (day 21 post-infection). IFNy in the 
NISV group was approximately half of the levels in the PBS splenocyte supernatants.
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Figure 5.1. (experiment S.l): Plasma IFNy levels o f 10-12 week old male BALB/c 
mice infected with P  chabaudi AS. Both groups (Pc and PcV) were injected i.v. with 
1x1 o’ pRBC on day 0 and received lOOpl s.c. o f PBS and NISV respectively on days 
-28 and -14. Results represent pooled samples o f 5 animals per group at each time 
point.
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Figure 5.2. (experiment S.2): Plasma IFNy level 10-12 week old male BALB/c mice 
infected with P  chabaudi AS. Both groups (Pc and PcV) were infected i.p. with 1x10’ 
pRBC on day 0 and received a s.c. inoculation o f lOOpl o f BPS or NISV respectively 
on days -28 and -14. Results represent pooled samples o f 5 animals per group at each 
time point.
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Figure 5.3. (experiment G.l): Plasma IFNy levels o f 10-12 week old male BALB/c 
mice infected with P. chabaudi AS. Groups Pc and PcV were injected i.v. with 1x10  ^
pRBC on day 0 and received s.c. inoculation o f lOOpl o f PBS or NISV respectively 
on days -28 and -14. Groups PBS and NISV were only injected s.c. with lOOpl o f  
PBS or NISV respectively on days -28 and -14.
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Figure 5.4. (experiment G.2): IFNy levels in whole blood o f 10-12 week old male 
BALB/c mice infected i.p. with P  chabaudi AS. Groups Pc and PcV were infected 
with 1x10^ pRBC on day 0 and received lOOpl s.c. o f  PBS and NISV respectively on 
days -28 and -14. PBS and VISV groups wre injected with lOOpl o f PBS or NISV 
respectively on days -28  and -14.
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Figure 5.5. (experiment G.l); 72hr IFNy levels in splenocyte supernatants o f male 
BALB/c mice infected with 1x10  ^ pRBC. Pc, PcV groups were infected with P. 
chabaudi AS i.p. on day 0 and had received lOOpl o f PBS and NISV respectively s.c. 
on days -28 and -14. PBS and NISV are 2 control groups, received lOOp.1 PBS or 
NISV respectively on days -28 and -14. CM (complete RPMI medium), ConA 
(concanavalin at lOpg/ml), nE (non-infected mouse red blood cells), pE (parasitized 
mouse red blood cells). Results represent spleens o f 2 animals per group at each time 
point.
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Figure 5.6. (experiment G.2): IFNy levels in 72hr splenic supernatants o f P. chabctudi 
AS-infected male BALB/c mice. Pc and PcV groups were infected i.p. with 1x10  ^
pRBC on day 0. Pc and PBS received 100|il o f  PBS on days -28  and -14. Groups 
PcV and NISV received 100pi o f NISV on days -28  and -14. CM; complete RPMI 
medium, ConA; lOpg/ml concanavalin, pE; parasitised red blood cells and nE; non­
infected red blood cells.
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Discussion:
The work done in the previous chapter showed that pretreatment of P. c  AS-infected 
BALB/c mice with NISV led to suppression o f the circulating T N F a  levels. Since 
IFNy has been reported to stim ulate T N F a production by macrophages (Murray et al., 
1985, Grau et a i,  1989), fFNy was also m easured in these mice to see if NISV- 
induced suppression of T N F a  occurred through mechanisms involving IFNy. The 
results presented here are discussed in the context o f the effects o f NISV on fPNy 
levels and the relation between IFNy levels and disease severity.
Plasm a IFNy levels in the three experiments (S. 1, S .2 and G. 1) were not elevated early 
during infection. This is in contrast to results reported by other groups which showed 
a transient increase in IFNy 2-3 days prior to primary peak parasitaem ia which 
correlated with protection in P. c. AS infections in female C57B1/6, BALB/c (H-2d) 
and DBA (H-2d) mice (Slade and Langhorne, 1989, Langhorne et a l ,  1989). It is 
possible, however, that IFNy was not detected because blood was collected from the 
animals after IFNy had disappeared from the circulation by binding to its widely 
distributed receptors (reviewed by Farrar and Schreiber, 1993). Also in experiments
S .l , S.2 and G .l plasma IFNy levels were found to increase in both Pc and PcV 
groups later during infection following the primary peak parasitaemia. In all these 
experiments no consistent difference was seen between the two groups in their IFNy 
levels in relation to the use of NISV or in relation to disease severity (in all 
experiments, the PcV group exhibited a less severe disease in terms o f parasitaem ia 
levels, degree of weight loss and health status score). In experiment G .l, however, 
IFNy was found to peak on day of peak parasitaem ia in both groups without any 
significant difference in the two groups. As m entioned earlier, in this particular 
experiment, the Pc group exhibited a less severe disease in terms o f weight loss, 
percent parasitaemia and health status score. W ith the three experim ents taken 
together, it can be said that the plasm a IFNy levels did not reflect disease severity nor 
were they altered by the use of NISV.
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High levels of splenic CFNywere seen on days 4 and 7 in experim ent G .l (peak 
parasitaem ia occurred on days 8  and 9 in the PcV and Pc groups respectively) and 
days 6  and 8  in experiment G .2 (peak parasitaemia was on day 9 and 10 in the Pc and 
PcV groups respectively). It m ust be noted, however, that the amount detected on day 
4 in experiment G .l (Figure 5.5) is much higher than that detected on day 7 of 
experiment G.2 (Figure 5.6). Since a lower level was also detected on day 6  in 
experiment G .l, this could well mean that a much higher level could have been 
m issed on day 4 in experiment G.2. The high levels of IFNy seen prior to peak 
parasitaem ia agree with the previous findings of splenocytes producing IFNy 2-3 days 
prior to peak parasitaemia (Langhorne et a l ,  1989, Stevenson et a i ,  1990). No 
correlation, however, was seen between the use of NISV and the ex~vivo splenic levels 
of IFNy.
An im portant observation made during this work on measurement of cytokines by 
ELIS As is that IFNy could also be m easured in lysed whole blood samples. This, to 
date, has not been reported and was thought of in an attempt to save time. Again no 
significant difference was seen between the NISV-treated and untreated groups. 
M oreover, no significant difference was seen between the two control groups PBS and 
NISV. Any differences seen in the IFNy levels between the two groups (Pc and PcV) 
in plasma, blood or splenocyte supernatants could simply reflect normal variable 
activity between different cells at any single time point.
In view of the above results, it is clear that pre-infection treatm ent with NISV does 
not affect IFNy levels in the treated mice. This, therefore means that the NISV- 
induced suppression of T N F a  (reported in the previous chapter) does not occur 
through IFNy. This is in agreement with the hypothesis suggested by the investigators 
of the NISV (Dr. Brewer, Division of Immunology, Infection and Inflamm ation, 
W estern Infirmary, Glasgow and Alexander, Strathclyde University) who suggested 
that NISV acted on the macrophages directly to suppress T N F a production (personal 
communication).
An interesting observation made in the IFNy levels in whole blood samples was the 
fact that high levels were seen early in the infection and prior to peak parasitaemia.
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This is in contrast to the plasm a levels, which did not increase until after peak 
parasitaemia. It is difficult to comm ent on these results since no previous studies 
reported using whole lysed blood for measurements of cytokines and since this work 
was done only once. It would useful to repeat it again before drawing any 
conclusions.
The conclusion arrived at from work done in this chapter is that since it was seen from 
the last chapter that pre-infection treatment of animals with NISV led to suppression 
o f the circulating T N F a  levels regardless of the clinical outcom e and since it is 
reported that IFNy stimulates the production of T N F a  from m acrophages, it seems 
that the NISV do not suppress T N F a  levels by mechanisms related to the IFNy levels. 
It seems that the NISV act on the macrophages and are probably engulfed by them 
and suppress their ability to secrete T N F a in response to stimuli such as m alaria 
antigens or IFNy.
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Chapter six
Effects of pre-infection treatment with NISV on the levels of IL-4 in 
male BALB/c mice infected with Plasmodium chabaudi chabaudi AS.
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Introduction:
Follow ing my work on the effects of the administration of NISV pre-infection on the 
subsequent course of Plasmodium chabaudi AS infection in male BALB/c mice, it 
was considered important to measure not only the T hl response but also the Th2 
response o f the CD4^ T cells in these mice. The importance of this was two fold, first 
to see if NISV did have any immunoregulatory effects on the T h l/T h 2  polarization 
and secondly to find the m echanism  of T N F a suppression. The Th2 cytokines chosen 
for m easurem ent were IL-4 and BL-10. In the event the standards in the IL-10 ELISA 
kit were found to be unreliable by others and m yself in the department and therefore 
only IL-4 results are included in this chapter.
IL-4:
IL-4 is a 20kDa glycoprotein, initially identified as a B cell growth factor found in the 
supernatants of mouse thymom a EL4 cells (Howard et al., 1982) and so was named B 
cell stim ulatory fac to r-l(B S F-l). Human and m ouse IL-4 are 153 and 140 amino acid 
polypeptides respectively and are encoded by a gene on chrom osome 5 in humans and 
11 in mouse. The gene is part of a cytokine complex including genes for DL-3, EL-5 
and GM -CSF (Paul, 1991).
IL-4 is produced mainly by CD4^ Th2 cells. M ouse Th2 cells are a subset of T helper 
cells characterized upon activation by production of EL-4, EL-3 and m ast cell growth 
factor (M osmann et a l ,  1986). Other cellular sources of EL-4 include mast cells 
(Brown et al., 1987), yô T cells (Ferrick et al., 1995), CTL cells (Seder et al., 1992), a 
population of CD4'*' NKl.l"^ NKT cells (Yoshimoto et a l ,  1994) and non-B non-T 
cells (NBNT) (Helmby et al., 1998).
EL-4 exerts its effects by binding to complementary receptors on cell surfaces. EL-4 
has two different types of receptors, classical and alternative. The classical one is 
expressed predom inantly on haematopoetic cells and consists of a 140 kDa a  chain 
and a 64 kDa y chain, which is shared by the EL-2 receptor (Russell et al., 1993, 
Kondo et a l ,  1993). Stimulation of this receptor leads to the phosphorylation of JAK3
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which in turn stimulates the transcription factor STA T 6  (M urata et al., 1998, M urata 
et al., 1999). The alternative receptor, on the other hand, is predom inantly expressed 
on non-haem atopoetic cells and consists of the IL -4R a chain and IL-13R a  chain 
(M atthews et al., 1995, Obiri et a i ,  1995). Stim ulation of this receptor leads to the 
activation of JAK2 which also leads to the activation of STAT 6 . EL-4 receptors are 
widely spread, being expressed on B and T cells, mast cells, macrophages, cells of 
myeloid and erythroid lineage and a variety of non-haem atopoetic cells such as 
stromal cell lines from bone marrow, spleen thymus and brain (Ohara et al., 1987, 
'Parketal., 1987).
IL-4 has m ultiple functions in different arms o f the immune system. As mentioned 
previously it is involved in the growth and differentiation of B cells. IL-4 stimulation 
of B cells leads to upregulation of M HC class II molecules (Noelle et al., 1984, 
Roehm  et al., 1984), IL-4 receptor and CD23 (FceRIIb) expression ((Defrance et a l ,  
1987, Hudak et al., 1987). It also leads to class switch in imm unoglobulin production 
from IgM into the production of IgG l (Vitetta et a l ,  1985, Sideras et a i ,  1985) and 
IgE (Coffman et al., 1986).
IL-4 has also been shown to play a role in the growth of T cells and m ast cells (Lee et 
al., 1986, M osmann et al., 1986), granulocytes (Rennick et al., 1986), 
megakaryocytes and erythrocytes (Peschell et al., 1987). IL-4 has an important role in 
the polarization of CD4^ T helper subsets. The environm ent of the CD4^ T cells can 
influence their direction of development. Presence of IL-4 encourages the polarization 
towards Th2 cells (Essner et al., 1989). IL-4 was also shown to enhance the 
proliferation of precursors of cytotoxic T cells and their differentiation into CTL 
(W idm er and Grabstein, 1987, Trenn et al., 1988).
IL-4 was also reported to enhance antigen presentation by murine bone marrow- 
derived macrophages (Zlotnick et al., 1987) by upregulating M HC class I and II 
molecules on them.
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IL-4 has been described as anli-inflam malory because o f its ability to suppress 
proinflam matory cytokines such as IL-1 and TN Fa. Thus it was shown to suppress 
significantly T N F a release from peripheral blood m ononuclear cells o f patients with 
rheum atoid arthritis in response to LPS. Moreover, IL-4 suppressed the enhancing 
effect of IFNy on IL-1 production from human peripheral blood m ononuclear cells. 
The anti-inflammatory effect of IL-4, however, was not evident on all types of 
macrophages since those macrophages that were derived from the synovial fluids of 
same patients with rheumatoid arthritis, did not suppress their release of T N F a  (Hart 
et a i ,  1993). IL-4 was also reported to downregulate monocyte production of IL-1 
and PGE2 (Hart et a i ,  1989), EL- 6  (Cheung et al., 1990) and EL- 8  (Standiford et al., 
1990). IL-4 also suppresses m onocyte production of superoxide anions (Abramson 
and Gallin, 1990) and H 2 O 2  (Lehn et al., 1989). On the other hand, IL-4 increases the 
production of IL-IR  antagonist (Vannier et al., 1992), further suppressing pro- 
inflammatory activity. Recently IL-4 was also identified as a factor determ ining the 
type of eicosanoids produced by dendritic cells in response to growth factors such as 
stem cell factoi' and GM -CSF (Spanbroek et al., 2001). Here IL-4 was reported to 
suppress the 5-lipooxygenase pathway, which leads to the production of potent 
m ediators of inflammatory and allergic tissue reactions (Samuelsson et a l ,  1987).
IL-4 has been found to play a role in several infectious diseases. In L. m q/or-infected 
BALB/c mice, early production of IL-4 is associated with susceptibility to the 
infection, while resistance was noted in the IL-4 gene disrupted mice which produced 
a reduced Th2 response (K opf et a l ,  1996). EL-4 deficient mice, on the other hand, 
were found to be more susceptible during the initial phase of rapid proliferation of 
tachyzoites o f Toxoplasma gondii than their wild-type counterparts (Roberts et a l ,  
1996). During the chronic phase o f the infection, however, the IL-4 deficient mice 
exhibited less pathology.
In the case of the role of IL-4 in malaria, sequential appearance of T h l and Th2 cells 
has been reported to play an important role in protection against P. c. AS-infected 
mice (Langhorne et a l ,  1989) indicating a role for IL-4 late in the infection. 
M oreover, early production of IL-4 was found to correlate with susceptibility to P. 
chabaudi infection (Jacobs, Radzioch and Stevenson 1996). The mechanisms
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responsible for the switch from T h l to Th2, however, are not clear. Among 
mechanisms suggested for this switch, is the expansion of non-B non-T cells (NBNT) 
in the spleens and peripheral blood around the time of peak parasitaem ia and the 
secretion o f IL-4 by these cells (Helmby et a l ,  1998). This IL-4 in turn shifts the ThO 
differentiation into the Th2 direction, leading to further release o f IL-4 (Essner et a l ,  
1989).
The role of IL-4 in P. c AS-infected mice was specifically investigated by generating 
IL-4 gene knockout mice. CD4^ T cells obtained from these animals were found to be 
defective in generating Th2 cytokines in vitro (Kopf et a l ,  1993). Using the above 
mice and comparing them to wild type mice infected with P.c. c. A S  showed that the 
initial T h l response was intact in the IL-4'^' mice and that Th2 activity such as 
generation of IgE was not impaired but rather delayed during infection (Kopf et a l ,  
1993). IL-4-/- mice were able to control and clear the primary parasitaem ia but they 
had a higher recrudescence than their wild type counterparts. They were also found to 
have reduced mRNA levels for IL-5 and IL - 6  but not IL-10 early during infection but 
later all these cytokines were expressed equally (von der W eid et a l ,  1994). Other 
studies, however, have shown an effect on the primary parasitaemia in IL-4 deficient 
mice. P. c. AS-infected, IL-4 deficient BALB/c, B 6x l29  and 129SV mice all had a 
significantly higher primary peak parasitaem ia than their wild type counterparts, but a 
sim ilar rate of clearance o f the primary patent parasitaemia (Baimer, 1997). In P. 
chabaud adami and P, yoe/h'-infected IL-4-deficient mice, on the other hand, the 
course of infection was not significantly different from the wild type counterparts 
(von der W eid et a l ,  1994).
IL-4 on the other hand has been suggested to play an important role in the parasite 
evasion of the immune system. Pretreatm ent of human m onocytes/m acrophages with 
rIL-4 significantly suppressed their ability to phagocytose P. fa lc ipanun  parasitized 
red blood cells in vitro (Kumaratilake and Ferrante, 1992). The authors suggested that 
in vivo the parasites could be inducing the production of IL-4 which would, therefore, 
reduce their killing by the monocytes.
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The results presented in this chapter are lL-4 levels in plasma, lysed whole blood and 
splenocytes supernatant samples obtained from multiple experiments on P. c. AS- 
infected male BALB/c mice, a group of which was pretreated with NISV and the 
cytokine levels in both groups were compared. The same mice were followed up 
clinically with regards to weight loss, percent parasitaemia and health status score 
(see Chapter 3). T N F a  and IFNy were also measured (see Chapter 4 and 5 
respectively).
Results:
6.1. IL-4 Levels in plasma samples:
Twenty inbred male 10-12 week old BALB/c mice were infected i.v. with 10  ^ pRBC 
at Strathclyde University. Blood samples were collected by bleeding 5 mice at each 
time point (days 1-16 and days 19, 21, and 23 post-infection) from the tail vein into 
heparinised capillaries. Samples from each group were pooled together and stored at -  
20°C until further use. Samples were frozen and thawed about four times before IL-4 
levels were measured with ELISA. This is because ELISA of other cytokines was 
done first (details of ELISA in M aterials and Methods).
No IL-4 was detected in the plasm a of either group until late in the disease (day 12), 
during the recvovery phase o f the primary infection as was evident from the health 
status score, percent parasitaem ia and weight measurements. High levels of IL-4 were 
detected in the NISV-treated group (PcV) on days 12 (0.6jxg/ml), 14 (0.9pg/m l) and 
15 (1.5|ig/m l). In the untreated group (Pc), IL-4 was detected at a single time point 
only (day 12) when the levels were approximately half (0.3|lg/m l) of those in the 
NISV-treated group (Figure 6.1). In this particular experiment, the treated group 
(PcV) was the better one clinically in that the mice exhibited a lower parasitaemia and 
less weight loss than the untreated group (Pc) (see Appendix 2 for graphs of 
individual experiments).
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Figure 6.1. Plasma EL-4 concentration in 10-12 week old male BALB/c mice infected 
with P  chabaudi AS. Pc and PcV : animals infected i.v. with Ix 10^  pRBC on day 0 
and received lOOjil PBS and NISV respectively s.c. on days -28 and -14. Results 
represent means o f pooled plasma samples o f five animals run in triplicates.
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6. 2. Effect of NISV on lysed whole blood levels of IL-4:
W hole blood samples were collected from 25 inbred male 10-12 week old BALB/c 
mice. These mice were infected with P. c. AS and pretreated with either NISV or PBS 
as before. Blood samples were obtained through two ways, either 5 mice were bled 
from the tail vein on days 3, 4, 5, 7 ,9 ,  13, 15 and 19, or via cardiac puncture of 2 
mice sacrificed for their spleens on days 6 , 8 , 10, 11, 14, 17 and 21 post-infection. 
The samples of each group were pooled together and stored at -20®C until further use.
IL-4 was detected at three tim e points in the untreated group (Pc), on days 3, 7 and 14 
post-infection, with the levels being highest on day 14 (75U/ml). In the NISV-treated 
group (PcV), however, EL-4 was detected only once, on day 7, when it was about 
double the level found in the untreated group (Figure 6.2). In this particular 
experiment, the untreated group (Pc) was the better one clinically in terms of 
percentage parasitaemia and weight loss (see Appendix 2 for results of individual 
experiments).
6.3. Effect of NISV on the splenic levels of IL-4
The animals used here are the same as those from which lysed whole blood samples 
were removed i.e. 25 male BALB/c mice. Spleens o f two animals per group were 
rem oved aseptically on days 6 , 8 , 10, 11, 14, 17 and 21 and exposed to various 
stim ulating or control agents; concanavalinA, parasitised red blood cells (pE), non­
parasitized red cells (nE) and complete RPM I medium. On day 14, however, no pE or 
nE were available. The splenic cells were incubated with the above stim ulants for 72 
hr at 37“C in 5% CO2 in air, and their supernatants collected and stored at -2 0 “C until 
analysis.
In general, higher levels of IL-4 were detected in the NISV-treated group (PcV) from 
day 6  to day 10 post-infection than the untreated group (Pc). The untreated group 
(Pc), on the other hand produced higher IL-4 levels on day 11 (around peak 
parasitaemia) and on day 17 post-infection.
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No IL-4 was detected in the untreated group (Pc) to any stimulant on days 8 , 10 and 
21 post-infection (Figure 6.3). As mentioned above in this particular experim ent the 
untreated group (Pc) exhibited a less severe disease that the NISV-treated group 
(PcV) in term s of percent parasitaem ia and amount of weight loss (see Appendix 2 for 
results of individual experiments).
150
80 
70 
60 
ç  50 
è  40 
^  30 
20 
10 4 
0 J
8 10 11 
day post infection
■  PC
■  PcV
12 14 15
Figure 6.2. IL-4 concentration in lysed whole blood o f 10-12 week old male BALB/c 
mice infected with P. c AS. Both groups (Pc and PcV) were infected i.p. with 1x10  ^
pRBC and received lOOpl PBS and NISV respectively s.c. on days -28 and -14. 
Results represent pooled samples o f 2 animals per group at each time point indicated
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Discussion:
As m entioned earlier, the studies pi'esented in this thesis represent 4 experiments 
eonducted at two venues, Strathclyde University and Glasgow University. IL-4 results 
presented in this Chapter are from plasma samples of an experim ent conducted at 
Strathclyde University and from lysed whole blood and splenocytes supernatant of an 
experim ent conducted at University of Glasgow i.e. a total o f two experim ents out of 
four. The results presented here are discussed in two contexts, the relation between 
IL-4 levels and disease severity and the effect o f pre-treatment with NISV on the IL-4 
levels in P. c. AS-infected BALB/c mice.
IL-4 levels in the plasm a of the mice in the first experiment were not detected until 
late during infection (day 1 2 ), after the peak of parasitaemia which occurred on day 8 . 
In general higher levels of IL-4 were detected in the NISV-treated group (PcV) than 
the untreated group (Pc) on days 12-15. In this particular experim ent the treated group 
(PcV) was the better one clinically with regards to percent parasitaemia, amount of 
weight loss and health status score. Higher IL-4 levels in the PcV group, therefore, 
could be due to pretreatment with NISV or it could merely reflect the disease severity 
in this group in comparison with the untreated group. Since no plasm a samples were 
available for IL-4 level measurements from m ore than one experim ent, it becomes 
difficult to attribute the high levels in the PcV group to the NISV. W ith regards to the 
relation between IL-4 levels and disease severity, Langhorne and colleagues (1989) 
have shown a sequential appearance of T hl cells, with production o f IFNy, and Th2 
cells, with production of IL-4, in P. c. AS-infected resistant C57B1/6 mice (Langhorne 
et al., 1989). Early production o f IL-4, on the other hand was found to correlate with 
susceptibility in P. c. AS-infected susceptible A/J mice (Jacobs, Radzioch and 
Stevenson, 1996). It could be said that the plasm a IL-4 levels shown here agree with 
these studies in the sense that high levels produced late in the infection following peak 
parasitaem ia in the PcV group correlate with resistance to infection since this group 
exhibited a less severe disease than the Pc group in this experiment. This, therefore, 
indicates that even within the same mouse species (BALB/c in this case) high IL-4 
levels late in the disease could reflect resistance to infection.
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Lysed whole blood samples and splenocytes supernatants were obtained from the 
same anim als in a single experiment eondueted at Glasgow University. To date I am 
not aware of whole blood samples being used for m easurem ent o f cytokines by 
ELISA which, therefore, does not allow any comparison to be m ade with other 
results. Also these samples were collected from a single experim ent and a repeat is 
needed to confirm  the results. It can, however, be seen that high IL-4 levels late in the 
infection (day 14) in the untreated (Pc) group in the whole blood and in the 
splenocytes supernatants correlated with protection from infection. On the other hand, 
high levels in the splenocytes supernatants in the NISV-treated group (PcV) 
correlated with disease susceptibility since in this experiment, the untreated group 
exhibited a less severe disease with regards to percent parasitaemia, degree of weight 
loss and health status score.
Several studies have shown that IL-4 deficiency in IL-4 gene KG mice produces a 
higher peak parasitaemia and a higher recrudescence but does not im pair parasite 
clearance i. e. does not abrogate immunity (von der W eid et a l ,  1994, Baimer, 1997). 
The results presented here also seem to agree with these studies. In both experiments, 
both Pc and PeV groups whether had a high or a low level of IL-4 at any time during 
infection, both cleared the parasites and made a full recovery. Also, the two groups 
had a sim ilar mortality in both experiments.
Collectively the above results indicate that p re treatment o f P. c. A S-infected male 
BALB/e mice with NISV does not alter IL-4 levels in their circulation or those 
produced by their splenocytes. It can also be said that the difference in IL-4 levels 
between the two groups here merely reflects the difference in their degree of illness 
and is not due to pretreatment with NISV. Several possibilities have been discussed 
to explain the difference in the disease severity between the two groups (see Chapter
3).
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Chapter 7
Effects of non-ionic surfactant vesicles in in vitro setting.
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Introduction:
Il was seen in Chapter 4 that pretreatment o f P. c. AS-infected male BALB/c mice 
with subcutaneous injections o f NISV led to suppression of circulating T N F a  levels 
but the clinical outcome was different in different experiments. To increase 
knowledge about the activity o f NISV, their effects in vitro was investigated.
Two parameters were chosen initially to investigate the in vitro effects of NISV. 
These were, T N F a production from macrophages and splenocyte proliferation in 
response to selected stim ulating agents in the presence of NISV. Some of the in vitro 
work involved the use o f naïve female ICR m ice due to shortage of male BALB/c 
mice from the suppliers.
7. 1. a. Effects of NISV on T cell proliferation in vitro:
Results
Splenocytes (IxlO^cell/well) from naive 10-12 week old male BALB/e mice were 
obtained aseptically and stim ulated with the m itogen ConA (lOpg/m l) in the presence 
or absence of NISV. Three different concentrations of NISV 2.5, 5 and lOjil/well 
containing a total volume of 2 0 0 |il were used to investigate any dose-dependent 
response to the NISV. Splenocytes were incubated at 37°C in 5% CO 2  in air for 72 hr 
when they were pulsed with V2  jiCi o f ^H-methyl-thymidine (Am ersham) and 
incubated for a further 18 hr. Cells were then harvested onto a filter paper and air- 
dried. The beta activity of each sample was determined by a scintillation counter (see 
M aterials and M ethods for details).
Initial results showed that NISV had a suppressive effect on splenocyte proliferation 
in response to ConA and that the suppression was dose-dependent. See Figure 7.1.
To confirm these preliminary results, this work was repeated but with a different 
protocol of NISV addition to the cells to avoid handling very small volumes which 
could stick to the walls of the wells rather than mix with the contents. See Table 7.1.
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Table 7.1: Sequence o f addition of substances to culture wells. ConA; concanavalin at 
lOgg/ml, CM; complete RPM I medium.
protocol Sequence of addition of materials to culture plate wells
0 Splenocytes (lOOpl) then lOOpl o f CM or Con A (lO pg/m l)
1 splenocytes (lOOpl), ConA (lOOpl), NISV (2.5, 5 or lOjLtl)
2 splenocytes (lOOpl), [ConA (lOOjil) +NISV (2.5, 5 or lOjiil)] m ixed well 
with Con A
3 splenocytes (lOOjil), ConA (50 pi o f lOpg/ml), NISV(2.5, 5, lOpl made 
up to 50pl in CM.
4 splenocytes (lOOpl), NISV (2.5, 5, or lOpl made up to 50pl), ConA 
(50pl)
Follow ing the above protocols of adding NISV to splenocytes, revealed an as yet 
unreported property of NISV. It showed that the suppressive effect was dependent on 
the protocol of NISV addition to the spleen cultures. W hile addition o f small volumes 
to the wells exerted dose dependent inhibitory effects on the proliferation, using 
bigger volumes (but same doses) of NISV completely inhibited splenocyte 
proliferation regardless of the dose and regardless what the NISV were m ixed with. 
This clearly indicated that small volumes of NISV added to the wells did not mix well 
w ith the cells and may have form ed a film on the surface and hence producing only 
lim ited effects while good mixing with the cells produced the full effect (Figure 7.1)
This total suppression of splenocytes by NISV was an unexpected finding even to the 
suppliers o f NISV (Dr. J. Brewer, Division of Immunology, Infection & 
Inflamm ation, Glasgow). One hypothesis suggested to explain this observation was 
that ConA diffused into the NISV and so was no longer available for splenocytes. The 
experim ent was, therefore, repeated with other stim ulating agents namely 
lipopolysaccharide (LPS), pRBC and nRBC in addition to com plete medium. It was 
again found that NISV mixed in relatively large volumes, totally suppressed 
splenocytes proliferation in response to any of the above stim ulants regardless of the 
NISV dose (Figure 7.2). The hypothesis that ConA diffused into NISV and was,
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therefore, not available to stim ulate the splenocytes was rejected because proliferation 
was suppressed in response to all stimulants used, some of which, such as 
erythrocytes, are in fact larger than the vesicles (7-8pm v. 255nm).
In order to investigate the mechanisms of this suppression, splenocytes were exposed 
to NISV for different lengths o f time (1 and 3 hr) and then centrifuged in a hope that a 
lipid film containing NISV would form on the surface. The plan was to remove this 
film and expose the cells to ConA or com plete medium to see if the time of exposure 
to NISV had any effect on the proliferative response of splenocytes to ConA. 
Contrary to the belief of the suppliers (Dr. J. Brewer, Division o f Immunology, 
Infection & Inflammation, Glasgow), this expected film did not form no matter what 
speed of centrifuge was used. In order to rem ove NISV from the cells, cells were first 
washed three times in big volumes (30 ml) o f complete medium and were then further 
incubated for 72 hr in the presence or absence o f ConA. It was seen that although 1 hr 
incubation of splenocytes with NISV was not sufficient to suppress their proliferation 
in response to ConA, 3 hr incubation was sufficient. It was also seen that 1 hr 
incubation with NISV led to a greater response to ConA than cells not exposed to 
NISV. See Figure 7.3.
One hypothesis suggested by the suppliers o f NISV (Brewer and Alexander, personal 
communication) was that the NISV were toxic to the splenocytes due to the detergent 
effects o f their components (eholestrol, dieetylphosphate and m onopalm itoly glycol). 
To investigate this hypothesis, cells viability was cheeked with trypan blue exclusion 
m ethod and by M TT assay. At the same time splenocyte proliferation was exam ined 
with the uptake. Cell viability studies showed that the exposed cells were in fact 
viable (Figure 7.4). This clearly indicated that in the presence of NISV, splenocytes 
remained viable but non-proliferating in response to ConA.
In view of the above results, it was decided to investigate NISV effects on splenocytes 
in ex-vivo settings.
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Figure 7.1 : Effect o f different methods o f addition o f NISV to splenocytes in culture 
on proliferation o f splenocytes in response to ConA. Splenocytes obtained aseptically 
from a naive male BALB/c mouse, were stimulated with lOpg/ml o f ConA. Three 
concentrations o f NISV were used, 2.5, 5 and lOpl per 200pl well. Results represent 
means o f three wells and error bars are the standard deviations. Details on the 
protocols are in Table 7.1. ConAVO; [ConA (Ipg) + NISV (Opl)] / 200pl, ConAVIO; 
[ConA (Ipg) + NISV (lOpl)] /  200pl, ConAV5; [ConA (Ipg) + NISV (5pl)] / 200pl 
and ConAV2.5: [ConA(lpg) + NISV (2.5pl)] /  200pl.
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Fig 7.2. NISV effects on splenocytes obtained from a naïve maie BALB/c mouse. 
NISV (2.5, 5 or lOpl/well) were mixed with the stimulating agent to a final volume o f 
lOOpl. CM; complete RPMI medium, LPS; lipopolysaccharide (3pg/ml), pE; 
parasitized mouse red blood cells, nE; normal mouse red blood cells. VO; no NISV, 
V2.5; NISV (2.5pl/well), V5; NISV (5pl/well), VIO; NISV lOpl/well).
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Figure 7.3: Splenocyte proliferation in response to ConA after prior incubation with 
NISV. Splenocytes were incubated with NISV for 1 or 3 hr. NISV dose chosen here 
was Spl/well. CM; complete RPMI medium, ConA; concanavalin (lOpg/ml). Results 
represent means o f 3 wells and the bars are the standard errors o f means.
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Figure 7.4; Splenocyte viability checked with trypan blue exclusion method. 
Splenocytes were exposed to 3 concentrations o f NISV (2.5, 5 and lOpl/well) mixed 
with ConA (lOpg/ml) to a final volume o f lOOjil. CM; complete RPMI medium, 
ConA; concanavalin (lOpg/ml), V2.5, V5 and VIO (NISV 2,5, 5 and lOpl/ml 
respectively). Results represent means o f 3 wells and bars are standard deviations
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7.1.1). Effects of NISV on proliferation of splenocytes from P.c, AS-infected male 
BALB/c mice: 
Results
The results shown here are the combination of two experiments with sim ilar clinical 
outcome. In both experiments, which were conducted at Glasgow University, the 
NISV-treated group (PeV) developed a more severe disease than the untreated group 
(Pc) in terms of level of parasitaemia, degree of weight loss and health status score 
(see Appendix 2). Twenty and twenty-five male BALB/c mice per group in 
experiments G .l and G.2 respectively were infected with 1x10^ pRBC on day 0. 
Groups Pc and PcV were inoculated subcutaneously with lOOji.1 o f PBS or NISV on 
days -2 8  and -14 . Spleens of two animals per group were obtained aseptieally at 
selected tim e points (days 1, 4, 7, 10 and 16 and days 6 , 8 , 11, 13, 14, 17 and 2 1  post 
infection in experiments G .l and G.2 respectively). Splenocytes from the PBS and 
NISV groups were obtained on all time points o f experiment G .l and on day 21 only 
of experim ent G.2. Splenocytes from each pair o f mice were pooled and exposed to 
various stimulating or control agents Con A (lOjLtg/ml), parasitized erythrocytes, 
uninfected mouse erythrocytes and complete RPM I medium. After 72 hrs, cells were 
pulsed with ^H-methyl-thyraidine (Am ersham) and further incubated for 18hr. 
Splenocytes were then harvested on a filter paper and the beta activity was read using 
a scintillation counter (see Material and M ethods for details).
The com bined ex-vivo studies on splenoeyte proliferation revealed several points. 
They showed that, in general, splenocytes proliferative response is greatest to ConA. 
The two infected groups, Pc and PcV, had a greater response than the control groups 
on day 1 post-infection only, while a lower response than the control groups was seen 
at all other time points. The PcV group showed a slight and non-significant lower 
response than the Pc group at all time points except day 10 when the PcV response 
was slightly higher. A depressed response of the Pc and PcV groups is seen on days 
10-16 post-infection. No difference was seen between the PBS and NISV. An 
interesting point is that the two control groups PBS and NISV showed a low response 
on day 1. It can be seen that NISV did not completely suppress splenocytes
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proliferation at any time point (Figure 7.5). Results of day 21 post-infeetion 
(experim ent G.2) are not included due to contam ination of the culture with a fungal 
growth. In the two control groups, PBS and NISV, a variablility in splenoeyte 
proliferation response to ConA was seen at different time points. This variability 
indicates that the proliferation responses of splenocytes in different m edia could not 
be com pared with each other at different time points but rather at each single time 
point.
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Figure 7.5. a, b: Splenoeyte proliferation o f male BALB/c mice infected with P. c AS .  
Pc and PcV groups were infected with 1x10^ parasitized red blood cells on day 0 and 
inoculated subcutaneously with lOOpl of PBS or NISV respectively on days -2 8  and -  
14. Groups PBS and NISV were injected subcutaneously with lOOpl o f PBS or NISV 
respectively on days -2 8  and -1 4  but were not infected. CM; com plete RPM I 
medium, ConA; concanavalin A(10p.g/ml), LPS; lipopolysaccharide (3pg/m l), pE; 
parasitized red blood cells and nE; normal red blood cells. Results represent means of 
three wells of pooled splenocytes and the bars are the standard deviations.
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The next step was to investigate the m echanism s of N ISV -induced splenoeyte 
suppression in vitro. Several agents are known to suppress T cell proliferation in vitro 
such as nitric oxide (Ahvazi et al., 1995) and PGE2 (Riley at a l ,  1989). It was, 
therefore, decided to measure these chemicals in the supernatants of splenocytes 
exposed to NISV. Nitric oxide levels were m easured first and are presented here.
7.2,a. Effects of NISV on the production of nitric oxide from macrophages in 
vitro:
Nitric oxide in a biological setting was first described in 1987 when it was recognized 
to be the biological agent known to relax endothelium  smooth muscle named 
endothelium  derived relaxing factor (EDRF) (Palm er et a l ,  1987).
Nitric oxide is produced from the terminal guanidine nitrogen o f the amino acid E- 
arginine during its conversion to L-citrulline, a reaction catalysed by the enzyme 
nitric oxide synthase. Three major forms of this enzyme have been identified. The 
neural and endothelial forms (Dinerman et a l ,  1994) are expressed constitutively, 
produce limited amounts o f NO and are calcium and calm odullin-dependent (Bredt 
and Snyder, 1990). The macrophage type is not normally expressed but can be 
induced by a variety o f factors and hence is known as inducible NO synthase ( iNOS). 
The inducible enzyme produces greater amounts of NO and is Ca-independent 
(reviewed by Clark and Rockett 1996). Induction of iNOS requires gene transcription 
which occurs rapidly in response to various stimuli including TNFot, IFNy, TNF(3, IL- 
1 (Rockett et a l ,  1992). It is down regulated by IL-4, fL-5, IE-8 , IE -10 and 
glucocorticoids (reviewed by Cox and Eiew, 1992).
Nitric oxide itself cannot be measured because it undergoes rapid oxidation in 
aqueous solutions to form nitrite and nitrate and it is these products that are m easured 
in blood or urine. The rapid oxidation of NO is due to its cheiuical nature. NO is a 
radical molecule with a free unpaired electron in its outer orbit, m aking it highly 
unstable and so it reacts rapidly with the surrounding radicals such as superoxide to 
form highly reactive derivatives such as peroxy ni trite ion which is highly toxic to
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many m olecules including nucleic acid, lipids and proteins (van der Vliet et a l,
1994).
Nitric oxide is produced by a variety of cell types including neurons, vascular 
endothelial cells (Oswald et a i ,  1994), platelets, neutrophils (McCall et a l ,  1989), 
adrenal cells, respiratory epithelial cells, activated m acrophages (Stuehr et a i ,  1985), 
hépatocytes (Nüssler et a l ,  1991) and mast cells.
NO is involved in a wide range o f biological functions. For exam ple it acts as a 
neurotransm itter as is thought to be in the case of non-adrenergic, non-cholinergic 
bronchodilating neurons and it has been used in the treatment of adult respiratory 
distress syndrome. It is thought to be a major controller of cerebrovascular tone (Wei 
et a l ,  1993). Moreover, it is thought to be the principal cytotoxic m ediator of effector 
molecules involved in intracellular parasite killing (Rockett et a l ,  1991). NO inhibits 
iron-sulphur-dependent enzymes involved in cellular respiration, energy production 
and reproduction (Hibbs et a l ,  1988). Also, NO 2 " synthesis has been shown to 
correlate directly with intracellular killing of Leishmania major  (Green et a l ,  1990).
In the case of malaria, although a saturated solution o f NO did not inhibit P. 
falciparum  growth in vitro, its downstream products, nitrite and nitrate ions, however, 
were found to be toxic in m illimolar concentrations (Rockett et a l ,  1991). In vivo 
studies also indicated a role for NO in protection against malaria and emphasized that 
the site and time of NO production were important. Plasmodium chabaudi-infQct&d 
resistant and susceptible mice were found to produce high levels of iNOS in their 
spleens early during infection and in the liver late in infection respectively (Jacobs, 
Radzioch and Stevenson, 1996). This follows the same pattern as T N F a  production 
by susceptible and resistant mice infected with P. c. AS (Jacobs, Radzioch and 
Stevenson, 1996) indicating that NO could be the downstream m ediator of T N F a -  
induced resistance. This was confirmed in P. c AS-infected mice were treated with 
anti-IFNy and anti-TN Fa monoclonal antibodies. These mice had a reduced splenic 
iNOS m RNA production and reduced circulating NOy levels by 50% in mice treated 
with anti-IFNy antibodies and 100% in those treated with an ti-T N Fa antibodies 
(Jacobs, Radzioch and Stevenson, 1996). CD4^ Thl cells were found to be the major
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source o f NO during P.c. AS blood stage infection. W hen mice depleted of C D E ' cells 
and reconstituted with T h l cells were treated with L-N^-monomethyl arginine (L- 
NM M A), they produced little or no detectable nitrates and developed a greater blood 
parasitaemia (Taylor-Robinson and Phillips, 1994). It is important to note, however, 
that NO was found not to be essential in protection against malaria. Treatm ent of mice 
with L-NM M A and hydroxybutyrate did not significantly increase parasitaem ia or 
alter the course of the disease in P. vinkei and P. c. adami infections (Clark et a i ,  
1987). The authors suggested that this was due to the rapid scavenging of NO by the 
surrounding haemoglobin. This was in agreement with previous study by .Tones and 
colleagues. TO mice infected with P. berghei o f P. \nnkei peteri, lung, liver, kidney 
and spleen iNOS activity remained unchanged in the lethal and non-lethal infections 
(Jones et al., 1996).
Nitric oxide, however, was also reported to play a role in the pathogenesis of 
experimental cerebral m alaria (ECM). TNFot/p double KO mice infected with P. 
berghei ANKA were protected against CM. NO production was im paired in these 
mice suggesting that TN Fa-induced NO had a role in CM pathology (Rudin et a l ,
1997). Other studies, however, found no correlation between NO and ECM. 
Treatm ent of P. berghei ANKA-infected CBA mice with L-NM M A did not prevent 
the development of ECM  (Kremsner et a l ,  1993). Also, it was found that P. c AS- 
infected C57B1/6 mice deficient in iNOS and given aminoguanidine to block other 
NOS ran a similar course of infection to w ild mice with no difference in the 
parasitaem ia course, survival and haematological values (Favre, Ryffel and Rudin, 
1999).
In human P. falciparum  malaria, some studies reported a protective role of NO. 
Leukocyte N 0 S 2  was not detected in children with CM, while in all those with 
subclinical infection and in controls, N 0 S 2  was detectable. The authors suggested 
that NO synthesis protected against clinical disease (Anesty et a i ,  1996). Other 
studies, however, reported a pathological role for NO in CM. Serum levels of reactive 
nitrogen intermediates were found to correlate positively with the depth of com a in 
children with CM at admission and its duration (Al-Yaman et al, 1996).
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Apart form its effects on the blood stage malaria, NO was also found to play a part in 
the immune response mounted against the intra-hepatic forms of the m alaria parasite. 
L-NM M A was found to block EFNy-induced inhibition of sporozoite growth in vitro 
indicating that the inhibition was mediated through NO (M ellouk et a l ,  1991). NO 
was found to promote the accumulation of CD4^ and CD 8  ^ T cells round infected 
hepatocytes in P. berghei infected Brown Norway rats (Scheller et a l ,  1997).
M oreover, NO was shown to reduce gametocyte infectivity in both rodent (M otard et 
a l ,  1993) and human m alaria (Naotunne et a l ,  1993). Gametocyte infectivity to A. 
stephensi was reduced when the m osquito feeding occurred during tim e of schizogony 
in the P. vinkei peterLinfected mice. This, however could be prevented by treatm ent 
of the mice with L-arginine analogue Nw-nitro-L-arginine (NwNLA) prior to 
mosquito feeding, indicating that the suppression of the gametocyte infectivity was 
due to nitrogen reactive intermediates (Motard et a l ,  1993).
On the other hand, NO has been reported to be responsible at least in part for 
imm unosuppression (Ahvazi et a l ,  1995) which occurs during acute m alaria infection 
(Rockett et a l ,  1994). It has been reported that lymphocytes froiu malarial mice 
develop a poor proliferative response to ConA (Correa et a l ,  1980) and foreign red 
blood cell antigens (Greenwood et a l ,  1971). It is this last property, which is of 
interest to the work done here.
Results:
Splenocytes cells were obtained aseptieally from naïve 10-12 week old female ICR 
mice. 1x10^ cells per well were stim ulated with LPS (3pg/ml) and NISV was added to 
the cells in three different concentrations (2.5, 5 and lOpl/well). Sam ples were run in 
triplicates with each well containing a final volume of 200|Ltl. Cells were incubated for 
72 hrs at 37°C in 5 % CO 2  in air and the supernatants were collected and stored at - 
20°C until further analysis. The same procedure was applied to adherent murine 
hepatic and bone marrow (BM) cells. Production of NO was measured as nitrates by 
the Greiss reaction (for details see M aterials and Methods).
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It was found that LPS did not stimulate NO production from splenocytes and liver 
adherent cells more than that produced in the presence of complete RPM I medium. 
LPS, however, did induce NO production by BM adherent cells. NO production was 
enhanced by NISV in a dose-dependent m anner from all three cell types (see Figure 
7.6 a and b). In view of these results, it was decided to investigate the effect of L- 
NM M A on the reversal of NISV-induced suppression of splenocytes proliferation and 
whether NO was the only agent involved or others were also involved. Initially only 
one L-NM M A dose (500pM7well) was used and it showed that there was some 
recovery of splenoeyte proliferation of cells exposed to 2.5pl o f NISV/well (see 
Figure 7.7).
In view of the above results, it was decided to investigate the effects of NISV 
treatment of splenoeyte NO production in ex- vivo.
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Figure 7.6 a. Nitric oxide production from adherent liver and bone marrow cells. Cells 
were removed aseptieally from naive female ICR mice and stimulated with LPS in the 
absence or presence o f three different concentrations o f NISV (2.5, 5 and lOpl/well). 
CM; complete RPMI medium, LPS; lipopolysaccharide (3pg/ml), V2.5; NISV 
(2.5pl/well), V5; NISV (5pl/well), VIO; NISV (lOpl/well). Results represent means 
of 3 wells.
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Figure 7.6 b. NO production from splenocytes in response to LPS and NISV. CM; 
complete RPMI medium, LPS; lipopolysaccharide (3p,g/ml), V2.5; NISV at 2.5 
pl/well, V5; NISV at 5pl/well and VIO; NISV at lOpl/well. Results represent means 
o f three wells. Note that NISV induces production o f nitrates by splenocytes in a 
dose-dependent manner.
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Figure 7.7: Splenoeyte proliferation in response to ConA (lOpg/ml) and presence o f  
NISV (2.5, 5 or lOpl/well) and LNMMA (500pM/well). Spleens were obtained from 
a naive female ICR mouse. Results represent means o f three wells and bars are 
standard deviation. CM; complete RPMI medium, ConA; concanavalin (lOpg.ml), L; 
L-NMMA (500|iM/well). Note that there was some recovery o f proliferation by cells 
exposed to 2.5pl/well o f NISV.
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7.2.1). Effects of NISV treatment on the ex-vivo production of NO from  
splenocytes:
Results:
Twenty five male BALB/c mice per group were infected with 1x10^ pRBC on day 0. 
Groups Pc and PcV were treated subcutaneously with lOOpl o f PBS or NISV 
respectively on days -28  and -14 . Spleens o f two mice per group were removed 
aseptieally at selected time points (days 6 , 8 , 11, 14, 17 and 21 post-infection) during 
infection and pooled. Spleens were obtained from the PBS and NISV groups on day 
21 post-infection only. Splenocytes were then exposed to various stim ulating agents 
including; ConA, pRBC, nRBC plus complete RPM I medium and incubated at 37°C 
in 5% CO 2  in air for 72 hrs, at which time supernatants were collected and stored at -  
20°C until further analysis. N itrate was then m easured by the Greiss reaction in 
samples run in duplicates.
The NISV-treated group produced less NO than the untreated group on days 14 and 
17 in response to ConA. On the other hand, NO production was higher in the treated 
group (PcV) on days 6  in response to ConA, parasitized and non-parasitized 
erythrocytes. It was also found that both the Pc and PcV groups produced high 
amounts of NO on day 21 post-infection in response to all stim ulants even complete 
RPM I medium. No difference was seen between the PBS and NISV groups (Figure 
7.8).
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Figure 7.8: NO production by splenocytes o f male BALB/c mice infected with P.c. 
AS. 25 male BALB/c mice per group were infected with 1x10  ^ pRBC on day 0. 
Groups Pc and PcV were given lOOpl o f PBS or NISV respectively on days -28  and -  
14 via subcutaneous inoculation. CM; complete RPMI medium, ConA; concanavalin 
(lOpg/ml), pE; parasitesed red blood cells, nE; normal erythrocytes
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7. 3. Effects of NISV on TNFa production in vitro:
As seen in Chapter 4, pretreatinent of male BALB/c mice with NISV led to 
suppression of circulating T N F a  but with a variable clinical outcom e in different 
experiments. Also previous work with the vesicles revealed that they suppressed 
T N F a  production in vitro from murine bone marrow derived m acrophages and human 
peripheral blood lymphocytes exposed to LPS (Roberts, Brewer and Alexander patent 
application, 1995). One o f the aims of this project was to confirm  the suppressive 
effects of NISV on T N F a  production in vitro.
Results:
Spleens o f naive 10-12 week old male BALB/c mice were rem oved aseptieally. 
Splenocytes (1x10^ cells/well) were incubated with LPS (3p.g/ml) for various lengths 
o f time (2, 4, 6 , 18, 24 and 48hr). Supernatants were then collected and stored at -20° 
C until further analysis. Initially no T N F a  was detected at any tim e point chosen and 
so cells were exposed to a combination of LPS (250ng/ml) and IFNy (lOOU/ml). 
Again T N F a  was not detected and the LPS was thought to have expired. The above 
work was repeated with using fresh LPS but still without success. It was then decided 
to obtain m acrophages from the bone marrow and investigate NISV effects on T N F a  
production. This seemed very reasonable since previous work by the NISV suppliers 
(Dr. I. Brewer, Division of Immunology, Infection & Inflam m ation, W estern 
Infirmary, Glasgow) involved the use of bone marrow derived m acrophages (Roberts, 
Brewer and Alexander, 1995 patent application). Bone marrow of 10-12 week old 
female naive ICR mouse was obtained aseptieally and cells were allowed to grow for 
a week in DM EM  supplem ented with 20% FCS and 30% supernatants o f L-929 cells 
in 5% CO 2  in air (W olfanu et a i ,  1996), Non-adherent cells were then removed and 
the adherent cells were collected, washed twice and stimulated with LPS (3pg/ml), 
LPS (250ng/ml) + IFNy (lOOU/ml) or complete DM EM  medium in the presence of 
NISV (2.5, 5, lOpl/well). Cells were incubated for various lengths of time and 
supernatants collected and stored at -20°C  until further use. Hepatic adherent cells 
were also exposed to the above agents and NISV.
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W ith regards to liver and bone marrow adherent cells, here too T N F a  proved to be 
difficult to detect and experiments had to be repeated several times. T N F a  was never 
detected in supernatants of cells stim ulated with LPS or a com bination of LPS and 
IFNy. T N F a  was never seen to be suppressed by NISV in any experiment, in fact in 
some, it was seen to induce its production. T N F a  was detected in supernatants of 
BM -derived macrophages stim ulated with parasitized erythrocytes in presence of 
5pl/well of NISV at two hr incubation. At six hr incubation, T N F a  was detected in 
the supernatants of BM -derived macrophages stim ulated with LPS + IFNy and with 
parasitized red blood eells in the presence of lOpl/well of NISV (Figures 7.9 a and 
b). T N F a  was also detected in the supernatants of hepatocytes incubated with LPS + 
IFNy and NISV 5pl/well for two hrs (Figure 7.10).
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Figure 7.9 a and b: TNFa production by bone marrow macrophages o f female naïve 
ICR mouse. Cells were stimulated by LPS (250ng/ml) and XFNy (lOOU/mi) or 
parasitized red blood cells in the presence of 3 doses o f NISV(2.5, 5, and 10p,Fwell). 
Supernatants were collected at 2, 4, and 6 hr. CDM; complete DMEM medium, L/l; 
LPS and IFNy, pE; parasitized erythrocytes, V2.5; NISV (2.5|iFwell), V5; NISV 
(5|ul/well), VIO; NISV (10|ul/weU).
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Figure 7.10; TNFa production from liver adherent cells obtained from female ICR 
mouse and stimulated with LPS and XFNy. Cells were exposed to 3 different doses o f  
NISV (2.5, 5 and lOp-l/well) and supernatants were collected at 2 and 4 hr intervals. 
CM; complete RPMI medium, L/I; LPS (250ng/ml) and IFNy (lOOU/ml), V2.5; NISV  
(2.5^1/weli), V5; NISV (5^1/well), VIO; NISV (10^1/well).
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7. 4. Comparison between different samples in measuring cytokines:
As m entioned before, difficulty was faced in m easuring T N F a  by the ELISA method. 
Results presented in this thesis were achieved after several unsuccessful attempts. In 
view of the difficulty of measuring TN Fa, it was decided to measure cytokine levels 
in different samples (serum, plasma and whole blood). It was also decided to 
investigate the effects of repeated freezing and thawing of the samples on the levels of 
cytokines detected.
Results:
Seven fem ale ICR mice (age 12-14weeks) were infected with 1x10^ parasitized red 
blood eells on day 0. Two animals were sacrificed on days 4, 8  and 10 post infection 
and blood was collected via cardiac puncture. Blood was divided equally into 3 
Eppendorfs with one Eppendorf containing heparin (lOOpl/ml). The aim was to have 
plasma, serum  and whole blood. To obtain plasm a, blood was centrifuged at 13000 
rpm ( ll,6 0 0 g ) for 3 min, plasm a removed and stored at -20"C  until further use. 
Serum was obtained by leaving blood at room tem perature overnight to coagulate. 
Serum was then collected and stored at -20^C until further use. Since whole blood did 
not contain any anticoagulant, it clotted. In order to keep the whole blood samples in a 
liquid state to allow their use in ELISA, a few drops o f ddHgO were added to whole 
blood before freezing it (lOOpl/lml of blood). W hole blood sam ples (containing 
ddHzO) were than stored at -20°C  until further analysis. Packed blood cells rem aining 
following the removal of were also liquidized by addition of ddH iO  and stored at -  
20°C.
As mentioned previously, steps in the ELIS As were m odified when working with 
whole blood (see M aterials and Methods). Follow ing 1 hr incubation of whole blood 
samples with the coating monoclonal antibody, plates were kept at 37“C over night 
and washed the following day. The rest of the steps followed the usual ELISA method 
steps.
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W ith regards to TN Fa, it can be seen that no T N F a  was detected in the plasm a 
samples at any time points while some T N F a  was detected in the serum samples on 
days 8  and 10 post infection and in whole blood at all the 3 time points. Highest levels 
o f T N Fa, however, were detected in the packed cells remaining after the removal of 
plasma, followed by packed blood cells rem aining after the removal o f serum. On day 
8  post infection, no samples were available for packed blood cells remaining 
following the removal of plasm a or serum (Eppendorfs were discarded by mistake). In 
this preliminary experiment, control samples were obtained from a PBS treated male 
BALB/c mouse from the previous experiments. Note that there is a difference in the 
levels detected in whole blood haemolysed with ddH 2 0  and that without it. No 
T N F a  was detected in the control group. See Figure 7.11.
IFNy was m easured repeatedly in the above samples following second, third and 
sixth time thawing of the samples. Levels shown here were detected after the second 
and sixth thawing of the samples. IFNy was not detected in either plasm a or serum 
samples at any time point. No IFNy was detected in blood with or without water after 
the second thawing of the samples at any tim e point. After the sixth thawing, 
however, sim ilar levels of IFNy were detected in blood with and without water (no 
sample for blood without water was available on day 10 post-infection). Sim ilar levels 
o f IFNy were detected in the whole blood with ddH 2 0  and whole blood without 
ddH 2 0  on days 4 and 8  post-infection after the sixth time thawing of the samples (no 
samples o f whole blood without ddH 20 were left on day 10 after the sixth thawing). 
IFNy level in paeked cell rem aining after removal of plasma (Bp) on day 4 was 
approximately 200 U/ml following the second and the sixth time thaw ing of the 
samples, while no IFNy was detected in packed cells remaining after the removal of 
serum (Bs) at this time point. Furthermore, IFNy levels in Bs on day 10 post-infection 
were <50U/ml after the second thawing while levels >140U/ml were detected after the 
sixth time thawing of the sample. Approximately 200U/ml of IFNy were detected in 
Bp on day 10 after second and sixth thawing of the sample (Figures 12.7. a and b).
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Figure 7.11. Circulating TNFa levels in different specimens from P. c AS-infected 
female ICR mice. Animals were infected with 1x10  ^pRBC. Results represent means 
of three wells containing pooled samples o f two mice per time point. Bs; packed cells 
remaining following the removal o f serum. Bp; packed blood cells remaining 
following the removal o f plasma, Bw; whole blood with ddH20 (lOOpl/ml), blood; 
whole blood without ddH20. Results shown were obtained following thawing the 
samples for the sixth time.
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Figure 7.12. a and b. Circulating IFNy lev e ls 'm P. c AS-infected female ICR mice. 
Bloodw, whole blood with ddH]0, blood; whole blood without ddHzO, Bs; packed 
blood cells remaining following removal o f serum, Bs; packed red cells remaining 
following removal o f serum. Figure 7.12.a; results obtained following second thawing 
of the samples, figure 7.12.b; results obtained following sixth time thawing o f the 
samples. Results represent o f three wells containing pooled samples o f two mice at 
each time point.
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Discussion:
As m entioned previously, one o f the aims of this research was to investigate the 
hypothesis that NISV suppressed T N F a  production by stim ulated macrophages, 
suggested by the m anufacturers o f NISV (Dr. J. Brewer, Division of Immunology, 
Infection & Inflammation, W estern Infirmary, Glasgow). It was show in Chapter 4 
that NISV did indeed suppress circulatory T N F a  production in P. c AS-infected male 
BALB/c mice. The studies done here aimed at confirming NISV -induced suppression 
of T N F a  production in vitro.
NISV effects on splenoeyte proliferation in vitro revealed several properties of the 
NISV, among these is the fact that NISV do not mix easily with the culture medium. 
This could be due to their hydrophobic outer layer (Brewer, 1993) (see M aterials and 
M ethods) forming a surface interphase. In fact, when adding NISV to culture medium 
in Bijoux tubes, a distinguished white fluid would be seen which did not mix readily 
with the culture medium unless well shaken. The difficulty o f NISV to mix with the 
culture m edium  could explain why, upon adding small volumes of NISV to the wells, 
(following addition of cells and ConA) a dose-dependent suppression o f splenoeyte 
proliferation resulted. On the other hand, m ixing NISV vigorously with the culture 
medium in relatively large volumes resulted in total suppression of splenocytes 
proliferation regardless of the NISV concentration indicating that addition o f small 
volumes to the wells as a last step resulted in NISV floating on the surface of the 
culture m edium  and hence producing only a local suppressive effect on the underlying 
splenocytes. This was also suggested by the difference in splenoeyte proliferation 
results obtained from protocols 3 and 4. Adding NISV to the splenocytes after the 
addition of ConA resulted in some proliferative response while adding NISV to 
splenocytes before the addition of ConA led to total suppression of proliferation 
although NISV were added in relatively large volumes in both cases (SOjil) suggesting 
that the NISV formed a barrier between the cells and ConA in the latter case.
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Another property of NISV revealed by these studies was that the NISV-indiiced 
suppression of splenocytes proliferation was not due to NISV toxicity but rather other 
m echanism s were involved. An important point noted is that the splenoeyte 
suppression was dependent on the exposure tim e to NISV.
In the ex-vivo work, however, NISV were seen to suppress splenoeyte proliferation of 
the treated group only slightly and at certain tim e points only. This slight statistically 
non-significant suppression could be a genuine finding or it could m erely represent a 
normal biological variation. Biological variation was indeed obvious in the response 
of the two control groups PBS and NISV on day 1 post infection when their 
proliferation was much lower than the rest o f time points. It could also, however, 
represent errors made by the operator in counting the splenocytes.
Among agents known to suppress splenoeyte proliferation are PGE2 and NO (Riley ef 
al, 1989, Ahvazi et aL, 1995). It was seen that the NISV did indeed induce NO 
production from splenocytes, bone marrow-derived macrophages and liver adherent 
cells and that NO induction by NISV was dose-dependent. W ith the use o f LNM M A 
in vitro, it was seen that some recovery o f splenoeyte proliferation was achieved. This 
was true for cells exposed to the lowest concentration of NISV (2.5j-tl/well), while no 
proliferation was seen in presence of a higher concentration of NISV. This could be 
due to the fact that LNM M A dose (500|iM /well) used was not enough to block all NO 
production induced by NISV concentrations of 5 or lOpl/well (25 or 50 jil/ml 
respectively). This work could, therefore, be m odified by exposing the splenocytes to 
NISV for various time intervals and to several concentrations o f LNM M A with 
subsequent measurement of splenoeyte proliferation and NO levels in the 
supernatants. The mechanism involved in the induction of NO by NISV is not known 
and more work is needed to investigate this. It, however, seems that NISV stim ulate 
production of NO from splenocytes by direct contact. This hypothesis could explain 
why a dose-dependent proliferation response was seen upon addition of NISV in 
small volumes to the splenocytes and why the splenoeyte proliferative response was 
also dependent on the exposure time to NISV. In other words, it seem s that addition 
of the NISV to the splenocytes leads to accumulation of the NISV on the surface of 
the culture medium and through close contact with the splenocytes underneath, they
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induce the production of NO form these splenocytes which in turn leads suppression 
of splenocytes proliferation. It, therefore follows that the amount of NO induced is 
dependent on the number o f cells stimulated by NISV. M ixing the NISV well with the 
splenocytes allowed a greater num ber of splenocytes to be stim ulated with the NISV 
with production of sufficient amounts of NO to cause total suppression of the 
splenocytes. This hypothesis could be investigated by adding NISV to splenocytes 
according to the protocols m entioned earlier and m easuring the NO levels in the 
supernatants of the splenocytes. The results also indicate that 1 hr incubation with 
NISV does not induce the production of sufficient amounts of NO to cause splenoeyte 
suppression. Three hour or longer incubation, on the other hand, seems to be 
sufficient to stimulate the signal for NO production and hence causing splenoeyte 
suppression even after the removal of NISV. It would, therefore be useful to expose 
the splenocytes to various concentration of NISV for various lengths of time and 
m easuring NO levels in the supernatants along with the splenoeyte proliferation. It 
would also be useful to m easure the levels o f PGE2 to if splenoeyte suppression is 
m ediated partly by it.
Another important finding here is that, contrary to the previous findings of NISV 
causing T N F a  suppression (Roberts, Brewer and Alexander, 1995 patent application), 
no such effect was seen in these experiments. Am ong cells tested in previous studies 
were m urine bone marrow m acrophages from female BALB/c mice and human 
peripheral blood lymphocytes (Roberts, Brewer and Alexander, 1995 Patent). M urine 
bone m arrow derived m acrophages from fem ale ICR mice were tested here but no 
T N F a  was detected not even in response to LPS (3|ig/ml) or LPS (250ng/ml) and 
IFNy (lOOU/ml) although the same T N F a antibodies were used. In some of these 
experim ents it was seen that NISV induced the production of T N Fa. Also previous 
studies have only reported low level detection of T N F a  in the range o f 0.09-0.12 
U/ml and 0.5-3ng/ml while the levels detected here were greater in the range o f 4- 
18U/ml. Previous studies (Roberts, Brewer and Alexander, 1995, patent application) 
also showed detection of T N F a  at several tim e points (1.5, 4, 20, 24, 40, 48 and 
60hr) which was never achievable in the experiments done here. The reason could be 
due to the use of a different strain of mice which means the above work should be 
repeated using BALB/c mice. The difficulty faced in measuring T N F a  levels in the
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studies presented here could also be attributed to the rapid clearance half life of the 
circulating T N F a  (Beutler et a i ,  1985) which could also explain the detection of 
T N F a  in BM -derived macrophages at two hrs but not at 4 and 6 hr (Figures 7.9 a and 
b). It must be mentioned, however, induction o f T N F a  production by NISV agrees 
with the finding of their induction of NO production since NO has been shown to be a 
downstream product of T N F a  (Rockett et al., 1992).
In view of the above results, it could be concluded that NISV induced the production 
of NO form splenocytes in viti^o which could explain at least partly the splenocyte 
proliferation suppression by NISV. No such conclusion, however, can be made with 
regards to NISV effects on splenocyte proliferation and their NO production in ex- 
vivo settings. The low proliferation response o f  the Pc and PcV groups observed on 
days 10-17 agrees with the previous reports on m alaria-induced imm unosuppression 
(Cdrrea et at., 1980).
It can also be concluded that NISV do not cause T N F a  suppression from 
macrophages obtained from female ICR mice and that T N F a  detection in general is in 
fact difficult. This work needs to be done on female BALB/c mice to confirm  the 
previous results (Roberts, Brewer and Alexander, 1995, patent application)
The results obtained by measuring cytokines in different types of blood samples 
(whole blood, serum and plasma) and after repeated freezing and thawing of the 
samples clearly indicate the need to explore this area in order to interpret the ELISA 
results accurately. T N F a  levels were detected in whole blood especially with addition 
of ddH 20  and also in the packed red cells rem aining after removal o f plasm a and 
serum, while no T N F a  was detected in the serum  or plasm a samples. This could be 
due to the release and detection of the m em brane bound T N F a  (Decker et al., 1987, 
Kreigler et a l,  1988) upon destruction o f the blood cells (peripheral blood 
mononuclear cells). It could also due to induction of T N F a  production by damaged 
erythrocytes. Damaged erythrocytes had been shown to induce T N F a  production by 
peripheral blood mononuclear cells (PBMC) with parasitized red cells inducting x 200 
T N F a  levels induced by non-parasitized red cells (Bate et a l ,  1994). IFNy was also 
detected in whole blood while it was absent in plasm a and serum samples. Upon
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binding with ils receptors IFNy is rapidly internalized and eventually degraded in the 
lysosomes (Anderson, 1983). The levels of IFNy detected in whole blood and in 
liquidized packed cells rem aining after removal of serum or plasm a could reflect the 
release o f internalized IFNy upon damage of PBM N by freezing. Detection o f IFNy 
after sixth time thawing of the samples could therefore represent release of IFNy from 
a greater nuiuber of damaged PBM N following repeated freezing and thawing. The 
absence of IFNy in the Bp samples after sixth time thawing could be due to IFNy 
levels being above range o f detection. This could be clarified by using serial dilutions 
of this sample.
In view of the above results, it becomes clear that more work is required in com paring 
cytokine levels in different types of blood samples and after repeated freezing and 
thawing o f these samples. This could help interpret the results obtained by different 
studies and to explain the disagreem ent seen between some studies with regards to 
circulating cytokine levels.
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Chapter 8 
General Discussion
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The studies presented in this thesis cover two main areas: firstly, they investigate the 
effects of pre-infection treatment with empty NISV on the course of P. chabaudi AS 
malaria in male BALB/c mice and secondly, they examine a hypothesis suggesting that 
NISV suppress T N Fa production from macrophages.
The use of empty NISV in these studies follows an accidental finding that pre-infection 
treatment with NISV in Toxoplasma gondii -infected mice resulted in a less degree of 
weight loss in the treated mice compared with the non-treated mice (Brewer, 1993). 
Further studies were planed to investigate the effects of NISV on other pathologies 
characterized by weight loss and high TN Fa levels such as septic shock (Beutler and 
Cerami, 1989) (Roberts, Brewer and Alexander. 1995, patent application). Malaria, on 
the other hand, imposes a huge burden on people morbidity and mortality and there is a 
great difficulty to control the disease for several reasons among which are; antigenic 
variation exhibited by the parasites, parasite resistance to anti-malarial drugs and 
mosquito resistance to insecticides. It is, therefore, important to improve our current 
methods of combating the disease and also to explore new avenues. Investigating the 
effects of NISV was considered as one of these new methods since malaria is also 
characterized by weight loss and high T N Fa levels (Grau et a i ,  1987, Grau et al., 1989, 
Kern é ta l ,  1989, kwiatkowski et al., 1990).
The hypothesis that NISV suppressed TN Fa production was based on previous reports 
associating high TN Fa levels with cachexia (Buetler et al., 1985, Fein stein el a l, 1993). 
In fact high T N Fa levels have been associated with several pathologies including septic 
shock (Beutler and Cerami, 1989), HIV, (Lahdevitra et al., 1988), end stage chronic heart 
failure (Levine et al., 1990) and parasitic infections (Scuderi et al., 1986) including 
malaria.
The concept of suppressing T N Fa in malaria is not new and anti-TN Fa monoclonal 
antibodies have been used experimentally in both human and murine malaria (Grau et a., 
1989). It was thought that if NISV did indeed suppress T N Fa levels, then it would 
provide several advantages over the anti-TNFa monoclonal antibodies including the
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cheapness and the ease of their synthesis and storage. Also, anti-TN Fa antibodies in 
some studies on human cerebral malaria increased the neurological sequelae which was 
thought to be due to prolongation of T N Fa in circulation (van Hensbroek et al., 1996). 
By suppressing TN Fa production all together, NISV should not risk such serious 
consequences.
The initial studies conducted at the first venue (Strathclyde University) showed that pre­
infection treatment of P. c. AS-infected mice resulted in a less severe course of illness 
as measured by a lower degree of weight loss, a lower level of parasitaemia and a higher 
health status score. The rate of mortality, however, was not significantly different 
between the two groups. These studies also showed a lower level of circulating T N Fa in 
the NISV-treated mice agreeing, therefore, with the previous reports associating high 
circulating T N Fa levels with the severity of malaria pathology (Grau et al., 1987, Grau et 
al., 1989, Al-Yaman et a l, 1990, Kern et al., 1989,). The results also agreed with the 
hypothesis that NISV suppressed circulating T N Fa levels (Brewer, personal 
communication). In repeat studies which were condueted at Glasgow University, 
however, although there was a reduced circulating level of T N F a  in the NISV-treated 
group, the disease severity was greater in the treated group with regards to the same 
parameters of weight loss, level of parasitaemia and health status score. As mentioned 
previously in Chapter 3 a number of possibilities were considered to explain the 
difference in the clinical outcome in the experiments. Among these were the possibility 
of infection of the animals at the first venue by unknown pathogens, variable PABA 
levels in the water supply and errors in the synthesis of NISV. All these possibilities 
however, were eliminated but the difference in the clinical outcome in different 
experiments persisted. Another factor considered as a possible cause for the difference in 
the clinical outcome was the size of vesicles. The size of NISV had been reported to 
determine which arm of the T helper cell immune response was enhanced (Brewer et al.,
1998). Vesicles of >225nm in diameter preferentially induced Th 1 -type responses, while 
vesicles of <155 nm diameter induced Th2-type response. This possible explanation, 
however, was rejected for several reasons. The relationship between the NISV size and 
the arm of T  helper cell response promoted has been observed with NISV containing
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antigen (Brewer et al., 1998), while in the experiments presented here, empty NISV were 
used. Also, the empty NISV used here were of mixed sizes, which had been observed 
previously to suppress T N Fa levels (Brewer, 1993) and not to enhance either arm of the 
Th cell immune response. Furthermore, even in the experiments where the NISV-treated 
group developed a worse disease than the untreated group, TN Fa was in fact suppressed.
Another possibility was that NISV caused suppression of T N Fa in an uncontrolled 
manner. As mentioned previously, in murine malaria, T N Fa has been reported to play a 
dual protective and pathological role depending on its levels (Stevenson and Ghadirian, 
1989), timing and site of production (Jacobs et al., 1996). The dual action of T N Fa could 
be explained on the basis of the known functions of TN Fa. T N Fa has been reported to 
cause the production of NO (Rockett el al., 1991, 1992). NO has been shown to cause 
asexual blood stages killing in vitro (Rockett et al., 1991) and resistance against asexual 
blood stage malaria in mice has been reported to correlate with NOS mRNA expression 
in the liver (Jacobs, Radzioch and Stevenson, 1995). High levels of circulating nitrates, 
however, have been reported in association with the depth and duration of coma in 
human malaria (Al-Yaman et a l, 1990) due to NO interference with brain 
neurotransmitters (Clark el a l ,  1991). NO also cause vasodilatation (reviewed by 
Moncada, Palmer and Higgs, 1991) which could be thought of as a beneficial action by 
counteracting the mechanical obstruction caused by binding of parasitized erythrocytes to 
endothelium. One can envisage, however, that excessive vasodilatation can lead to 
hypotension and shock as seen in septic shock (Beutler and Cerami, 1988). In addition, 
T N Fa has been reported to be an endogenous pyrogen (Dinarello et al., 1986) and indeed 
anti-TNFa antibodies in human malaria have been reported to prevent fever in children 
with cerebral malaria (Kwiatkowski et al., 1993). Febrile temperatures have been shown 
to suppress the growth of P. falciparum in vitro (Kwiatkowski, 1989) but it can also 
induce epileptic seizures. T N Fa has also been reported to suppress erythropoiesis and 
promote erythrophagocytosis in murine malaria (Clark and Chaudhri, 1988; Miller et a i ,  
1989). Although the resultant reduction in red blood cells could be thought of a 
mechanism to reduce parasitaemia and hence control the infection, it can also be seen that 
it can lead to severe anaemia (Taverne el a l ,  1994).
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Add to the above the fact that in P. c. AS  infection, protection is associated with 
sequential appearance of Thl and Th2 responses (Langhorne el a i ,  1989). Till cells 
produce IL-2 and IFNy (Mosmann el a i ,  1986) and IFNy in turn enhances the production 
of T N Fa from macrophages (Grau el ciL, 1989, Murray el a l ,  1985) and increases the 
expression of TN Fa receptors (Tsujimoto et a i ,  1986). This means that IFNy and T N Fa 
are important in the early stages of infection to reduce primary parasitaemia to sub-patent 
levels. Suppressing TN Fa early in the infection, therefore, could result in harmful effects.
It follows that certain levels of T N Fa are required at certain period during the illness to 
induce the changes needed to combat the disease but above a certain level (Clark et al., 
1987), T N Fa induces the changes which are pathological to the host (Stevenson and 
Ghadirian, 1989). T N Fa is, however, not the only molecule that has dual effects. 
Everything in nature studied so far shows dual effects depending on its levels including 
essential elements such as water and oxygen. Perhaps the problem with T N F a is that the 
range of its beneficial levels is very narrow. This means that if NISV do cause an 
uncontrolled suppression of circulating T N Fa levels, then they could indeed be 
dangerous in some individuals due to excessive suppression of TN Fa. NISV could also 
be dangerous in certain pathologies requiring the presence of T hl response such as 
Leishmania major (Bretscher et al., 1992). It also means that NISV should not be 
administered prior to infection but should be used therapeutically and only in those 
individuals exhibiting a severe disease. The amounts given should be titrated in the 
individual patients to prevent deprivation of the host of beneficial levels of T N Fa needed 
to combat the disease. Therapeutic use of NISV could be beneficial not only in malaria 
but in any pathology associated with high circulating levels of T N Fa such as septic shock 
(Beutler and Cerami, 1989).
A third possibility to explain the development of a more severe disease in the NISV- 
treated group despite a lower circulating T N Fa levels could be that the disease severity in 
the two groups was not a genuine one but merely a chance event. Two points are in 
favour of this possibility. First the fact that when the experiments were combined, no real
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difference was seen between the NISV-treated and untreated groups with regards to 
weight loss, level of parasitaemia, health status score and mortality and secondly the fact 
that differences were seen among animals of the same group. This means that in the 
system used here, NISV-induced suppression of T N Fa did not produce a significant 
impact on the clinical outcome. It would, therefore, be interesting to examine NISV 
effects in systems such as ECM in CBA/Ca mice infected with P. berghei ANKA where 
suppression of TN Fa by antibodies reduced the development of CM (Grau el al., 1987c) 
outcome not only in malaria but perhaps in other pathologies such as septic shock 
(Beutler and Cerami, 1989).
To study the mechanisms of NISV-induced suppression of circulating TN Fa, cytokines 
known to regulate T N Fa levels such as IFNy and lL-4 were also measured. IFNy is 
produced by CD4^ Thl cells (Mosmann et a l, 1986) and is known to stimulate T N Fa 
production by macrophages (Grau et a l ,  1989, Murray et a l, 1985). If T N Fa suppression 
were through NISV acting on T hl lymphocytes, one would expect IFNy levels to be low 
as well. However, IFNy levels were found to be unaffected by NISV treatment. IL-4, on 
the other hand, is produced by Th2 cells (Mosmann et al., 1986) cells. IL-4 has been 
described as an anti-inflammatory cytokine because of its ability to suppress pro- 
inflammatory cytokines. IL-4 was shown to suppress TN Fa production from human 
PBMN (Hart et a l,  1993). If NISV induced T N Fa suppression by acting on the Th2 
cells, one would have expected circulatory IL-4 levels to be elevated in the NISV-treated 
group. Plasma IL-4 levels were found to be higher in the NISV-treated group, but they 
were high from day 13 on wards, while T N Fa suppression was seen early in the infection 
around time of primary parasitaemia. Also, the results were obtained from one 
experiment only and further work would be needed before reaching a conclusion 
regarding the in vivo effects of NISV on circulating IL-4 levels.
It was hoped that the in vitro studies would shed some light on the mechanisms of the 
NISV-induced suppression of TN Fa. Previous studies had reported suppression of 
T N Fa production from murine peritoneal macrophages and human peripheral cells
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(Roberts, Alexander and Brewer, 1995, patent application). TN Fa suppression seen in 
these studies was reported at multiple time points including 1.5, 4, 24, and 48hr. In 
contrast, the in vitro studies presented here showed that TN Fa was induced by NISV 
treatment of splenocytes, hepatic adherent cells and bone marrow-derived macrophages. 
The NISV induction of T N Fa production agrees with the findings that NISV also 
induced NO production since NO is known to be a downstream product of 
T N Fa (Rockett et al., 1991). Induction of NO production by NISV explains the 
suppressive effects of NISV on splenocyte proliferation since NO has been reported to 
suppress lymphocyte proliferation (Ahvazi et a l, 1995). The studies showed that close 
contact was needed between NISV and splenocytes to cause suppression of splenocyte 
proliferation. It is not known whether external contact between NSV and splenocytes is 
sufficient or that NISV are actually engulfed by the macrophages where they stimulate 
intracellular mechanisms for NO production. Direct effect of NISV on the macrophages 
could explain why neither IFNy nor IL-4 levels were affected by NISV treatment in vivo.
The metabolic fate of NISV is not known. This makes it difficult to interpret the above in 
vivo and in vitro findings. Combining the in vitro and in vivo findings together, it can 
envisaged that macrophages are stimulated by NISV to produce NO immediately (NO 
detected in the first 2hr in vitro). Later on it seems, however, that macrophages start to 
degrade the NISV. During this time macrophages seem to be some how paralyzed and 
unable to produce T N Fa when stimulated with antigens such as malaria antigens. To test 
this hypothesis several modifications have to be introduced in this work. The in vivo and 
in vitro studies must be made very similar to each other unlike the studies presented here 
where in vivo administration of the NISV was long time (4 and 2 weeks) before infection, 
while in the in vitro studies NISV were added at the same time as the parasitized red 
cells. It would therefore, be useful and interesting to administer NISV in vivo on the same 
day of infection and measure both circulating T N F a  and nitrate levels from day 0. 
Similarly, it would be interesting to expose splenocytes to NISV for several days in vitro 
before stimulation with ConA or parasitized red cells and measure NO and T N Fa in the 
supernatants. It would also be very useful to label the NISV perhaps radioactively and 
trace their metabolic fate both in vivo and in vitro and elucidate when their degradation
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by macrophages start. Since whole splenocytes were used in the in vitro studies presented 
here, it would also be useful to measure the levels of IFNy and IL-4 in the supernatants.
The studies done on comparing the cytokine levels measured in different types of blood 
samples (plasma, serum, lysed whole blood and lysed packed blood cells remaining 
following removal of serum or plasma) and following repeated freezing and thawing of 
the samples alert toward standardization of methods of measuring the cytokines by 
ELISA among all operators (variation in methodology was noted, personal experience). 
The studies clearly show an effect for blood haemolysis on the levels of T N Fa detected.
In Summary, these studies have shown a T N F a suppressive effect by the NISV in vivo 
but an inducing one in vitro which agrees with their NO production induction in vitro. To 
explain this difference between the in vivo and in vitro settings, further modified work as 
described above is needed. Further work is also needed to investigate the in vivo fate of 
the NISV. In addition, it would be useful to measure the levels of TNFp which shares 
T N Fa properties and receptors (Ferrante et a l,  1990, Rockett et a l ,  1992) and the levels 
of membrane bound from of the T N Fa (Decker et a l ,  1987; Kreigler et al., 1988). It 
would also be useful to investigate the NISV effects on models where T N F a  suppression 
by anti-TNFa antibodies resulted in a beneficial outcome such as P. hergei ANKA 
infection in CBA/Ca mice (Grau et a l ,  1987c). It would also be useful to investigate 
therapeutic effects of NISV. Finally, further work in needed to define the effects of 
repeated freezing and thawing of the samples and different types of samples on the 
cytokine levels detected.
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Phosphate buffered saline (pH 7.2)
60g Na 2 HP 0 4 -I 2 H 2 O
13.6g N a 2 H P 0 4 .2 H 2 0
8.5g NaCl
M ade up to 1 litre with de-ionised distilled water.
RPMI 1640 stock medium
10.39g RPMI 1640 powdered ( with L-glutamine) (Gibco)
5.94g N2-hydroxyethylpiperazine-N-2 ethane sulphonic acid (HEPES) 25mM 
M ade up to 1 litre with de-ionised and distilled water, filter sterilised
(M ilipore/Gelman filter 0.22pm  size ) and adjusted to pH7.2
Incomplete RPMI 1640 medium
To stock RPM I 1640 medium the following were added:
11ml L-glutamine ( Gibco)
5.5ml NaHCO]
0.55ml 2-M ercaptoethanol (O.IM)
22ml Fungizone (Gibco)
2.2ml Gentamycin (Sigma)
In some of the RPMI 1640 stock instead of fungizone and gentamycin, penicillin and 
streptom ycin were added.
Complete RPMI 1640 medium
Heat inactivated foetal calf serum (Gibco) was added to incomplete RPM I 1640 
m edium  at a final concentration of 1 0 %.
Giemsa’s Buffer:
3 g Na2HP04 
0 .6 g KH 2 PO 4
M ade up to 1 litre with distilled water and adjusted to pH 7.4 
Giemsa’s stain:
G iem sa’s stain ( Gurr BDHLtd) was diluted 1:10 in G iem sa’s buffer.
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PBS/Tween 20 (washing buffer);
Tween 20 (polyoxyethylene sorbitan m onolaurate)
M ade up to 1 litre with PBS to give a final concentration of 0.05%
Blocking buffer:
Heat inactivated foetal calf serum added to phosphate buffer saline to give a final 
dilution o f 1 0 %
Tris buffered saline
9g NaCl
1.6g T risH C l
The pH was adjusted to pH 7.6 with HCl and made up to final volume of 1 litre with 
deionised and distilled water.
Carbonate/Bicarbonate coating buffer (0.05)
1.59g Na2C03
2.93g NaHCO]
0 .2 g NaHa
M ade up to 1 litre with deionised and distilled water and adjusted to pH 9.6
Bicarbonate coating buffer
8.4g NaHCOs
M ade up to 1 litre with ddHiO and pH adjusted to 8.2 
NISV:
49.6m g monopalmityl-rac-glycerol 
16.4mg dicetyl phosphate 
46.6m g cholestrol
RPMI 1640 Malaria stock medium:
10.39g RPMI 1640 powdered medium (with L-glutamine) (Gibco)
5.94. N2-hydroxyethylpiperazine-N-2 ethane suphonic acid (Hepes) (25mM ) 
M ade up to 960 ml with distilled water and filter sterilised.
2 0 0
Incomplete malaria medium:
To 100 ml aliquots of RPMI 1640 of m alaria slock medium, the following were 
added:
4.2 ml 5% NaHCOs 
0.25 ml gentamycin (sigma)
complete malaria medium:
heat inactivated human AB serum was added to incom plete malaria m edium  at a final 
concentration of 10%.
Boyl’s solution:
0.415g Am m onium  chloride, made up to 5ml in ddH 2 Û (pH 7.2)
0.103g 2-am ino-20(hydroxym ethyl)-l,3-propendiol (Tris), made up to 50ml in
ddHzO (pH 7.2).
The two chemicals were mixed at a ratio of 9:1 and passed through a filter of 0.22pm  
before use
MTT:
M ade up to a concentration of 5mg/ml in ddH20. The solution was filtered 
im m ediately prior to use by passing it through a 0.2pm  filter. The solution was finally 
diluted to 1 mg/ml with RPMI 1640.
2 0 1
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117
112  - ■
107 -■
102 -
87 ■
82 PcV
Pc77 -
72
10 12 14 16 18 20 22 24 26 286 82 40
day post infection
60
PcV
Pc50 -
40 -
10 -
DPI
Experiment S.l: percent weight and parasitaemia in 10-12 week old male BALB/c 
mice infected with P. c. AS. Pc and PcV groups were infected with 1x10^ pRBC on 
day 0 and received 100ml o f PBS or NISV respectively on days -28  and -14.
203
105 --
100
95 --
PBS
NISV
PcV
PC
85 -
80 --
75
14
days post infection
Pc
PcV30 -
25 -
10 -
1514
day post infection
Experiment S.2: percent weight and parasitaemia in 10-12 week old male BALB/c 
mice infected with P. c. AS. Pc and PcV groups were infected with 1x10  ^ pRBC on 
day 0 and received lOOfil o f PBS or NISV respectively on days -28  and -14. PBS and 
NISV groups received 100p,l o f PBS or NISV respectively on days -28  and -14.
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108
104
100
96
PBS
NISV
PcV
Pc
92
88
80
day post infection
40
PcV
Pc
35
30
days post infection
Experiment G.l: percent weight and parasitaemia in 10-12 week old male BALB/c 
mice infected with P.c. AS. Pc and PcV groups were infected with 1x10  ^ pRBC on 
day 0 and received lOOpl o f PBS and NISV respectively on days -28  and -14. PBS 
and NISV groups received lOOpl o f PBS and NISV respectively on days -2 8  and -14.
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NISV
8 10 12 14 16 18
day post infection
22 24
35
30 Pc
PcV
25
o.
10
6 8 10 
day post infection
Experiment G.2; percent weight and parasitaemia in 10-12 week old male BALB/c 
mice infected with P. c. AS. Pc and PcV groups were infected withlxlO^ pRBC on 
day 0 and received lOOpl o f  PBS and NISV respectively on days -28  and -14. PBS 
and NISV groups received lOOpl o f PBS and NISV respectively on days -28  and -14.
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I %AjiA—v*^  ^\-A«jl]i k^**wa—A— .^A»i— A
' j  'Vi j/S^ '^ û  %uz^ ^  'o tr S^\J,
Part of the poem  by Al M utanabbi (915-965 AD). W ho wrote it in 959 AD describing 
fever he was suffering from during his stay in Egypt.
It translates as follows;
M y visitor acts like she is shy for she does not visit m e except at night.
Ref; Dar Sader. Beyrouth.
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